Details of Disease

General Information of Disease (ID: DISZR48F)

• Disease Name: Solid tumour/cancer
• Disease Class: 2A00-2F9Z: Solid tumour/cancer
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISZR48F: Solid tumour/cancer
• ICD Code:
  ICD-11: ICD-11: 2A00-2F9Z
  ICD-10: ICD-10: C00-D48
  ICD-9: ICD-9: 140-199
  Expand ICD-9: 1.40E+179
• Disease Identifiers:
  MONDO ID: MONDO_0004992
  MESH ID: D009369
  UMLS CUI: C0006826
  MedGen ID: 14297
  SNOMED CT ID: 1240414004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 137 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
131i-chtnt	DM1R9L6	Approved	NA	[1]
2-deoxyglucose	DMIAHVU	Approved	Small molecular drug	[2]
Actimmune	DM3APM9	Approved	NA	[3]
Alloferon	DMQ1ZG2	Approved	NA	[1]
Alpelisib	DMEXMYK	Approved	Small molecular drug	[4]
Aprepitant	DM053KT	Approved	Small molecular drug	[5]
Arglabin	DMIB6I1	Approved	Small molecular drug	[1]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[6]
Avelumab	DMSZLJR	Approved	Monoclonal antibody	[3]
Belzutifan	DML1KTO	Approved	NA	[3]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[3]
Buserelin acetate	DMZQSA1	Approved	Small molecular drug	[7]
Cabazitaxel	DMPAZHC	Approved	Small molecular drug	[8]
Capivasertib	DM9SKW8	Approved	Small molecular drug	[9]
Carzinophilin	DMZPXRC	Approved	Small molecular drug	[1]
Celmoleukin	DMMG46O	Approved	NA	[1]
Ceruletide	DM2WE5K	Approved	Small molecular drug	[10]
Chromic phosphate P 32	DMWE70C	Approved	Small molecular drug	[1]
Chromomycin a3	DM750LD	Approved	Small molecular drug	[1]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[11]
Colchiceine amide	DM0IQ68	Approved	NA	[1]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[1]
Cyclophosphamide	DM4O2Z7	Approved	Small molecular drug	[12]
Dactinomycin	DM2YGNW	Approved	Small molecular drug	[13]
Daunorubicin	DMQUSBT	Approved	Small molecular drug	[14]
Demecolcine	DMCZQGK	Approved	Small molecular drug	[1]
Deslorelin	DMJIDH9	Approved	Small molecular drug	[1]
Dhaq diacetate	DMU3FGB	Approved	Small molecular drug	[15]
Docetaxel	DMDI269	Approved	Small molecular drug	[16]
Doxifluridine	DMDVNBQ	Approved	Small molecular drug	[1]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[17]
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[3]
Elliptinium acetate	DMZC6GT	Approved	Small molecular drug	[1]
Emdogain	DMZ05CC	Approved	NA	[1]
Enocitabine	DMX5VQL	Approved	Small molecular drug	[1]
Entrectinib	DMMPTLH	Approved	Small molecular drug	[18]
Epipodophyllotoxin	DM1XN59	Approved	Small molecular drug	[1]
Epirubicin	DMPDW6T	Approved	Small molecular drug	[19]
Eptaplatin	DM411K2	Approved	NA	[1]
Erdafitinib	DMI782S	Approved	NA	[20]
Etanidazole	DMT9BMR	Approved	Small molecular drug	[1]
Etoposide	DMNH3PG	Approved	Small molecular drug	[21]
Floxuridine	DM04LR2	Approved	Small molecular drug	[22]
Fludeoxyglucose F 18	DMAIL4L	Approved	Small molecular drug	[1]
Fluorouracil	DMUM7HZ	Approved	Small molecular drug	[23]
Fosfestrol	DMD072M	Approved	Small molecular drug	[1]
Fotemustine	DMV62ED	Approved	Small molecular drug	[1]
Fruquintinib	DMHOSCQ	Approved	NA	[24]
Futibatinib	DMWM4D0	Approved	NA	[3]
Gabapentin	DM6T924	Approved	Small molecular drug	[25]
GDC-0199	DMH0QKA	Approved	Small molecular drug	[26]
Gefitinib	DM15F0X	Approved	Small molecular drug	[27]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[28]
GlycoPEG-GCSF	DMND6ZZ	Approved	NA	[29]
Gonadoreline-6-d-trp acetate	DMKWNQ2	Approved	Small molecular drug	[1]
H-101	DMZNS9E	Approved	NA	[1]
Herbimycin A	DM6YWBF	Approved	Small molecular drug	[30]
Hexyl aminolevulinate	DM6GME9	Approved	Small molecular drug	[1]
HMPL-002	DMX6WH4	Approved	NA	[31]
Hydroxyprogesterone	DMIKQH5	Approved	Small molecular drug	[23]
Hylenex	DMVAIH4	Approved	NA	[32]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[3]
Ifosfamide	DMCT3I8	Approved	Small molecular drug	[33]
Infigratinib	DMNKBEC	Approved	Small molecular drug	[34]
Interferon gamma-1a	DMQD0LF	Approved	NA	[1]
Iobitridol	DMXN1CL	Approved	Small molecular drug	[1]
Isovanillin	DMX7LKS	Approved	Small molecular drug	[35]
Lactoferrin	DMA7QTC	Approved	Small molecular drug	[1]
Larotrectinib	DM26CQR	Approved	NA	[3]
Lentinan	DMX4QO4	Approved	Small molecular drug	[36]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[3]
Leucovorin Calcium	DMNWZJG	Approved	Small molecular drug	[1]
LEURUBICIN	DMQMXIO	Approved	Small molecular drug	[37]
Lucanthone	DMZLBUO	Approved	Small molecular drug	[38]
Lurbinectedin	DMEFRTZ	Approved	Small molecular drug	[3]
LY2835219	DM93VBZ	Approved	Small molecular drug	[39]
Medroxyprogesterone	DMBGWPH	Approved	Small molecular drug	[1]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[40]
Methotrexate Sodium	DM5XH2C	Approved	Small molecular drug	[1]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[1]
Methyltestosterone	DMWLFGO	Approved	Small molecular drug	[41]
Mifamurtide	DMGBGLC	Approved	Small molecular drug	[42]
Mitomycin	DMH0ZJE	Approved	Small molecular drug	[23]
Mitomycin A	DM4PF81	Approved	Small molecular drug	[23]
Mitoxantrone	DMM39BF	Approved	Small molecular drug	[43]
Mobenakin	DM6XLW6	Approved	Small molecular drug	[1]
Mogamulizumab	DMISH0Z	Approved	Monoclonal antibody	[3]
Monocrotaline	DMPXW12	Approved	Small molecular drug	[1]
Nadrolone phenylpropionate	DMZVLY8	Approved	Small molecular drug	[1]
Neocarzinostatin	DMPWCTH	Approved	Small molecular drug	[1]
Nirogacestat	DMUP5Z0	Approved	Small molecular drug	[3]
Nitric Oxide	DM1RBYG	Approved	Small molecular drug	[44]
Norethindrone	DMTY169	Approved	Small molecular drug	[1]
NSC-631570	DMHPZ8I	Approved	NA	[1]
OctreoScan	DMOLP5A	Approved	NA	[1]
PACIS	DMKVBVX	Approved	NA	[1]
Palbociclib	DMD7L94	Approved	Small molecular drug	[45]
Pegaspargase	DM2S26S	Approved	NA	[1]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[3]
PF-04449913	DMSB068	Approved	Small molecular drug	[3]
Plicamycin	DM7C8YV	Approved	Small molecular drug	[46]
Pralsetinib	DMWU0I2	Approved	NA	[3]
Prednimustine	DMVVPQX	Approved	Small molecular drug	[1]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[1]
Recombinant human endostatin	DMMPCFX	Approved	NA	[47]
Repotrectinib	DM9FB2T	Approved	NA	[3]
Retifanlimab	DMRKTCP	Approved	Antibody	[3]
Rexin-G	DML5FRY	Approved	NA	[1]
RHuEPO	DMALNG0	Approved	NA	[1]
Ripretinib	DM958QB	Approved	NA	[3]
Romurtide	DMI5CG8	Approved	Small molecular drug	[1]
Sarkomycin	DMH7N9A	Approved	Small molecular drug	[1]
Schizophyllan	DMFI0OL	Approved	Small molecular drug	[1]
Solamargine	DMQ1ENZ	Approved	Small molecular drug	[1]
Sterile Water	DM4GMJY	Approved	Small molecular drug	[1]
Tasonermin	DMPN0QQ	Approved	NA	[1]
Taxol	DMUOT9V	Approved	Small molecular drug	[1]
Tazemetostat	DMWP1BH	Approved	Small molecular drug	[3]
Teceleukin	DM348X1	Approved	NA	[1]
Tegafur	DM31ZQM	Approved	Small molecular drug	[1]
Tepotinib	DMUQ0E8	Approved	Small molecular drug	[48]
Tiazofurin	DM5JWV9	Approved	Small molecular drug	[49]
Tisotumab vedotin	DMF8FK3	Approved	NA	[3]
Tolonium chloride	DM36UAP	Approved	Small molecular drug	[1]
Topotecan	DMP6G8T	Approved	Small molecular drug	[50]
Trabectedin	DMG3Y89	Approved	Small molecular drug	[51]
Tremelimumab	DMOQ9H1	Approved	Monoclonal antibody	[52]
Triptorelin	DMTK4LS	Approved	Small molecular drug	[53]
UFT	DMX3O0D	Approved	Small molecular drug	[54]
Vandetanib	DMRICNP	Approved	Small molecular drug	[55]
Vapreotide acetate	DMNI12C	Approved	Small molecular drug	[56]
Vinblastine	DM5TVS3	Approved	Small molecular drug	[57]
Vinflunine	DMTJAEP	Approved	Small molecular drug	[1]
Vinorelbine	DMVXFYE	Approved	Small molecular drug	[58]
Zotarolimus	DMRMCXW	Approved	Small molecular drug	[59]
HBI-8000	DMDWYUN	Registered	Small molecular drug	[60]
Coenzyme Q10	DM8D9H5	Phase 4	Small molecular drug	[61]

This Disease is Treated as An Indication in 1 Approved

Drug Name	Drug ID	Highest Status	Drug Type	REF
Relatlimab	DM28AZV	Approved	NA	[3]

This Disease is Treated as An Indication in 1458 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IP-112	DMXE6FD	Preregistration	NA	[62]
99mTc-EC-DG	DMANM2B	Phase 3	NA	[63]
AB154	DMUES7Y	Phase 3	Antibody	[64]
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[3]
ABT-263	DMNE56X	Phase 3	Small molecular drug	[26]
ABT-869	DMREDYP	Phase 3	Small molecular drug	[65]
Aldoxorubicin	DMHKCIS	Phase 3	NA	[66]
AM0010	DMGMNUE	Phase 3	NA	[67]
AMD-070	DMVOY6B	Phase 3	Small molecular drug	[3]
Andecaliximab	DMLDB1X	Phase 3	NA	[6]
ARQ-087	DM02BVQ	Phase 3	NA	[68]
ASP1929	DMR71ST	Phase 3	Antibody	[69]
AT-406	DMVJW0S	Phase 3	Small molecular drug	[26]
AT9283	DMQ94CT	Phase 3	Small molecular drug	[70]
ATOFLUDING	DMDZ8EW	Phase 3	Small molecular drug	[71]
BAY 86-9766	DMPW5SB	Phase 3	Small molecular drug	[72]
Beloranib	DM71CK8	Phase 3	Small molecular drug	[73]
BGB-A317	DM7NJYC	Phase 3	NA	[6]
BI-695500	DMT0NTL	Phase 3	NA	[3]
BMS-986205	DM3MAYQ	Phase 3	NA	[3]
Botulinum toxin type A gel	DMJBPN7	Phase 3	NA	[74]
BSI-201	DMM0VO3	Phase 3	Small molecular drug	[75]
Camptothecin	DM6CHNJ	Phase 3	Small molecular drug	[76]
Canfosfamide	DM4FHQR	Phase 3	Small molecular drug	[77]
Cat-SPIRE	DMCEOEY	Phase 3	NA	[78]
CHLORIDE	DM1TJXA	Phase 3	Small molecular drug	[79]
CHML	DMMJC1Y	Phase 3	NA	[80]
CMS-024-02	DMC4X7L	Phase 3	NA	[81]
CMX-001	DM9Y3B5	Phase 3	Small molecular drug	[82]
CORT-125134	DMBS3UG	Phase 3	NA	[3]
Cotellic	DMF9M57	Phase 3	Small molecular drug	[83]
CT-2584	DMU2ZFK	Phase 3	Small molecular drug	[84]
Curcumin	DMQPH29	Phase 3	Small molecular drug	[85]
DFP-10917	DM1WNGJ	Phase 3	Small molecular drug	[86]
Doranidazole	DMTEJJT	Phase 3	Small molecular drug	[87]
DSP-7888	DM781D6	Phase 3	Vaccine	[88]
E-3810	DM42PFT	Phase 3	Small molecular drug	[89]
Exatecan	DMCA7FN	Phase 3	Small molecular drug	[90]
Fenretinide	DMRD5SP	Phase 3	Small molecular drug	[3]
GDC-0032	DMT4QHD	Phase 3	Small molecular drug	[91]
GDC-0068	DMWBZJD	Phase 3	Small molecular drug	[92]
GDC-0853	DMBEL3Q	Phase 3	NA	[93]
Gp100	DM5HCHR	Phase 3	NA	[94]
GS-5745	DMP8MDW	Phase 3	NA	[95]
Hemomex I	DMSIHXS	Phase 3	NA	[96]
Hu5F9-G4	DMBER0Q	Phase 3	NA	[6]
IB-MECA	DM9G5XD	Phase 3	Small molecular drug	[97]
IMO-2125	DM735FA	Phase 3	NA	[3]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[98]
INCSHR1210	DMZA2K0	Phase 3	Monoclonal antibody	[6]
IRISQUINONE	DMY6HIV	Phase 3	Small molecular drug	[99]
ISIS 23722	DMQZI7K	Phase 3	NA	[100]
IT-101	DMNDGWE	Phase 3	NA	[101]
KI-0502	DM3ZNY0	Phase 3	NA	[102]
KI-1001	DMDGG0G	Phase 3	NA	[103]
L-651582	DMWTPCA	Phase 3	Small molecular drug	[104]
Laromustine	DMH2EA1	Phase 3	Small molecular drug	[105]
LEE011	DMMX75K	Phase 3	Small molecular drug	[106]
Marizomib	DME9QGW	Phase 3	Small molecular drug	[107]
MBG453	DMBPY9Z	Phase 3	NA	[3]
MEDI4736	DM5X849	Phase 3	Monoclonal antibody	[108]
MGN-1703	DMCJRL1	Phase 3	NA	[3]
MK-7684	DMN7H5K	Phase 3	NA	[3]
MLN8237	DMO8PT9	Phase 3	Small molecular drug	[109]
Mycobacterial cell wall-DNA complex	DMJO3DB	Phase 3	Small molecular drug	[110]
Napabucasin	DMDZ6Q3	Phase 3	NA	[111]
NKTR 214	DM376WT	Phase 3	NA	[3]
Nolatrexed	DMOF0CA	Phase 3	Small molecular drug	[112]
Oltipraz	DMHQEA0	Phase 3	Small molecular drug	[113]
OSI-906	DMHKZLF	Phase 3	Small molecular drug	[114]
PDR001	DM53J6B	Phase 3	Antibody	[6]
Peg-G-CSF	DMBKWAF	Phase 3	NA	[115]
Pegargiminase	DMQKFWX	Phase 3	Recombinant protein	[3]
PF-06439535	DMVHZDP	Phase 3	Antibody	[116]
RG7388	DMF5GZI	Phase 3	Small molecular drug	[26]
Rigosertib	DMOSTXF	Phase 3	Small molecular drug	[117]
Rivoceranib	DM13V0P	Phase 3	Small molecular drug	[3]
Rostaporfin	DM7SAKN	Phase 3	Small molecular drug	[118]
RRx-001	DMQM2FH	Phase 3	Small molecular drug	[3]
S-110	DMXY34J	Phase 3	NA	[3]
SAR408701	DMXGE3O	Phase 3	Antibody drug conjugate	[119]
Savolitinib	DMALFKX	Phase 3	NA	[120]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[121]
Selumetinib	DMC7W6R	Phase 3	Small molecular drug	[122]
SID-530	DMMNZEJ	Phase 3	NA	[123]
Squalamine	DM3PS2E	Phase 3	Small molecular drug	[124]
Sulfatinib	DMPOTM4	Phase 3	NA	[125]
Talabostat	DM1IZ5D	Phase 3	Small molecular drug	[3]
Tivantinib	DMNVP8Q	Phase 3	Small molecular drug	[126]
Toca 511/Toca FC	DM65FF6	Phase 3	NA	[3]
Trebananib	DMOG2X1	Phase 3	Recombinant protein	[127]
Ultimab IgG1 antibody	DM6GJ7G	Phase 3	Monoclonal antibody	[128]
XL019	DMJ6F5C	Phase 3	Small molecular drug	[129]
XR-1500	DMAZ9CA	Phase 3	NA	[130]
AlloStim	DMC9T4O	Phase 2/3	NA	[131]
AZD4547	DM3827C	Phase 2/3	Small molecular drug	[132]
Batabulin	DMHWE5R	Phase 2/3	Small molecular drug	[133]
GSK3359609	DM4WYGA	Phase 2/3	Antibody	[3]
Indium-111	DMC3794	Phase 2/3	Antibody	[134]
Legumain-cleavable doxorubicin prodrugs	DMEUGZL	Phase 2/3	NA	[135]
LY2157299	DMP8HW1	Phase 2/3	Small molecular drug	[3]
MGCD516	DM752PU	Phase 2/3	NA	[136]
Naptumomab estafenatox	DM901ZW	Phase 2/3	NA	[137]
Rinfabate	DML9FD4	Phase 2/3	NA	[138]
13-DEOXYADRIAMYCIN HYDROCHLORIDE	DM4EP6Y	Phase 2	NA	[139]
131I-CLR-1404	DMZONKL	Phase 2	NA	[140]
177Lu-labelled NeoBOMB1	DM2TSMD	Phase 2	Radiopharmaceutical therapy agent	[141]
3F8	DMQIEZ8	Phase 2	NA	[142]
5-Fluoro-2-deoxycytidine	DMAVFG9	Phase 2	Small molecular drug	[143]
9-ING-41	DM57TY3	Phase 2	Small molecular drug	[144]
ABI-009	DMQ6KZM	Phase 2	NA	[145]
ABT-510	DMPDVM8	Phase 2	Small molecular drug	[146]
ABT-751	DMNG35S	Phase 2	Small molecular drug	[147]
ACT-GRO-777	DMMG61B	Phase 2	Aptamer	[148]
Ad-p53	DMJSWXL	Phase 2	NA	[149]
ADP-A2M4	DMRYH3M	Phase 2	NA	[150]
ADU-S100	DM8HBUI	Phase 2	NA	[3]
AEB1102	DMB5CKZ	Phase 2	NA	[3]
AGEN2034	DMPO7UG	Phase 2	Monoclonal antibody	[3]
ALKS 4230	DME3ZYC	Phase 2	Protein	[151]
ALRN-6924	DMLBWT1	Phase 2	NA	[3]
ALT-803	DMK3U1X	Phase 2	NA	[152]
ALXN6000	DMH5LFR	Phase 2	Antibody	[6]
AMG 208	DMPQHOR	Phase 2	Small molecular drug	[153]
AMG 232	DM65PTO	Phase 2	NA	[154]
AMG 337	DMIOUEY	Phase 2	NA	[155]
Amsilarotene	DMOB01U	Phase 2	Small molecular drug	[156]
Anetumab ravtansine	DMKFRWU	Phase 2	Antibody drug conjugate	[157]
Anti-CD137	DMHVZ27	Phase 2	Antibody	[158]
AP26113	DMYBQEF	Phase 2	Small molecular drug	[159]
APG-115	DMIFA0L	Phase 2	NA	[3]
APN401	DMEXN7V	Phase 2	Small interfering RNA	[3]
Apolizumab	DMKVP7E	Phase 2	Monoclonal antibody	[160]
APR-246	DMNFADH	Phase 2	Small molecular drug	[161]
APX005M	DMX2P5G	Phase 2	Antibody	[6]
APX3330	DMU6NBO	Phase 2	Small molecular drug	[162]
Aroplatin	DMOAA5G	Phase 2	NA	[163]
ARQ 092	DM5WK0J	Phase 2	NA	[164]
ARQ 761	DMH5CAL	Phase 2	NA	[165]
ARRY-382	DM0VGDC	Phase 2	NA	[3]
ARRY-520	DMTOI7S	Phase 2	Small molecular drug	[166]
ASN002	DM92X7N	Phase 2	NA	[3]
ASTX660	DMMKW8L	Phase 2	NA	[3]
ATL-104	DMD0I29	Phase 2	NA	[168]
ATN-224	DMQJ5DV	Phase 2	Small molecular drug	[169]
Aviscumine	DMIGYVA	Phase 2	NA	[170]
AXL-1717	DMTQ1Y3	Phase 2	Small molecular drug	[171]
AZD2014	DMOEARH	Phase 2	Small molecular drug	[172]
AZD4635	DM8SVIY	Phase 2	NA	[3]
AZD6738	DM0PFNC	Phase 2	Small molecular drug	[3]
BAY-57-9352	DMVA5NS	Phase 2	Small molecular drug	[173]
BAY-94-9392	DM08Z3L	Phase 2	NA	[174]
BAY1163877	DMCSGJ2	Phase 2	NA	[175]
BBI503	DMDSNIR	Phase 2	NA	[3]
BDB001	DMKFJXP	Phase 2	Antibody	[176]
Berubicin	DMJ2REU	Phase 2	Small molecular drug	[177]
Beta-Lapachone	DMMI84K	Phase 2	Small molecular drug	[178]
BEZ235	DMKBRDL	Phase 2	Small molecular drug	[179]
BGB-290	DMRO6XT	Phase 2	NA	[3]
BGB-3245	DM1X3L0	Phase 2	Small molecular drug	[180]
BI-1	DMS026F	Phase 2	Small molecular drug	[181]
BI-836826	DMWH7Z5	Phase 2	Antibody	[6]
BIBH 1	DMHYZEK	Phase 2	Antibody	[182]
Birinapant	DM6PBUM	Phase 2	Small molecular drug	[26]
BLZ-945	DMG1LVA	Phase 2	Small molecular drug	[3]
BMS-184476	DMDPLEM	Phase 2	Small molecular drug	[183]
BMS-188797	DML1CK2	Phase 2	Small molecular drug	[184]
BMS-275183	DMQL3VS	Phase 2	Small molecular drug	[185]
BMS-599626	DMDPQV5	Phase 2	Small molecular drug	[186]
BMS-813160	DMKY638	Phase 2	NA	[3]
BMS-986012	DMVJXOH	Phase 2	Antibody	[187]
BMS-986156	DMXNI8G	Phase 2	NA	[188]
BMS-986253	DM42B0C	Phase 2	Antibody	[189]
BVD-523	DMNB4XK	Phase 2	NA	[190]
Cabiralizumab	DMGE058	Phase 2	NA	[6]
CAP-7.1	DMJKLHU	Phase 2	NA	[191]
CB-839	DM094UH	Phase 2	NA	[3]
CC-401	DMPMO6G	Phase 2	Small molecular drug	[192]
CC-90011	DM0EDHJ	Phase 2	Small molecular drug	[3]
CDX-1401	DMCGNJ6	Phase 2	NA	[193]
CDX-301	DMKRFCO	Phase 2	NA	[193]
CDX-3379	DM5GKYD	Phase 2	NA	[6]
CEN-109	DMXC05I	Phase 2	NA	[194]
CetuGEX	DMAWKSM	Phase 2	Antibody	[195]
CG201	DMWY609	Phase 2	Small molecular drug	[196]
CJM112	DMTSVJM	Phase 2	NA	[6]
CKD602	DMW9F1G	Phase 2	Small molecular drug	[197]
CLR-1404	DMAW4EL	Phase 2	NA	[198]
CMB305	DMYYEM5	Phase 2	NA	[88]
Combidex	DMZ3H5N	Phase 2	NA	[199]
CP-547632	DMX054A	Phase 2	Small molecular drug	[200]
CPX-POM	DMK7DFM	Phase 2	Small molecular drug	[3]
CRLX101	DMQUWXY	Phase 2	NA	[201]
CRYPTOPHYCIN 52	DM16IMT	Phase 2	Small molecular drug	[202]
CVX-045	DMCN9GX	Phase 2	NA	[203]
CX-072	DMVZT2I	Phase 2	Antibody	[204]
CX-4945	DMWE7B9	Phase 2	Small molecular drug	[205]
CX2009	DMU62I8	Phase 2	Probody drug conjugate	[3]
CYCLOPLATAM	DMXR8WN	Phase 2	Small molecular drug	[206]
CYSTEMUSTINE	DM0DT45	Phase 2	Small molecular drug	[207]
Cytorex-EBV	DMWLRR4	Phase 2	NA	[208]
Debio 1347	DMZW50O	Phase 2	NA	[209]
Depatuxizumab	DM7GPMB	Phase 2	NA	[6]
DI-VAL-L-DC	DM1A5NP	Phase 2	Small molecular drug	[210]
Diethylnorspermine	DMYMIXG	Phase 2	Small molecular drug	[211]
DIFLOMOTECAN	DM20ATW	Phase 2	Small molecular drug	[212]
Dilpacimab	DMCATH2	Phase 2	Antibody	[213]
DOLASTATIN-10	DMDUV1S	Phase 2	Small molecular drug	[214]
E7820	DMZRXTL	Phase 2	Small molecular drug	[215]
E7850	DM8K5IF	Phase 2	Small molecular drug	[216]
EC-145	DM0KVJC	Phase 2	NA	[217]
EFT508	DMX6RZG	Phase 2	NA	[3]
Elsamitrucin	DMR50I7	Phase 2	Small molecular drug	[218]
Emibetuzumab	DMT4MKF	Phase 2	NA	[6]
Encapsulated cancer cells	DMLH9VI	Phase 2	NA	[219]
Endostatin	DM8NLDI	Phase 2	NA	[220]
Enoblituzumab	DMDS20X	Phase 2	NA	[6]
EP-100	DMY1JJV	Phase 2	Peptide	[221]
EP-302	DM3UHGF	Phase 2	Small molecular drug	[222]
EQ-917	DMD4YRG	Phase 2	NA	[223]
Exherin	DMC1I56	Phase 2	Small molecular drug	[224]
F-16-IL-2 fusion protein	DMJ4BKT	Phase 2	NA	[225]
FAD-104	DMXB6KG	Phase 2	Small molecular drug	[226]
Famitinib	DMSFWT7	Phase 2	Small molecular drug	[227]
FANG vaccine	DM0OV22	Phase 2	Vaccine	[3]
FARANOXI	DMFFK8M	Phase 2	Small molecular drug	[228]
FF21101	DMS23ON	Phase 2	Antibody	[229]
Fluciclatide F-18	DME01HT	Phase 2	Small molecular drug	[230]
FolateImmune	DMB9ADM	Phase 2	Small molecular drug	[231]
FP-1039	DMUAXS5	Phase 2	NA	[232]
G-202	DMQR9I8	Phase 2	NA	[233]
GDC-0077	DMY6WUV	Phase 2	NA	[234]
GDC-0980/RG7422	DMF3MV1	Phase 2	Small molecular drug	[235]
GDC0941	DM1YAK6	Phase 2	Small molecular drug	[236]
GI-6301	DMOMS7R	Phase 2	Vaccine	[237]
GM-CSF cancer vaccine	DML6PO5	Phase 2	Vaccine	[238]
GO-203-2c	DMLWKZ7	Phase 2	NA	[239]
GSK2110183	DMZHB37	Phase 2	Small molecular drug	[240]
GSK3326595	DMJRD7A	Phase 2	NA	[3]
GTP-200	DM03NQS	Phase 2	NA	[241]
HER1-VSSP vaccine	DMX6B95	Phase 2	Vaccine	[242]
HF10	DMG5146	Phase 2	Oncolytic virus therapy	[243]
HI-con1	DMDWGTG	Phase 2	NA	[244]
HLA-A, B7.1-transfected adenocarcinoma vaccine	DMPXN0X	Phase 2	NA	[245]
HM-5016504	DMLQDBH	Phase 2	NA	[120]
HM-78136B	DMZ3BER	Phase 2	Small molecular drug	[246]
HPPH photodynamic therapy	DMYRJNE	Phase 2	NA	[247]
HQK-1004	DM3WX0K	Phase 2	NA	[248]
IMGN901	DMIUC3M	Phase 2	NA	[249]
IMM-101	DMUGYYL	Phase 2	NA	[250]
IMO-2055	DM6IQ3V	Phase 2	NA	[251]
INCAGN01876	DMNUXKA	Phase 2	Antibody	[252]
INCB86550	DMJN9PU	Phase 2	Small molecular drug	[253]
INGN-241	DM6P91T	Phase 2	NA	[254]
Iodine-124-labeled F-16 scFv antibody	DM3HNMZ	Phase 2	NA	[255]
IODOSTEARIC ACID	DM38343	Phase 2	Small molecular drug	[256]
IPI-549	DMG5Q7F	Phase 2	NA	[3]
ISIS-EIF4E	DMRN543	Phase 2	Antisense drug	[257]
Ispinesib	DMP2BWX	Phase 2	Small molecular drug	[258]
JI-101	DMM02VJ	Phase 2	Small molecular drug	[259]
JM216	DMJSVRL	Phase 2	Small molecular drug	[260]
JNJ 63723283	DMBXWJ5	Phase 2	Monoclonal antibody	[6]
JNJ-26481585	DMKIE9C	Phase 2	Small molecular drug	[261]
JTX-2011	DMGXTOP	Phase 2	NA	[3]
Kevetrin	DMFO6MH	Phase 2	Small molecular drug	[262]
KN035	DMKLMG6	Phase 2	Antibody	[263]
KW-2478	DMJGL72	Phase 2	Small molecular drug	[264]
Labetuzumab-SN-38	DMUSGHP	Phase 2	Monoclonal antibody	[265]
LB-100	DMC04SR	Phase 2	Small molecular drug	[266]
LCL161	DMTM4QA	Phase 2	NA	[267]
LE-SN38	DMW50NF	Phase 2	Small molecular drug	[268]
Lexatumumab	DMOS5JZ	Phase 2	Antibody	[269]
Lirilumab	DMNGT89	Phase 2	Monoclonal antibody	[3]
LY-2875358	DMQV1OU	Phase 2	Antibody	[270]
LY2606368	DM4XMF7	Phase 2	NA	[271]
LY2801653	DM0KJDY	Phase 2	Small molecular drug	[272]
LY2874455	DMZ0DMY	Phase 2	Small molecular drug	[273]
LY3023414	DMD9KYF	Phase 2	NA	[274]
LY333531	DMGMC8H	Phase 2	Small molecular drug	[275]
LYC-55716	DMV8WU9	Phase 2	NA	[3]
M4112	DMYB8FH	Phase 2	NA	[3]
M7824	DMJCULI	Phase 2	Antibody	[3]
MEHD-7945A	DMHOF7T	Phase 2	NA	[276]
MG-4101	DM6FKOW	Phase 2	NA	[277]
MGAH22	DMIXT2Y	Phase 2	NA	[278]
MGCD-0103	DM726HX	Phase 2	Small molecular drug	[279]
MGCD265	DMRPCF2	Phase 2	Small molecular drug	[3]
Milataxel	DM50Z4U	Phase 2	Small molecular drug	[280]
MK-1454	DMEDITW	Phase 2	NA	[3]
MK-1775	DM3WDZ5	Phase 2	Small molecular drug	[3]
MK-5890	DM0XV88	Phase 2	NA	[3]
MK8242	DMRRHOB	Phase 2	NA	[26]
MKT-077	DM3I71U	Phase 2	Small molecular drug	[281]
MLN2480	DMBR8NF	Phase 2	Small molecular drug	[3]
MM-141	DM2RJ4D	Phase 2	NA	[282]
MNX-100	DMQA3MV	Phase 2	NA	[283]
MP40X	DM75VU7	Phase 2	NA	[284]
MP470	DMELUAK	Phase 2	Small molecular drug	[285]
mRNA-4157	DMVTTBZ	Phase 2	Vaccine	[3]
Multivalent carbohydrate-based vaccine	DMZ5MIN	Phase 2	NA	[286]
Mutant ras vaccine	DMM6KZR	Phase 2	Vaccine	[287]
MVA E2 vaccine	DMWIVGC	Phase 2	NA	[288]
NDDP	DM6S83X	Phase 2	Small molecular drug	[289]
NHS-IL2-LT	DMDY01J	Phase 2	NA	[290]
NIR178	DMPER4A	Phase 2	NA	[3]
NIS793	DM8LBYT	Phase 2	NA	[3]
Nivatrotamab	DMAOUZV	Phase 2	Antibody	[291]
NMK-36	DMD0O71	Phase 2	NA	[292]
NSC-364432	DMWL9PF	Phase 2	Small molecular drug	[293]
NVP-AUY922	DMTYXQF	Phase 2	Small molecular drug	[294]
NY-ESO-1 T-cell receptor therapy	DM7O6TV	Phase 2	NA	[6]
Obatoclax	DMPF9ZM	Phase 2	Small molecular drug	[295]
OBI-3424	DM5D6Y7	Phase 2	Small molecular drug	[296]
ONC201	DMM5SCF	Phase 2	NA	[3]
Oncoprex	DMQ2N8Y	Phase 2	NA	[222]
Oprozomib	DM16RIC	Phase 2	Small molecular drug	[297]
ORG 34517/34850	DMR3P98	Phase 2	Small molecular drug	[298]
Ortataxel	DM1EK5D	Phase 2	Small molecular drug	[299]
Oshadi D	DMM7MPB	Phase 2	NA	[300]
Oshadi R	DM3A2TT	Phase 2	NA	[301]
P54	DMCBEYH	Phase 2	NA	[302]
Pankomab-GEX	DMAZ460	Phase 2	Antibody	[303]
PBI-05204	DM05WIU	Phase 2	NA	[304]
PCM-075	DMYFRTB	Phase 2	NA	[3]
PDX-101	DM6OC53	Phase 2	Small molecular drug	[305]
PELITREXOL	DMR6USG	Phase 2	Small molecular drug	[306]
PERFOSFAMIDE	DMVUU4J	Phase 2	Small molecular drug	[307]
PF-03446962	DMTJWNE	Phase 2	NA	[308]
PF-04518600	DMZMUIL	Phase 2	NA	[309]
PF-05212384	DMBL3VD	Phase 2	Small molecular drug	[310]
PF-06463922	DMKM7EW	Phase 2	Small molecular drug	[311]
PI-88/Taxotere	DM4FIWC	Phase 2	NA	[312]
PK1	DMKEV7N	Phase 2	Small molecular drug	[313]
PLX8394	DMRTD7I	Phase 2	NA	[3]
PM-00104	DMMKOPX	Phase 2	Small molecular drug	[314]
PNT-2258	DMUVON0	Phase 2	Antisense drug	[315]
Poly-ICLC	DM2570B	Phase 2	Small molecular drug	[3]
Polyglutamate camptothecin	DMXROM7	Phase 2	NA	[316]
Prolarix	DMZIQ8G	Phase 2	Small molecular drug	[317]
PRX-321	DM7YWVT	Phase 2	Small molecular drug	[318]
PTC299	DMP9TKE	Phase 2	Small molecular drug	[319]
PVX-410	DM6DK9A	Phase 2	NA	[320]
PX-12	DMLVHAJ	Phase 2	Small molecular drug	[321]
PX-866	DMYISJK	Phase 2	Small molecular drug	[322]
R-roscovitine	DMSH108	Phase 2	Small molecular drug	[323]
RAV-12	DMPZAHP	Phase 2	NA	[324]
RC-3095	DMIG98L	Phase 2	Small molecular drug	[325]
REGN1979	DMSJ3Z5	Phase 2	NA	[3]
Resten-NG	DMM4EJI	Phase 2	Antisense drug	[326]
RG6180	DMVE8CN	Phase 2	NA	[88]
RG7155	DM8JMNL	Phase 2	NA	[327]
RG7888	DM2SWI8	Phase 2	Antibody	[6]
Ro 31-7453	DM83QCL	Phase 2	Small molecular drug	[328]
RO-5126766	DM3U9BY	Phase 2	Small molecular drug	[329]
RO-5323441	DMUB3OY	Phase 2	NA	[330]
Ruthenium-based complexes	DMJORLT	Phase 2	NA	[331]
RX-0201	DMTBAV3	Phase 2	NA	[332]
RX-3117	DME8ARP	Phase 2	NA	[333]
RX-5902	DMBOZPH	Phase 2	NA	[334]
Sabarubicin	DMBZO8N	Phase 2	Small molecular drug	[335]
Salvicine	DM0298B	Phase 2	Small molecular drug	[336]
SAR-125844	DMJ34G6	Phase 2	NA	[337]
SAR-566658	DMT4FI5	Phase 2	Antibody	[338]
SAR245409	DMQM7IL	Phase 2	Small molecular drug	[339]
SAR256212	DMSE8XX	Phase 2	NA	[340]
SAR439859	DMR5CSZ	Phase 2	Small molecular drug	[3]
SAR566658	DM6Q295	Phase 2	Antibody	[341]
Saracatinib	DMBLHGP	Phase 2	Small molecular drug	[342]
SB-743921	DM6XJ9S	Phase 2	Small molecular drug	[343]
SCH-527123	DMPUAOE	Phase 2	Small molecular drug	[3]
SCH-900776	DM67EMK	Phase 2	Small molecular drug	[344]
SEphB4-HSA	DMD8RU0	Phase 2	Recombinant protein	[345]
SF1126	DML10K3	Phase 2	Small molecular drug	[346]
SGN-30	DMJ9M5D	Phase 2	Antibody	[347]
SGT-53	DMLYIPA	Phase 2	Gene therapy	[348]
Soblidotin	DMO4EYX	Phase 2	Small molecular drug	[349]
Sodium stibogluconate	DMH5MVE	Phase 2	NA	[350]
SPI-1620	DMNPRMC	Phase 2	Small molecular drug	[351]
T-607	DM5C70M	Phase 2	Small molecular drug	[352]
TAS-114	DM3D52L	Phase 2	NA	[353]
Terameprocol	DMC3P45	Phase 2	Small molecular drug	[354]
Tetrahydrouridine	DMR5GSB	Phase 2	Small molecular drug	[355]
TETRAPLATIN TETRANITRATE	DMGNK67	Phase 2	NA	[356]
TEW-7197	DM2LBC3	Phase 2	NA	[357]
TLC-388	DMGWP8L	Phase 2	NA	[358]
TLN-4601	DMVXLQ7	Phase 2	Small molecular drug	[359]
TM-601	DMKV5UM	Phase 2	NA	[360]
TRC102	DMPGDKG	Phase 2	NA	[361]
TROXACITABINE	DMAZ2L6	Phase 2	Small molecular drug	[362]
Urelumab	DM6RTVG	Phase 2	NA	[6]
Vadimezan	DMK7CYX	Phase 2	Small molecular drug	[363]
VATALANIB	DMY0UEQ	Phase 2	Small molecular drug	[364]
Veltuzumab	DM5BL4C	Phase 2	Monoclonal antibody	[3]
Verubulin	DMBQC3L	Phase 2	Small molecular drug	[365]
VLS-101	DMLT94F	Phase 2	Antibody drug conjugate	[366]
VS-6063	DMGBLI3	Phase 2	Small molecular drug	[367]
VX-680	DM93YKJ	Phase 2	Small molecular drug	[368]
VX-944	DME321B	Phase 2	Small molecular drug	[369]
X-82	DMW1NKO	Phase 2	NA	[370]
XL-820	DMMHX9K	Phase 2	NA	[371]
XL147	DMML7BE	Phase 2	Small molecular drug	[372]
XL880	DMHJTR2	Phase 2	Small molecular drug	[373]
ZD-6126	DMH85M0	Phase 2	Small molecular drug	[374]
BT1718	DMTXBUV	Phase 1/2a	Bicycle toxin conjugate	[375]
177-Lu-NeoB	DM6JLNT	Phase 1/2	Small molecular drug	[376]
8-chloro-adenosine	DMT0YQI	Phase 1/2	Small molecular drug	[377]
A166	DMGTOIX	Phase 1/2	Antibody drug conjugate	[378]
AB928	DMDOXMN	Phase 1/2	NA	[3]
ADG106	DM87H0S	Phase 1/2	Antibody	[379]
ADXS-HER2	DMW8C1D	Phase 1/2	NA	[88]
AEE-788	DMEOS5K	Phase 1/2	Small molecular drug	[380]
AEG35156	DM2HRYD	Phase 1/2	siRNA drug	[381]
AFM24	DMFTZX0	Phase 1/2	Antibody	[382]
AGEN1884	DMAP5B4	Phase 1/2	NA	[6]
ALX148	DMGQX0U	Phase 1/2	Protein	[3]
AMXI 5001	DMR9H6B	Phase 1/2	Small molecular drug	[383]
Anti-Mesothelin CAR-T cells	DM4NMBW	Phase 1/2	CAR T Cell Therapy	[384]
Anti-RAS-G12D mTCR-transduced PBL	DMF1ZL5	Phase 1/2	Cell therapy	[385]
Anti-RAS-G12V mTCR-transduced PBL	DM46OVU	Phase 1/2	Cell therapy	[386]
Anti-VEGFR2 CD8 cell therapy	DM2910G	Phase 1/2	NA	[387]
AO-176	DMXU98C	Phase 1/2	Antibody	[388]
APG-1252	DM8O3R9	Phase 1/2	Small molecular drug	[3]
APS-001	DMYKM63	Phase 1/2	NA	[3]
ASTX029	DMVZXIA	Phase 1/2	Small molecular drug	[389]
ASTX295	DM9EM5G	Phase 1/2	Small molecular drug	[390]
Autologous fat-derived stem cell therapy	DMF3T0Q	Phase 1/2	NA	[391]
AVID100	DMM5X5I	Phase 1/2	NA	[6]
AZD7648	DMD9Y5T	Phase 1/2	Small molecular drug	[392]
BAL-101553	DMPFGL8	Phase 1/2	Small molecular drug	[393]
BCT-100	DMZK7IT	Phase 1/2	NA	[394]
BDC-1001	DMJ5MPG	Phase 1/2	Antibody drug conjugate	[395]
BDTX-189	DMODTX5	Phase 1/2	Small molecular drug	[396]
BGB-283	DMVYTG7	Phase 1/2	Small molecular drug	[397]
BGB-A333	DM5VG6S	Phase 1/2	Antibody	[398]
BGB-A425	DMI42Q0	Phase 1/2	Antibody	[399]
BGT226	DMXKDUL	Phase 1/2	Small molecular drug	[400]
BIL010t	DMV1EA9	Phase 1/2	NA	[401]
BIO-300	DMJ7NVI	Phase 1/2	NA	[402]
BMS-753493	DMDQO0S	Phase 1/2	Small molecular drug	[403]
BMS-986016	DMDCHM7	Phase 1/2	NA	[404]
BMS-986158	DM6LDI4	Phase 1/2	NA	[405]
BMS-986178	DML2A2G	Phase 1/2	NA	[3]
BMS-986207	DMHPM7X	Phase 1/2	NA	[406]
BMS-986218	DM32144	Phase 1/2	NA	[407]
BMS-986288	DMM10J4	Phase 1/2	Probody	[408]
BMS-986315	DMTEY1L	Phase 1/2	Antibody	[409]
BN-2629	DMA9MP5	Phase 1/2	NA	[410]
BPX-501	DMIMA4V	Phase 1/2	NA	[3]
BSK01	DM9S4SB	Phase 1/2	NA	[3]
BT5528	DMYBKMV	Phase 1/2	Bicycle?toxin conjugate	[411]
BT8009	DM1FJW6	Phase 1/2	Bicycle?toxin conjugate	[412]
CAB-AXL-ADC	DMBSNY8	Phase 1/2	NA	[3]
CAB-ROR2-ADC	DM16CS0	Phase 1/2	NA	[3]
CAR-T cells targeting Muc1	DM5FKU1	Phase 1/2	CAR T Cell Therapy	[413]
CART-EGFR	DM3I267	Phase 1/2	CAR T Cell Therapy	[414]
CART-HER-2	DMMTDK1	Phase 1/2	CAR T Cell Therapy	[415]
CB3304	DMY8WDB	Phase 1/2	Small molecular drug	[416]
CBP-501	DMCWVPU	Phase 1/2	Small molecular drug	[3]
CC-223	DMMQYL9	Phase 1/2	Small molecular drug	[417]
CCS1477	DM9UZM1	Phase 1/2	Small molecular drug	[418]
CDK-002	DMT09US	Phase 1/2	NA	[419]
CEP-32496	DMAO04B	Phase 1/2	Small molecular drug	[420]
Ceramide	DMIPO5F	Phase 1/2	NA	[3]
Cetrelimab	DMJBQ96	Phase 1/2	Antibody	[421]
CFI-402411	DMB5KRA	Phase 1/2	Small molecular drug	[422]
CHR-3996	DMIXPNG	Phase 1/2	Small molecular drug	[423]
CHS-828	DMTV4L7	Phase 1/2	Small molecular drug	[424]
CLR-1401	DM2FSM5	Phase 1/2	NA	[425]
CNDO-109	DMQ5E8L	Phase 1/2	NA	[426]
ColoAd1	DM5OOAS	Phase 1/2	NA	[427]
CPI-0209	DMJEXLI	Phase 1/2	Small molecular drug	[428]
CRLX301	DMPZ1J6	Phase 1/2	NA	[3]
Crolibulin	DMAM28X	Phase 1/2	Small molecular drug	[429]
CUDC-907	DMHIQDC	Phase 1/2	Small molecular drug	[3]
CV-9103	DMSOSIA	Phase 1/2	NA	[430]
CVX-060	DM03LWZ	Phase 1/2	Antibody	[431]
CYT-0851	DME6NMJ	Phase 1/2	Small molecular drug	[432]
DCC-3014	DMHW289	Phase 1/2	Small molecular drug	[433]
DCVax-Direct	DMFYF1I	Phase 1/2	NA	[88]
Dendritic cancer vaccine	DMFDDDE	Phase 1/2	NA	[3]
DF1001	DMMZO71	Phase 1/2	Recombinant?protein	[434]
DF6002	DMZL5SB	Phase 1/2	Recombinant?protein	[435]
DRP-104	DMF9B50	Phase 1/2	Small molecular drug	[436]
DS-7300	DMK4VY9	Phase 1/2	Antibody drug conjugate	[437]
DSP-0509	DM7WK6N	Phase 1/2	Small molecular drug	[438]
DSP-107	DM8K0PR	Phase 1/2	Recombinant?protein	[439]
EDO-S101	DMI71FN	Phase 1/2	NA	[3]
eFT226	DMHRCQI	Phase 1/2	Small molecular drug	[440]
Elenagen	DM38UR1	Phase 1/2	NA	[88]
Enapotamab vedotin	DM1PQJO	Phase 1/2	Antibody	[441]
ETBX-011 cancer vaccine	DMQFDMH	Phase 1/2	NA	[442]
F-14512	DML6EVJ	Phase 1/2	Small molecular drug	[443]
FF-10502	DM72JE4	Phase 1/2	Small molecular drug	[444]
FGF401	DMWEJ0C	Phase 1/2	NA	[3]
FLX475	DMI7S39	Phase 1/2	Small molecular drug	[445]
G1	DMTV42K	Phase 1/2	Small molecular drug	[446]
GEN-009	DMFW4R6	Phase 1/2	Vaccine	[447]
GL-ONC1	DMEXNZN	Phase 1/2	Oncolytic virus therapy	[3]
GS-4224	DM1GE67	Phase 1/2	Small molecular drug	[448]
GS-9219	DMTJQ8S	Phase 1/2	Small molecular drug	[449]
HH2710	DM0C5MV	Phase 1/2	NA	[450]
HPN536	DM86OJ0	Phase 1/2	NA	[451]
HSV-1716	DMIDHGO	Phase 1/2	NA	[452]
HuMax-AXL-ADC	DMFT9LL	Phase 1/2	NA	[3]
HuMax-TF	DMD52PW	Phase 1/2	NA	[453]
IGF-MTX	DMXQEAA	Phase 1/2	NA	[454]
Imab-027	DMU46YC	Phase 1/2	Monoclonal antibody	[455]
IMC-F106C	DMHQ2U8	Phase 1/2	Recombinant protein	[456]
IMSA101	DM43ICH	Phase 1/2	Small molecular drug	[457]
IMX-110	DMNHZS4	Phase 1/2	NA	[3]
INCAGN1876	DM8XN4A	Phase 1/2	NA	[6]
INCAGN1949	DM7OE3X	Phase 1/2	NA	[6]
INCB01158	DM8124R	Phase 1/2	NA	[458]
INCB054329	DM7TZL0	Phase 1/2	Small molecular drug	[459]
INCB057643	DMG65CV	Phase 1/2	Small molecular drug	[460]
INT230-6	DMNZVO6	Phase 1/2	NA	[88]
IPP-204106	DM8E3N6	Phase 1/2	NA	[461]
ISIS-STAT3	DMDTNFB	Phase 1/2	Antisense drug	[462]
Isunakinra	DMA41DO	Phase 1/2	Recombinant protein	[463]
JAB-3312	DMNMV0D	Phase 1/2	Small molecular drug	[464]
KiroVAX-003	DMACXPP	Phase 1/2	NA	[88]
KiroVAX-004	DM4T0FD	Phase 1/2	NA	[88]
KY1044	DMXJ683	Phase 1/2	Antibody	[465]
L-377202	DMBEQ08	Phase 1/2	Small molecular drug	[466]
LAG525	DMQX5SN	Phase 1/2	NA	[3]
Lipoteichoic acid	DMEMRW0	Phase 1/2	NA	[467]
Long-acting IFN-alpha	DM8BTNO	Phase 1/2	NA	[468]
LXS196	DM65MEL	Phase 1/2	NA	[469]
LY-2228820	DMHXTNW	Phase 1/2	Small molecular drug	[470]
LY2812176	DMBZYZ1	Phase 1/2	NA	[471]
LY2880070	DMADEHZ	Phase 1/2	Small molecular drug	[472]
LY2940680	DMTJWIQ	Phase 1/2	Small molecular drug	[473]
LY3039478	DMC5SAW	Phase 1/2	Small molecular drug	[474]
LY3295668	DM8RJTB	Phase 1/2	Small molecular drug	[475]
LY3499446	DMA1CSR	Phase 1/2	Small molecular drug	[476]
M3814	DMK2L38	Phase 1/2	NA	[3]
ME-344	DM6JN19	Phase 1/2	Small molecular drug	[477]
MEDI6469	DMR9EOI	Phase 1/2	NA	[478]
Medusa IL-2	DMMB5CV	Phase 1/2	NA	[479]
MGC018	DM1KZW0	Phase 1/2	Antibody drug conjugate	[480]
MGD013	DMCVMUL	Phase 1/2	Antibody	[204]
MK-1308	DM25QKC	Phase 1/2	Antibody	[481]
MLN1117	DMCVBQD	Phase 1/2	NA	[482]
Monalizumab	DMG7XHE	Phase 1/2	Antibody	[6]
MORAb-202	DMGWRUL	Phase 1/2	NA	[483]
NBE-002	DMTAODR	Phase 1/2	Antibody drug conjugate	[484]
NC410	DMZSIV1	Phase 1/2	Recombinant protein	[485]
NKP-2235	DMSW83I	Phase 1/2	NA	[486]
NKR-2	DM2JLCC	Phase 1/2	NA	[6]
NKTR-262	DMYR8LF	Phase 1/2	NA	[487]
NT219	DMOYS1N	Phase 1/2	Small molecular drug	[488]
OBI-888	DMD2L1U	Phase 1/2	Antibody	[489]
OBI-999	DMPB9OD	Phase 1/2	Antibody drug conjugate	[490]
ODM-207	DMOKVJD	Phase 1/2	Small molecular drug	[491]
ONCOS-102	DMACFVN	Phase 1/2	Oncolytic virus therapy	[492]
ONO-7579	DMXLPYE	Phase 1/2	NA	[3]
OTX-015	DMI8RG1	Phase 1/2	Small molecular drug	[26]
PA-799	DMLSYJQ	Phase 1/2	Small molecular drug	[493]
PC14586	DMSJ54W	Phase 1/2	Small interfering RNA	[494]
PEN-866	DMLPTOF	Phase 1/2	NA	[3]
PLX2853	DMX168L	Phase 1/2	Small molecular drug	[495]
PLX9486	DM5DZEL	Phase 1/2	Small molecular drug	[3]
PRGN-2009	DMRLM1R	Phase 1/2	Vaccine	[496]
PRLX93936	DM8J5H1	Phase 1/2	NA	[497]
Promostem	DM2DJ3W	Phase 1/2	NA	[498]
RGX-104	DM5AIKR	Phase 1/2	NA	[3]
RP-3500	DM9FNC8	Phase 1/2	Small molecular drug	[499]
RP1	DMLH6WM	Phase 1/2	NA	[3]
RTX-240	DMBL7FH	Phase 1/2	Cell therapy	[500]
S-3304	DMCBQTF	Phase 1/2	Small molecular drug	[501]
SECTA belomycin	DMBFUOI	Phase 1/2	NA	[502]
SEL-24	DMH064K	Phase 1/2	NA	[503]
SGX201	DMR86L5	Phase 1/2	NA	[504]
SKB264	DMSTEFK	Phase 1/2	Antibody drug conjugate	[505]
SV-BR-1-GM cancer vaccine	DM70TX5	Phase 1/2	Vaccine	[222]
Sym013	DMZM6I2	Phase 1/2	NA	[6]
Sym015	DM9B7Z5	Phase 1/2	NA	[6]
TAEK-VAC-HerBy	DM2RCFU	Phase 1/2	Vaccine	[506]
Talotrexin	DM1AB4L	Phase 1/2	Small molecular drug	[507]
TAPA-pulsed dendritic cell vaccine	DMRNZJ3	Phase 1/2	Vaccine	[508]
TAS-0728	DM13AH8	Phase 1/2	Small molecular drug	[509]
TG02	DMZFIGQ	Phase 1/2	Small molecular drug	[510]
TI-061	DMCNIWW	Phase 1/2	NA	[3]
Timcodar dimesilate	DMDJLX7	Phase 1/2	Small molecular drug	[511]
TKM-PLK1	DMLROMP	Phase 1/2	siRNA drug	[512]
TLC178	DMP6BDX	Phase 1/2	NA	[3]
Tozaride	DMEVCHJ	Phase 1/2	Radiopharmaceutical therapy agent	[513]
TP-0903	DMHTG8P	Phase 1/2	NA	[3]
TPX-0046	DMIVE67	Phase 1/2	Small interfering RNA	[514]
Tractinostat	DM8D2LC	Phase 1/2	NA	[3]
TRICIRIBINE	DM8IC5H	Phase 1/2	Small molecular drug	[515]
Triciribine prodrug	DMBN1XS	Phase 1/2	NA	[516]
TRX-518	DMQS5DY	Phase 1/2	Antibody	[6]
USL311	DM6HPEC	Phase 1/2	NA	[3]
VAL-201	DM0092Q	Phase 1/2	NA	[517]
VE800	DMG8DDD	Phase 1/2	Live biotherapeutic product	[518]
VSSP	DMQ83RZ	Phase 1/2	NA	[519]
WP-1066	DMUGHWR	Phase 1/2	Small molecular drug	[520]
WX-554	DMRABOS	Phase 1/2	NA	[521]
Zenocutuzomab	DMMQGPE	Phase 1/2	Antibody	[522]
BMS-833923	DM459Q7	Phase 1b	Small molecular drug	[523]
1069C	DMSMRC1	Phase 1	Small molecular drug	[524]
123-Iodine-labeled MFE-23	DMCFPX8	Phase 1	Antibody	[525]
18F-BAY-85-8050	DMXYRDW	Phase 1	NA	[526]
212Pb-TCMC-trastuzumab	DM7HRLQ	Phase 1	Monoclonal antibody	[527]
225Ac-labelled FPX-01	DMNHLO5	Phase 1	Radiopharmaceutical therapy agent	[528]
4SC-203	DM8XMPT	Phase 1	NA	[529]
5-FP	DM0351T	Phase 1	Small molecular drug	[530]
609A	DMOIE05	Phase 1	Antibody	[531]
7HP349	DMDC0G0	Phase 1	Vaccine	[532]
8H9	DMQ789Z	Phase 1	Antibody	[533]
90Y-cG250	DMJR6TC	Phase 1	Antibody	[534]
9cUAB-30	DMYKPXJ	Phase 1	NA	[535]
AB122	DMV757W	Phase 1	NA	[3]
ABBV-085	DMSWPPB	Phase 1	NA	[3]
ABBV-151	DMIQXDJ	Phase 1	Antibody	[536]
ABBV-155	DMDG36X	Phase 1	Antibody drug conjugate	[537]
ABBV-176	DM7LGVE	Phase 1	NA	[3]
ABBV-181	DMXVIR7	Phase 1	NA	[3]
ABBV-321	DM4UTNE	Phase 1	NA	[3]
ABBV-368	DMV25OY	Phase 1	NA	[3]
ABBV-399	DMQGPRE	Phase 1	NA	[538]
ABBV-428	DMPD0KL	Phase 1	NA	[3]
ABBV-621	DM90EO3	Phase 1	Small molecular drug	[3]
ABBV-927	DMMSAJ1	Phase 1	NA	[3]
ABBV-CLS-579	DMPXDL6	Phase 1	Antibody	[539]
AbGn-7	DMHNWMO	Phase 1	NA	[540]
ABI-011	DM1KD7U	Phase 1	NA	[541]
ABM-1310	DMS1HR3	Phase 1	Small molecular drug	[542]
ABSK021	DMA4WEO	Phase 1	Small molecular drug	[543]
ABT-165	DMQ3O1U	Phase 1	NA	[3]
ABT-413	DM4KPV0	Phase 1	Antibody	[544]
ABT-767	DMFH3JM	Phase 1	NA	[545]
Ad-VirRx 007	DMWI8RB	Phase 1	NA	[6]
ADC-1013	DMNAT25	Phase 1	NA	[546]
ADCT-502	DMSU5HF	Phase 1	NA	[6]
ADG116	DMEXT97	Phase 1	Antibody	[547]
AFX-9901	DMK66IZ	Phase 1	NA	[548]
AG-024322	DMY4WVK	Phase 1	Small molecular drug	[549]
AG-270	DMYTJG7	Phase 1	NA	[3]
AG2034	DMFU58V	Phase 1	Small molecular drug	[550]
AGEN1181	DMV6JFK	Phase 1	Antibody	[551]
AGEN1223	DMQOER2	Phase 1	NA	[552]
AGEN2373	DMAXVZ1	Phase 1	Antibody	[553]
AGS-22ME	DMYK92D	Phase 1	NA	[554]
AGS-67E	DM78KH5	Phase 1	NA	[555]
AGS-6MF	DMZ7CLV	Phase 1	NA	[556]
AI-850	DMDA1UB	Phase 1	NA	[557]
AK107	DM4FOX0	Phase 1	NA	[3]
ALB-109564(a)	DMHD615	Phase 1	NA	[558]
ALPN-202	DMTD4EF	Phase 1	Protein	[559]
Altiratinib	DMUJCBT	Phase 1	NA	[560]
AMG 211	DMA1I04	Phase 1	NA	[6]
AMG 228	DMLQJ5P	Phase 1	Antibody	[561]
AMG 256	DMXYCZV	Phase 1	Protein	[562]
AMG 404	DMVQX5K	Phase 1	Antibody	[563]
AMG 506	DMG64PE	Phase 1	Protein	[564]
AMG 650	DMRHMZN	Phase 1	Small molecular drug	[565]
AMG 780	DMTGZN8	Phase 1	NA	[566]
AMG 820	DMB6Q19	Phase 1	NA	[567]
AMG 900	DMASGXJ	Phase 1	Small molecular drug	[568]
AMP-224	DMH9M62	Phase 1	Monoclonal antibody	[569]
AMXT1501	DMR35U4	Phase 1	Small molecular drug	[570]
Andes-1537	DMTTGO7	Phase 1	NA	[3]
Angiopoietin 2 mAb	DM1LA9K	Phase 1	NA	[6]
Anti-CD27 agonist	DMRENOX	Phase 1	NA	[3]
Anti-CD73 mAb	DMN6T9A	Phase 1	NA	[6]
Anti-CEA designer T cell therapy	DMG1CCR	Phase 1	NA	[571]
Anti-GITR antibody	DMU1BCP	Phase 1	NA	[6]
Anti-PD-L1	DM0UL47	Phase 1	Antibody	[572]
Anti-PD-L1 mAb	DMON8JH	Phase 1	NA	[3]
Anti-PSMA CAR-T cell therapy	DM5ALT2	Phase 1	NA	[6]
APG-1387	DMLEKUY	Phase 1	NA	[3]
APL-501	DM4WAC2	Phase 1	Antibody	[573]
APTO-253	DMXIKYR	Phase 1	NA	[574]
APX-3330	DMXIMQT	Phase 1	NA	[3]
ARQ 736	DMP9ZT1	Phase 1	NA	[575]
ARQ 751	DM7MWX0	Phase 1	NA	[3]
ARQ-171	DM1FTEC	Phase 1	NA	[576]
ARQ-751	DMBQWVR	Phase 1	Small molecular drug	[577]
ARRY-300	DMMPTCK	Phase 1	NA	[578]
ARRY-380	DMCNV0M	Phase 1	Small molecular drug	[579]
ASG-22ME	DM0Z3JS	Phase 1	Antibody	[580]
ASN003	DMJCX6D	Phase 1	NA	[3]
ASN007	DMYHEUA	Phase 1	NA	[3]
ASP1948	DMC80LV	Phase 1	Antibody	[581]
ASP1951	DMX4PWV	Phase 1	Antibody	[582]
ASP8374	DMA71OL	Phase 1	NA	[3]
ASP9801	DMCDMPW	Phase 1	Oncolytic virus therapy	[583]
ASP9853	DMZDA25	Phase 1	NA	[584]
AST-008	DM7C68W	Phase 1	NA	[3]
AST-1306	DMD83WO	Phase 1	Small molecular drug	[585]
AT001/r84	DMD2BIT	Phase 1	Antibody	[586]
AT13148	DMYIPKJ	Phase 1	NA	[587]
AT7519	DMCE08M	Phase 1	Small molecular drug	[588]
ATI-1123	DMP6EWY	Phase 1	NA	[589]
ATRC-101	DMTG9EV	Phase 1	Antibody	[590]
Atu-027	DML4SIE	Phase 1	NA	[591]
Autologous dendritic cell vaccines	DMUTQFS	Phase 1	NA	[592]
Autologous melanoma cell vaccine	DMARYFK	Phase 1	NA	[593]
Autologous stem cell-based cancer immunotherapy	DMFYAYL	Phase 1	NA	[3]
AutoSynVax	DM326VO	Phase 1	NA	[88]
AV-203	DMZLCTD	Phase 1	Antibody	[594]
AVB-S6-500	DMKCRMD	Phase 1	NA	[3]
AVID200	DMZ39T6	Phase 1	Small molecular drug	[595]
AvidinOx	DMCM83R	Phase 1	NA	[3]
Axatilamab	DMFBMU7	Phase 1	Antibody	[596]
AZD-1152-HQPA	DMMW72C	Phase 1	Small molecular drug	[3]
AZD-2461	DMIFSO3	Phase 1	Small molecular drug	[597]
AZD-5438	DMBQ2TF	Phase 1	Small molecular drug	[598]
AZD0156	DMWCJEU	Phase 1	NA	[3]
AZD1208	DMBEA6V	Phase 1	Small molecular drug	[599]
AZD4785	DMVWMUK	Phase 1	NA	[3]
AZD5153	DMW4GM2	Phase 1	NA	[3]
AZD7762	DM1FW0C	Phase 1	Small molecular drug	[600]
AZD8186	DMWYF1H	Phase 1	Small molecular drug	[601]
AZD8701	DM3EWUX	Phase 1	Antisense oligonucleotide	[602]
B7-2/GM-CSF	DM0LKHV	Phase 1	Small molecular drug	[603]
B7-2/GM-CSF cancer gene therapy vaccine	DM965LK	Phase 1	NA	[604]
BAY 1082439	DMLRGX1	Phase 1	Small molecular drug	[605]
BAY 1834942	DMQIKZG	Phase 1	Antibody	[606]
BAY 1905254	DMNVPI1	Phase 1	Antibody	[607]
BAY 2416964	DMD9N12	Phase 1	Small molecular drug	[608]
BAY 2701439	DM98EP5	Phase 1	Antibody	[609]
BAY 79-4620	DM14XQN	Phase 1	Antibody	[610]
BAY 87-2243	DME8HA3	Phase 1	NA	[611]
BAY 94-9343	DMCQEL6	Phase 1	NA	[612]
BAY-86-4367	DM5C0TC	Phase 1	NA	[613]
BAY-86-7548	DM195JA	Phase 1	NA	[614]
BAY-86-9596	DM9BM9L	Phase 1	NA	[615]
BAY1125976	DMTB4R8	Phase 1	NA	[616]
BAY1129980	DMLATOQ	Phase 1	NA	[617]
BAY1143572	DMVPAZ7	Phase 1	NA	[618]
BAY1161909	DMUK6YM	Phase 1	NA	[619]
BAY1179470	DM7L91K	Phase 1	NA	[620]
BAY1436032	DMPNBJ1	Phase 1	NA	[3]
BAY1895344	DML781M	Phase 1	NA	[3]
BBP-398	DM572ZL	Phase 1	Small molecular drug	[621]
BCA101	DMM0VBU	Phase 1	Antibody	[622]
Belvarafenib	DM0ZNAR	Phase 1	Small molecular drug	[623]
Benzimate	DMAZG29	Phase 1	NA	[624]
BGB-10188	DM84LXE	Phase 1	Small molecular drug	[625]
BGB-15025	DMUP6M5	Phase 1	Small molecular drug	[626]
BGB-A445	DMQMEDH	Phase 1	Antibody	[627]
BI 1701963	DMGMFXJ	Phase 1	Small molecular drug	[628]
BI 3011441	DMFJGUL	Phase 1	Small molecular drug	[629]
BI 754111	DMVH9CF	Phase 1	NA	[3]
BI 765063	DMZMAOW	Phase 1	Antibody	[630]
BI 860585	DMMQ12N	Phase 1	NA	[631]
BI 891065	DMDW5QN	Phase 1	Small molecular drug	[3]
BI 894999	DM7W5N2	Phase 1	NA	[3]
BI 905677	DMEPJ7C	Phase 1	Antibody	[632]
BI 905681	DMXO3PV	Phase 1	Antibody	[633]
BI 905711	DME9NYV	Phase 1	Antibody	[634]
BI 907828	DM2Z4YQ	Phase 1	Small molecular drug	[635]
BI-638683	DM2E50J	Phase 1	NA	[636]
BI-661051	DM1ASTU	Phase 1	NA	[637]
BI-754091	DM3JOIX	Phase 1	Monoclonal antibody	[204]
BI-831266	DMOJZUE	Phase 1	NA	[638]
BI-836845	DM4T916	Phase 1	NA	[639]
BI-836880	DMGFH7T	Phase 1	NA	[6]
BI-847325	DMY4B6J	Phase 1	NA	[640]
BI-853520	DMNOSYW	Phase 1	NA	[641]
BIIB 015	DM5AW7J	Phase 1	Antibody	[642]
BIIB 028	DMTRF71	Phase 1	NA	[643]
BioScavenger	DM95KQ4	Phase 1	NA	[644]
BIWA 4	DM61JH5	Phase 1	Antibody	[645]
BJ-001	DM5ICUT	Phase 1	Recombinant protein	[646]
BLY719	DMYHNV3	Phase 1	NA	[647]
BMS-908662	DM3K8VM	Phase 1	Small molecular drug	[648]
BMS-986148	DMYJ3C0	Phase 1	NA	[3]
BMS-986179	DM9I0SO	Phase 1	NA	[3]
BMS-986226	DMO0EE4	Phase 1	NA	[3]
BMS-986242	DMHP4AX	Phase 1	NA	[3]
BMS-986249	DMHTEZ8	Phase 1	Antibody	[3]
BMS-986258	DMPWCGR	Phase 1	NA	[3]
BMS-986299	DMTMUWJ	Phase 1	Small molecular drug	[3]
BMS-986301	DMM3DBU	Phase 1	Small molecular drug	[649]
BN-brachyury cancer vaccine	DMK13YW	Phase 1	NA	[3]
BNT131	DMHHGD7	Phase 1	Gene therapy	[650]
BOS172722	DMU790L	Phase 1	NA	[3]
BOS172738	DM9L0D8	Phase 1	Small molecular drug	[651]
BPI-9016 M	DMNY0U5	Phase 1	Small molecular drug	[652]
Briciclib	DMK7BND	Phase 1	Small molecular drug	[653]
BTP-114	DMVDWME	Phase 1	NA	[3]
BTRC4017A	DMIGUY9	Phase 1	NA	[3]
BVD-CNV	DMQ1ALY	Phase 1	NA	[654]
BXQ-350	DMKJO3A	Phase 1	Recombinant protein	[3]
C188-9	DMOV2ZD	Phase 1	NA	[3]
C4.4a-ADC	DMMUR6D	Phase 1	NA	[655]
CA-170	DMOUHR4	Phase 1	Small molecule immunotherapy	[3]
CA102N	DMYDNQ2	Phase 1	Small molecular drug	[656]
CALAA-01	DMT4Z5B	Phase 1	NA	[657]
CAR-T cells targeting CD80/86	DM6Z7AD	Phase 1	CAR T Cell Therapy	[413]
CAR-T cells targeting HER2	DMLI5VG	Phase 1	CAR T Cell Therapy	[413]
CAR-T cells targeting Lewis-Y	DMGI58S	Phase 1	CAR T Cell Therapy	[413]
CAR-T cells targeting Mesothelin	DMTZXSO	Phase 1	CAR T Cell Therapy	[413]
CAR-T cells targeting PSCA	DMU4G9J	Phase 1	CAR T Cell Therapy	[413]
Cavrotolimod	DMO53AD	Phase 1	Small molecular drug	[658]
CB-24	DMNHEBP	Phase 1	NA	[659]
CB-5083	DM12GN7	Phase 1	NA	[3]
CBLC137	DMY8CZP	Phase 1	Small molecular drug	[3]
CBT-101	DMOTLN4	Phase 1	NA	[3]
CBT-501	DMW1OKT	Phase 1	NA	[3]
CC-11006	DMAPGUI	Phase 1	NA	[660]
CC-122	DM0SRAN	Phase 1	Small molecular drug	[661]
CC-90002	DMK0QDO	Phase 1	Antibody	[6]
CC-90010	DMKH3Z9	Phase 1	NA	[3]
CC-95251	DM7E1W0	Phase 1	Antibody	[662]
CC49 humanized radioimmunoconjugates	DMXV6EZ	Phase 1	NA	[663]
CDX-0158	DM9RONX	Phase 1	NA	[3]
CDX-1127	DMPVUGE	Phase 1	NA	[664]
CDX-1140	DMUGN0J	Phase 1	Antibody	[3]
CDX-527	DMVDIWO	Phase 1	Antibody	[665]
CEP-11981	DMYDTJ6	Phase 1	Small molecular drug	[666]
CEP-37440	DMV632P	Phase 1	Small molecular drug	[667]
CFI-402257	DMH701Q	Phase 1	Small molecular drug	[668]
CG-200745	DM3U2VY	Phase 1	NA	[669]
CGM097	DMTCLM3	Phase 1	NA	[670]
CGTG-102	DMAY8I4	Phase 1	NA	[671]
CGX1321	DMDWATG	Phase 1	NA	[3]
CI-8993	DM2OB6S	Phase 1	Antibody	[672]
Cipatinib	DMJLNEF	Phase 1	NA	[673]
Citatuzumab bogatox	DMRJF2Q	Phase 1	Antibody	[674]
CK-301	DMXS7I7	Phase 1	NA	[3]
CKD-516	DMGSEB0	Phase 1	Small molecular drug	[675]
CKD-712	DMJX6SM	Phase 1	NA	[676]
CNTO888	DMUBP0V	Phase 1	Antibody	[677]
CNV-NT	DMK5MZI	Phase 1	NA	[3]
COH29	DMMEFO0	Phase 1	NA	[3]
COM701	DMXQOHV	Phase 1	Antibody	[678]
COM902	DMR6T8L	Phase 1	Antibody	[679]
CP-870,893	DM32TFO	Phase 1	Small molecular drug	[680]
CPI-006	DMJSFTX	Phase 1	Antibody	[681]
CPI-100	DMMXW73	Phase 1	NA	[682]
CPI-200	DMXA5K0	Phase 1	NA	[683]
CST-101	DMEE6NG	Phase 1	NA	[684]
CT-200	DMW16VR	Phase 1	NA	[685]
CTX-471	DMMPKN3	Phase 1	Antibody	[686]
CUDC-101	DM9ZOMD	Phase 1	Small molecular drug	[687]
CUDC427	DM2LNDV	Phase 1	NA	[26]
Curmucin	DM05P9R	Phase 1	NA	[688]
CVX-241	DMV74JC	Phase 1	NA	[689]
CWP-231	DMRGFBU	Phase 1	NA	[690]
CXD-101	DMRD2B0	Phase 1	NA	[691]
CXR-1002	DM4GJ50	Phase 1	NA	[692]
CYAD-01	DMWJRM8	Phase 1	NA	[3]
CYC065	DM9ODT6	Phase 1	NA	[3]
CYC116	DMUMHXT	Phase 1	Small molecular drug	[693]
Cyclopentenylcytosine	DMAWVTX	Phase 1	Small molecular drug	[694]
CYT-609	DMJ83Z7	Phase 1	NA	[695]
CYT-6091	DMJQYGR	Phase 1	NA	[695]
CZ-48	DMAY6X2	Phase 1	Small molecular drug	[696]
D-20133	DMTP9ER	Phase 1	Small molecular drug	[697]
D-3263	DM7V2OM	Phase 1	Small molecular drug	[698]
DABIS MALEATE	DMQR4HA	Phase 1	Small molecular drug	[699]
DAVLB-HYDRAZIDE	DM4A3U7	Phase 1	Small molecular drug	[700]
Debio 0932	DMWP3G1	Phase 1	NA	[701]
DFP 13318	DMI8QNB	Phase 1	NA	[3]
DFP-11207	DMY6QFH	Phase 1	NA	[702]
DFP-14927	DMGO4XJ	Phase 1	Small molecular drug	[703]
DKY709	DMPWOH9	Phase 1	Small molecular drug	[704]
DLYE-5953A	DM4MNY8	Phase 1	NA	[705]
DN1406131	DMQFX8R	Phase 1	Small molecular drug	[706]
DN1508052	DM0JT9C	Phase 1	Small molecular drug	[707]
DpC	DM4ZDOE	Phase 1	Small molecular drug	[708]
DRF-1042	DMJY9TW	Phase 1	Small molecular drug	[709]
Drug 2849330	DMM57CS	Phase 1	Antibody	[710]
DS-1055	DMPR3A6	Phase 1	Antibody	[711]
DS-2248	DMZNNEX	Phase 1	NA	[712]
DS-3032	DMA2B5Y	Phase 1	NA	[713]
DS-3078	DMG7I5J	Phase 1	NA	[714]
DS-6051	DM0RD4F	Phase 1	NA	[715]
DS-7423	DMCFJM3	Phase 1	NA	[716]
DS-8273	DMJPUDW	Phase 1	Antibody	[717]
DS-8895	DM31VNC	Phase 1	Antibody	[718]
DSP-0337	DM4ZCY0	Phase 1	Small molecular drug	[719]
DWP-418	DMU696J	Phase 1	NA	[720]
E-7107	DM3EDSA	Phase 1	Small molecular drug	[721]
E7766	DM8TU5R	Phase 1	Small molecular drug	[722]
EC0225	DMVKFYS	Phase 1	Small molecular drug	[723]
EC0489	DM8RD4T	Phase 1	Small molecular drug	[724]
EC1456	DM97KUZ	Phase 1	NA	[725]
EI1071	DMXAUB7	Phase 1	Small molecular drug	[726]
ELEMENE	DMJBZC9	Phase 1	Small molecular drug	[727]
ELOMOTECAN HYDROCHLORIDE	DMQPI4V	Phase 1	Small molecular drug	[728]
Emactuzumab	DM4W7Z0	Phase 1	NA	[6]
EMD-1204831	DM38JZU	Phase 1	NA	[729]
Enadenotucirev	DM5XXI3	Phase 1	NA	[3]
Enavatuzumab	DMBIPQL	Phase 1	Antibody	[730]
Enkastim-ev	DMGLHYU	Phase 1	NA	[731]
ENMD-1198	DM9BJ3G	Phase 1	Small molecular drug	[732]
Entolimod	DMMJXAR	Phase 1	NA	[3]
EOS100850	DMQ6GUY	Phase 1	Small molecular drug	[733]
Epstein Barr-based gene therapy	DMGN1RB	Phase 1	NA	[734]
ERY974	DM9YNTO	Phase 1	NA	[3]
ETC-1922159	DMY0HU6	Phase 1	NA	[3]
ETS-2101	DM9AJYN	Phase 1	NA	[735]
EZN-2968	DM2NBC7	Phase 1	NA	[736]
EZN-3042	DMXFY18	Phase 1	NA	[736]
FATE-NK100	DMT8WXM	Phase 1	NA	[3]
FAZ053	DM71HLX	Phase 1	Monoclonal antibody	[3]
FF-10502-01	DMX5290	Phase 1	NA	[3]
FFC-14A	DM2GHIP	Phase 1	NA	[737]
Fludarabine phosphate	DMX2PJD	Phase 1	NA	[738]
Fluorapacin	DMJOD9R	Phase 1	NA	[739]
FN-1501	DM7BMD6	Phase 1	Small molecular drug	[740]
FPA150	DMEPWVM	Phase 1	NA	[3]
FPI-1434	DMI9A1Z	Phase 1	Radiopharmaceutical therapy	[528]
FPT155	DMJINLQ	Phase 1	Recombinant protein	[741]
G1T28-1	DML028U	Phase 1	NA	[742]
GALAMUSTINE HYDROCHLORIDE	DMJLIQ2	Phase 1	Small molecular drug	[743]
GAP T cells	DMIXMQE	Phase 1	CAR T Cell Therapy	[744]
GBR1302	DM52O7W	Phase 1	Antibody	[745]
GDC-0152	DM1B3UM	Phase 1	Small molecular drug	[26]
GDC-0623	DMDY08K	Phase 1	Small molecular drug	[746]
GDC-0994	DMFC2OY	Phase 1	NA	[747]
GDC-5573	DMJA27W	Phase 1	NA	[3]
GEN1029	DMV8IWJ	Phase 1	Antibody	[748]
GEN1042	DMNP6T3	Phase 1	Antibody	[749]
GEN1044	DMQ9317	Phase 1	Antibody	[750]
GEN1046	DMEWRNZ	Phase 1	Antibody	[751]
Genz-644282	DMIXABW	Phase 1	Small molecular drug	[752]
GGTI-2418	DM8U23L	Phase 1	NA	[753]
Glypican3-ADC	DM0DKFY	Phase 1	NA	[6]
GM-CT-01	DMXTRNO	Phase 1	NA	[754]
GMI-1359	DML1KSA	Phase 1	Small molecular drug	[3]
GMX1777	DMIFSN2	Phase 1	Small molecular drug	[755]
GNX102	DMKMU2S	Phase 1	Antibody	[756]
Gp75 DNA vaccine	DMGHNTA	Phase 1	NA	[757]
GQ1001	DMFA2XQ	Phase 1	Antibody drug conjugate	[758]
GS-1423	DMS25DL	Phase 1	Antibody	[759]
GS-1811	DMCEMC6	Phase 1	Antibody	[760]
GS-5829	DMZVFOQ	Phase 1	NA	[3]
GSK-2256098	DMR24MI	Phase 1	Small molecular drug	[761]
GSK1070916A	DMCJUI9	Phase 1	NA	[762]
GSK1795091	DMC6QE4	Phase 1	NA	[3]
GSK2636771	DMCBGLW	Phase 1	Small molecular drug	[763]
GSK2661380	DMAK89L	Phase 1	Antibody	[569]
GSK2816126	DMJDVW4	Phase 1	Small molecular drug	[764]
GSK2820151	DMU1X8K	Phase 1	Small molecular drug	[765]
GSK2849330	DM6KE4G	Phase 1	Antibody	[710]
GSK3052230	DMCKNJX	Phase 1	NA	[766]
GSK3174998	DMDRLHR	Phase 1	NA	[6]
GSK3368715	DMVEGND	Phase 1	Small molecular drug	[767]
GSK3745417	DMRYNJD	Phase 1	NA	[768]
GSK3845097	DM1UQ4Y	Phase 1	TCR-T cell therapy	[769]
GSK3901961	DMN4I7P	Phase 1	TCR-T cell therapy	[769]
GSK4074386	DMI3FU6	Phase 1	Antibody	[769]
GSK461364	DM0P729	Phase 1	Small molecular drug	[770]
GSK525762	DMPAWBN	Phase 1	Small molecular drug	[771]
GSK6097608	DMWI0AL	Phase 1	Antibody	[772]
GWN323	DM2L2K0	Phase 1	NA	[6]
GX-G3	DM26RE4	Phase 1	NA	[773]
GZ17-6.02	DMVUZE6	Phase 1	NA	[774]
GZ402674	DMTWNLY	Phase 1	NA	[775]
HCBE-11	DMHI8RS	Phase 1	Antibody	[776]
HD-201	DME361E	Phase 1	NA	[777]
HDM201	DMVRTCW	Phase 1	NA	[3]
HER-2/HER-1 vaccine	DMXETUQ	Phase 1	Vaccine	[778]
HER2p63-71 peptide vaccine	DMJ52F9	Phase 1	Vaccine	[779]
Heterodimeric IL-15	DMOFWJH	Phase 1	NA	[6]
HGS-1029	DMS9WXG	Phase 1	NA	[26]
HH2853	DMQIE58	Phase 1	Small molecular drug	[780]
HKT288	DMQCKSB	Phase 1	NA	[6]
HPP-607	DM5VSZR	Phase 1	NA	[781]
HS-130	DMWBRPN	Phase 1	Cell therapy	[782]
HSP-990	DML6HP3	Phase 1	Small molecular drug	[783]
HTERT plasmid DNA cancer vaccine	DMC7C4E	Phase 1	NA	[784]
HTERT vaccine	DMVHC1X	Phase 1	NA	[785]
HTI-1066	DMJAL07	Phase 1	NA	[3]
HTI-1090	DMI4TEC	Phase 1	Small molecular drug	[786]
HuL2G7	DMKZZGE	Phase 1	NA	[6]
human allogeneic NK cell	DMLY92U	Phase 1	NA	[3]
Human and mouse gp100 DNA plasmid vaccines	DMPNRQF	Phase 1	NA	[787]
Human microbio modulator	DMYZP7G	Phase 1	NA	[3]
ICT-121	DM64LVS	Phase 1	Vaccine	[788]
IGM-8444	DMFJXDZ	Phase 1	Antibody	[789]
IM156	DM4MY9C	Phase 1	NA	[3]
IMA 203	DMD9U5Q	Phase 1	Cell therapy	[790]
IMA101	DMFEL1P	Phase 1	NA	[3]
IMA202	DMUI5A2	Phase 1	NA	[3]
IMC-002	DMWSI04	Phase 1	Antibody	[791]
IMC-3C5	DMXI5ON	Phase 1	NA	[792]
IMC-CS4	DMUYN26	Phase 1	NA	[793]
IMC-TR1	DM9FU4P	Phase 1	NA	[794]
IMF-001	DMG9WJO	Phase 1	NA	[795]
IMGC936	DMUVLC4	Phase 1	Antibody drug conjugate	[796]
IMGN-388	DMSYB83	Phase 1	Antibody	[797]
IMGN-853	DMR8OG2	Phase 1	NA	[798]
IMGN289	DMT9MHE	Phase 1	NA	[799]
IMP-701	DMXSMF9	Phase 1	Antibody	[6]
In-111-DAC imaging agent	DMU3YL2	Phase 1	NA	[800]
INB03	DMCQTLG	Phase 1	Protein	[801]
INBRX-105	DM2FH10	Phase 1	Antibody	[802]
INBRX-109	DMUNSPI	Phase 1	Antibody drug conjugate	[803]
INCAGN2390	DM5SO1T	Phase 1	Antibody	[804]
INCB81776	DMFOXGB	Phase 1	Small molecular drug	[805]
INCB99280	DMUC1M7	Phase 1	NA	[806]
ING-1	DM5WCBM	Phase 1	Antibody	[807]
INNO-105	DM601GL	Phase 1	NA	[808]
INO-1400	DMLN5E4	Phase 1	NA	[3]
INTOPLICINE	DMXPLMN	Phase 1	Small molecular drug	[809]
INV-1120	DMELYJ9	Phase 1	Small molecular drug	[810]
IPH5201	DMFEI6T	Phase 1	Antibody	[811]
IRX-5183	DMCED9U	Phase 1	NA	[3]
IT-139	DMBPV9W	Phase 1	NA	[812]
IT-141	DMAYD7O	Phase 1	NA	[3]
JAB-3068	DMSGEU6	Phase 1	Small molecular drug	[813]
JNJ-26483327	DMSQ3AZ	Phase 1	NA	[814]
JNJ-26854165	DMNSJ3C	Phase 1	Small molecular drug	[26]
JNJ-38877605	DMDIPW8	Phase 1	Small molecular drug	[815]
JNJ-61610588	DMSPQDM	Phase 1	NA	[6]
JNJ-63898081	DMJFK6X	Phase 1	Antibody	[816]
JNJ-64457107	DMJ814M	Phase 1	NA	[6]
JNJ-64619178	DMDBW2N	Phase 1	Small molecular drug	[817]
JNJ-70218902	DMTLGKX	Phase 1	Antibody	[818]
JNJ-74699157	DMY7CW1	Phase 1	NA	[819]
JS004	DMFMWLQ	Phase 1	Antibody	[820]
JSI-1187	DMVJWBS	Phase 1	Small molecular drug	[821]
JX-929	DMW5J9B	Phase 1	NA	[822]
KA2507	DMW0H9Y	Phase 1	NA	[3]
KAZ954	DM9BX64	Phase 1	NA	[823]
KD033	DMTYNRB	Phase 1	Recombinant protein	[824]
Keratinocyte growth factor	DMZK7N8	Phase 1	NA	[825]
KH-901	DMR14VE	Phase 1	Vaccine	[826]
KHK2455	DMLSUQ8	Phase 1	NA	[3]
Ki23819	DMIAVBL	Phase 1	NA	[827]
KITE-439	DMUB3H9	Phase 1	TCR-T cell therapy	[828]
KITE-718	DMBSI6Y	Phase 1	TCR-T cell therapy	[6]
KML-001	DM1D2O0	Phase 1	NA	[829]
KO-947	DMZMSBI	Phase 1	NA	[3]
KPT-9274	DM9JXMD	Phase 1	NA	[3]
KRN633	DMODGJU	Phase 1	Small molecular drug	[830]
KTN3379	DM8FQPX	Phase 1	Antibody	[831]
L-MDAM	DMU901D	Phase 1	Small molecular drug	[832]
LEQ-506	DM5INZP	Phase 1	NA	[833]
LErafAON	DMNHPOT	Phase 1	Antisense drug	[834]
LFA-102	DMI4O92	Phase 1	Antibody	[835]
LGK974	DMAG6BV	Phase 1	Small molecular drug	[836]
LHC165	DMYK52O	Phase 1	Small molecular drug	[837]
LMP744	DMUCQYW	Phase 1	Small molecular drug	[838]
LOXO-195	DMDXFBJ	Phase 1	NA	[3]
LP-261	DM39AME	Phase 1	Small molecular drug	[839]
Lpathomab	DMAWLB4	Phase 1	Monoclonal antibody	[840]
LTT462	DM94E6W	Phase 1	NA	[3]
LTX-315	DM3DORL	Phase 1	NA	[841]
LUpartumab amadotin	DME1MP7	Phase 1	NA	[3]
LVGN6051	DMPQE2S	Phase 1	Antibody	[842]
LY-203725	DM9WYVT	Phase 1	NA	[700]
LY-2334737	DMCBV20	Phase 1	Small molecular drug	[843]
LY-2584702	DML8M3B	Phase 1	Small molecular drug	[844]
LY2624587	DM289Z4	Phase 1	Antibody	[845]
LY2780301	DM93AJW	Phase 1	NA	[846]
LY3009120	DM6PFCN	Phase 1	NA	[847]
LY3022855	DMZRRA2	Phase 1	NA	[6]
LY3076226	DMYMOEC	Phase 1	NA	[6]
LY309887	DMJPCHK	Phase 1	Small molecular drug	[848]
LY3164530	DM9RTXM	Phase 1	Monoclonal antibody	[6]
LY3200882	DMQP6VB	Phase 1	NA	[3]
LY3214996	DMFDAY7	Phase 1	NA	[3]
LY3300054	DMOV2ML	Phase 1	Monoclonal antibody	[204]
LY3321367	DMD51GC	Phase 1	NA	[3]
LY3381916	DMONZ1L	Phase 1	NA	[3]
LY3405105	DMB51K2	Phase 1	Small molecular drug	[849]
LY3410738	DMFU0H5	Phase 1	Small molecular drug	[850]
LY3415244	DM5QO1A	Phase 1	Antibody	[851]
LY3475070	DMZLIWX	Phase 1	NA	[852]
LYS-6KAKT1	DMLXGAI	Phase 1	NA	[853]
LZM009	DMHDCSL	Phase 1	Monoclonal antibody	[204]
M1774	DMP8QY2	Phase 1	Small molecular drug	[854]
M2698	DM3PVBJ	Phase 1	NA	[855]
M3541	DMG98QO	Phase 1	NA	[3]
M4344	DMQBO3V	Phase 1	NA	[3]
M6223	DM6J085	Phase 1	Antibody	[856]
M802	DM132EG	Phase 1	Antibody	[857]
M8891	DMZ9NVP	Phase 1	NA	[3]
M9831	DM59TI2	Phase 1	NA	[3]
MAGE-A4 TCR	DMY7DHS	Phase 1	NA	[3]
MB-311	DMJEUN7	Phase 1	NA	[858]
MBS301	DM85AXS	Phase 1	Antibody	[859]
MCLA-145	DM8CGUV	Phase 1	Antibody	[860]
MCLA-158	DMF0O3X	Phase 1	Antibody	[861]
MDAM (y-methylene-10-deazaaminopterin)	DM1DISM	Phase 1	NA	[862]
MDX-018	DML5FX2	Phase 1	NA	[6]
MDX-1203	DM0RIQF	Phase 1	Antibody	[863]
MDX-1411	DM3402P	Phase 1	Antibody	[864]
ME-143	DMHYW5E	Phase 1	Small molecular drug	[865]
MEDI-0639	DM3D8GV	Phase 1	NA	[866]
MEDI-547	DM3WP70	Phase 1	Antibody	[867]
MEDI-573	DMNL8MO	Phase 1	NA	[868]
MEDI0562	DMYVBU6	Phase 1	NA	[3]
MEDI0680	DMPLFBV	Phase 1	Monoclonal antibody	[869]
MEDI1191	DMD9OVI	Phase 1	mRNA therapy	[870]
MEDI1873	DM10OTV	Phase 1	NA	[3]
MEDI3617	DM0H5JD	Phase 1	Antibody	[871]
MEDI4276	DMNI60O	Phase 1	NA	[3]
MEDI5083	DMO75Z3	Phase 1	NA	[3]
MEDI5395	DMR1455	Phase 1	Oncolytic virus therapy	[872]
MEDI5752	DMJ1E24	Phase 1	Antibody	[873]
MEDI6383	DM1YSMD	Phase 1	Antibody	[874]
MEDI9197	DM0J7UR	Phase 1	NA	[3]
MEDI9447	DMKLLXB	Phase 1	NA	[6]
MG-1102	DMQE4IX	Phase 1	NA	[875]
MGD009	DME4B8I	Phase 1	NA	[3]
MGD019	DM2BYWI	Phase 1	Antibody	[876]
MGN-1706	DMTS5VF	Phase 1	NA	[877]
Minnelide	DMDER9S	Phase 1	NA	[3]
MINT-1526A	DMHZI6H	Phase 1	NA	[878]
Mivebresib	DMCPF90	Phase 1	NA	[3]
MK-0482	DM30YFY	Phase 1	NA	[879]
MK-0731	DM2TAUR	Phase 1	Small molecular drug	[880]
MK-1248	DMRS1CM	Phase 1	NA	[3]
MK-1496	DME1ZAH	Phase 1	NA	[881]
MK-2118	DMKNH8B	Phase 1	Small molecular drug	[3]
MK-4166	DML5V76	Phase 1	Antibody	[882]
MK-4280	DMCA1NX	Phase 1	Antibody	[3]
MK-4621	DMN40DU	Phase 1	NA	[883]
MK-4830	DMCT37W	Phase 1	Antibody	[884]
MK-5108	DMFGYKS	Phase 1	Small molecular drug	[885]
MK-7162	DMBSXZ1	Phase 1	NA	[3]
MK-7252	DME1Q91	Phase 1	NA	[3]
MK-8033	DMA1EDN	Phase 1	Small molecular drug	[886]
MK-8353	DMLCTI5	Phase 1	NA	[3]
MKC-1106-PP	DMSDYWI	Phase 1	NA	[887]
MLN7243	DMWK951	Phase 1	NA	[888]
MLN8054	DMUANF3	Phase 1	Small molecular drug	[889]
MM-151	DMXQHZC	Phase 1	NA	[890]
MM-310	DMGMDA5	Phase 1	NA	[3]
MN-201	DMTST96	Phase 1	NA	[891]
MNK-010	DM811L4	Phase 1	NA	[892]
MORAb-066	DMTUKW9	Phase 1	Antibody	[3]
MORAb-28	DMPH27Y	Phase 1	NA	[893]
MOv18IgE	DM0GS0Z	Phase 1	NA	[894]
MPC-2130	DMF7V9W	Phase 1	NA	[895]
MPC-3100	DM3RU6N	Phase 1	Small molecular drug	[896]
mRNA-2416	DMFTAWU	Phase 1	mRNA therapy	[3]
mRNA-2752	DMUKBI2	Phase 1	mRNA therapy	[897]
MRX-2843	DMM5N8P	Phase 1	Small molecular drug	[898]
MS201408-0005A	DM9L0G6	Phase 1	NA	[3]
MS201408-0005B	DMVH2UB	Phase 1	NA	[3]
MS201408-0005C	DM7N9HJ	Phase 1	NA	[3]
MSB2311	DMH8VXE	Phase 1	Monoclonal antibody	[204]
MSC-1	DM6XTZL	Phase 1	Antibody	[899]
MSC2015103B	DMV6X6I	Phase 1	NA	[900]
MSX-122	DM1N9YS	Phase 1	Small molecular drug	[901]
MT-110	DMPCUN5	Phase 1	Antibody	[902]
MT-112	DMT0EBU	Phase 1	Antibody	[903]
MT-5111	DM5SN0A	Phase 1	Recombinant?protein	[904]
MTIG7192A	DM26YYC	Phase 1	NA	[3]
MTRN-2696	DMZ8L8S	Phase 1	NA	[905]
MUC-1 CD40L dendritic cell vaccine	DMC6PT0	Phase 1	NA	[88]
MUC-1 dendritic cancer vaccine	DMG4QDT	Phase 1	Vaccine	[906]
MVA p53 vaccine	DMYU9BX	Phase 1	NA	[88]
MVA-BN Brachyury	DMVN996	Phase 1	Vaccine	[907]
MVA-BN brachyury vaccine	DM9X3FA	Phase 1	NA	[6]
MVT-1075	DM8X0L6	Phase 1	NA	[3]
MVT-5873	DMEJ4C1	Phase 1	NA	[3]
Namitecan	DMMKZYV	Phase 1	Small molecular drug	[908]
NBM-BMX	DM5OWXA	Phase 1	Small molecular drug	[909]
NC-4016	DMM2SNG	Phase 1	NA	[910]
NC-6300	DM8WXJX	Phase 1	NA	[3]
NEO-201	DM830EN	Phase 1	Antibody	[911]
NeoTCR-P1	DM6FOK4	Phase 1	TCR-T cell therapy	[912]
Nesvacumab	DM59ZDN	Phase 1	Antibody	[913]
NEV-801	DM9XKES	Phase 1	NA	[3]
NG-348	DMO5SY7	Phase 1	NA	[3]
NG-350A	DMQK5ET	Phase 1	Gene therapy	[914]
NG-641	DMITVHM	Phase 1	Gene therapy	[915]
NGM120	DMF21XQ	Phase 1	Antibody	[916]
NHS-IL 12	DMU6CQ7	Phase 1	NA	[917]
NIZ985	DMFVT1Z	Phase 1	NA	[3]
NK-314	DMGSDPL	Phase 1	NA	[918]
NKP-1339	DM5AWK1	Phase 1	Small molecular drug	[919]
NKTR-105	DMHW111	Phase 1	NA	[920]
NLG802	DMP9J5V	Phase 1	NA	[3]
NLG919	DMYPWHD	Phase 1	Small molecular drug	[921]
NM-3	DM5INE7	Phase 1	Small molecular drug	[922]
NMS-03305293	DM2XIRW	Phase 1	Small molecular drug	[923]
NOUS-209	DM54JZO	Phase 1	Vaccine	[924]
NOV1501	DME2QUZ	Phase 1	Antibody	[925]
NP-G2-044	DMZ72BD	Phase 1	NA	[3]
NSC-281612	DMKMYS4	Phase 1	Small molecular drug	[926]
NSC-639829	DMTYGWV	Phase 1	Small molecular drug	[927]
NUC-3373	DMQ0F5P	Phase 1	Small molecular drug	[928]
NV-196	DMZ7QN8	Phase 1	Small molecular drug	[929]
NY-ESO-1 vaccine	DM0EKUQ	Phase 1	Vaccine	[930]
NZV930	DMWN2FP	Phase 1	Antibody	[931]
OBP-801	DMPLV9G	Phase 1	NA	[932]
OKI 179	DMSJWTE	Phase 1	Small molecular drug	[933]
Oleclumab	DMLVNWO	Phase 1	NA	[3]
OM-174	DM2THBX	Phase 1	NA	[934]
OMN-54	DMWHZEG	Phase 1	NA	[935]
OMP-131R10	DMTFU8Q	Phase 1	Antibody	[936]
OMP-18R5	DMWK679	Phase 1	NA	[937]
OMP-21M18	DMX1D0S	Phase 1	NA	[938]
OMP-313M32	DM9CL9V	Phase 1	NA	[3]
OMP-336B11	DMVTOMR	Phase 1	NA	[3]
OMP-52M51	DMGWC86	Phase 1	Antibody	[939]
Omtriptolide	DMZU1Z1	Phase 1	Small molecular drug	[940]
ONC-392	DM8B40M	Phase 1	Antibody	[941]
ONCR-177	DMIPQTK	Phase 1	Oncolytic virus therapy	[942]
ONO-4578	DME63VK	Phase 1	NA	[3]
ONT-10	DMUZFVH	Phase 1	Vaccine	[943]
ONX-0801	DMNOQST	Phase 1	NA	[944]
OPB-111077	DM7YFW5	Phase 1	Small interfering RNA	[3]
OPB-51602	DM760FA	Phase 1	NA	[945]
Oradoxel	DMXW33H	Phase 1	NA	[3]
Oral-Vimo-001	DMHBOC2	Phase 1	NA	[3]
Oratecan	DMWW1YB	Phase 1	NA	[946]
ORB-101	DMKI3EJ	Phase 1	NA	[3]
ORIC-101	DMR12S0	Phase 1	NA	[3]
OSI-930	DMF2CZ9	Phase 1	Small molecular drug	[947]
P-7170	DMIYQEM	Phase 1	NA	[948]
P1446A-05	DMXHKYJ	Phase 1	NA	[949]
P28 cell penetrating peptide	DMA2JQD	Phase 1	NA	[950]
PAN-90806	DMY9LG1	Phase 1	NA	[951]
PB-357	DMHS9TC	Phase 1	NA	[952]
PBF-999	DMBSQH9	Phase 1	Small molecular drug	[953]
pbi-shRNA STMN1	DM529QO	Phase 1	Short hairpin RNA	[954]
PCA062	DM1GNEH	Phase 1	NA	[6]
PD-L1 mAb + LY	DMU4K5P	Phase 1	NA	[3]
PD-L1 t-haNK	DMLJHM2	Phase 1	CAR T Cell Therapy	[955]
PDM-08	DMZYTWR	Phase 1	NA	[956]
PENCLOMEDINE	DMTEG6B	Phase 1	Small molecular drug	[957]
Perifosine	DMVYRH2	Phase 1	Small molecular drug	[958]
PF-00337210	DM5PUO0	Phase 1	Small molecular drug	[959]
PF-05082566	DMAEK3L	Phase 1	NA	[6]
PF-06263507	DM5KBDY	Phase 1	Antibody	[960]
PF-06647020	DM3RFYY	Phase 1	NA	[3]
PF-06647020	DMNLK5Y	Phase 1	NA	[6]
PF-06647263	DMUUTE9	Phase 1	NA	[961]
PF-06650808	DMF8RZM	Phase 1	NA	[962]
PF-06664178	DMM8SXQ	Phase 1	NA	[963]
PF-06671008	DMK19V6	Phase 1	NA	[3]
PF-06688992	DM2VCI3	Phase 1	NA	[3]
PF-06747775	DM96AKV	Phase 1	NA	[3]
PF-06801591	DMDE9I6	Phase 1	Antibody	[204]
PF-06804103	DMWKFFV	Phase 1	NA	[3]
PF-06939999	DM7BOFR	Phase 1	NA	[964]
PF-06940434	DMYP9WR	Phase 1	NA	[965]
PF-06952229	DMDQJEZ	Phase 1	Small molecular drug	[966]
PF-07062119	DME3BJL	Phase 1	Antibody	[967]
PF-07265807	DMSMNRQ	Phase 1	Small molecular drug	[968]
PF-3732010	DMG2IE5	Phase 1	Antibody	[969]
PF-3758309	DM36PKZ	Phase 1	Small molecular drug	[970]
PF-4217903	DMU2A6D	Phase 1	Small molecular drug	[971]
PF-562271	DMSLE03	Phase 1	Small molecular drug	[972]
PFK-158	DMIR21F	Phase 1	NA	[973]
PHA-793887	DM2Y4FG	Phase 1	Small molecular drug	[974]
PIN-2	DMRPVJO	Phase 1	Peptide	[3]
PL-225B	DMIHWTP	Phase 1	NA	[975]
PLX51107	DMXLHVW	Phase 1	NA	[3]
PLX73086	DMED2WN	Phase 1	NA	[3]
PLX7486	DM0IVGU	Phase 1	NA	[3]
PM-060184	DMFVQOW	Phase 1	NA	[976]
PRN1371	DMR7BAO	Phase 1	NA	[3]
PRS-050	DMSOK2F	Phase 1	NA	[977]
PRS-343	DM2A9XT	Phase 1	NA	[3]
PRT543	DMHNZ3U	Phase 1	Small molecular drug	[978]
PRT6207	DMP5CLY	Phase 1	NA	[979]
PT-112	DMB6M1P	Phase 1	Small molecular drug	[980]
PTX-100	DMAWO5I	Phase 1	NA	[3]
PTX-35	DM38F50	Phase 1	Antibody	[981]
PU-H71	DMIYHAW	Phase 1	Small molecular drug	[982]
PU3	DMJO0BP	Phase 1	Small molecular drug	[983]
PV-701	DMUVZ38	Phase 1	NA	[984]
PWT-33597	DMJY15D	Phase 1	NA	[985]
PX-478	DM4AU8K	Phase 1	Small molecular drug	[986]
Pyrotinib	DMW7K39	Phase 1	NA	[3]
QBI-139	DMSVHR5	Phase 1	NA	[987]
QBS10072S	DM0SZQY	Phase 1	NA	[988]
RBBX-01	DM3V2EH	Phase 1	NA	[989]
RBN-2397	DMAP6CS	Phase 1	Small molecular drug	[990]
Recombinant human Erbb3 fragment therapeutic tumor vaccine	DMK9Y71	Phase 1	Vaccine	[991]
REGN-421	DMWJ0IH	Phase 1	Antibody	[992]
REGN-910	DMHR7D4	Phase 1	Antibody	[993]
REGN1400	DME3VU8	Phase 1	Antibody	[994]
REGN3767	DM8XMBQ	Phase 1	NA	[6]
RG6139	DMJFM3O	Phase 1	Antibody	[995]
RG6146	DMIHC4R	Phase 1	NA	[3]
RG6189	DMYFGN4	Phase 1	NA	[996]
RG6279	DMSM0IJ	Phase 1	Recombinant protein	[997]
RG6290	DM417QZ	Phase 1	NA	[998]
RG6292	DMBRYZ7	Phase 1	Antibody	[999]
RG6330	DMSX5NJ	Phase 1	NA	[1000]
RG7112	DME47TX	Phase 1	NA	[26]
RG7116	DM6XVCO	Phase 1	NA	[1001]
RG7304	DMGFAVQ	Phase 1	NA	[1002]
RG7347	DMOE5NQ	Phase 1	NA	[1003]
RG7386	DMVZYLR	Phase 1	NA	[3]
RG7461	DM5OTGR	Phase 1	NA	[3]
RG7741	DMK6P9J	Phase 1	NA	[3]
RG7813	DMACLIH	Phase 1	NA	[1004]
RG7827	DMRGHKN	Phase 1	Recombinant protein	[1000]
RG7841	DM1CLNZ	Phase 1	NA	[1005]
RG7842	DMMMTSL	Phase 1	NA	[1006]
RG7876	DM7686Z	Phase 1	NA	[6]
RHAMM-R3 peptide vaccine	DMHPXTQ	Phase 1	NA	[1007]
RHIgM12B7	DM1HUA3	Phase 1	Antibody	[1008]
RiMO-301	DMY6AHK	Phase 1	NA	[1009]
RLY-1971	DMUT4YZ	Phase 1	Small molecular drug	[1010]
RLY-4008	DM3O52N	Phase 1	Small molecular drug	[1011]
RO-09-4889	DMQ65YW	Phase 1	NA	[1012]
RO-5212054	DML4C3Q	Phase 1	NA	[1013]
RO-5458640	DMVXQ5W	Phase 1	NA	[1014]
Ropidoxuridine	DM6OKBJ	Phase 1	Small molecular drug	[1015]
Rosmantuzumab	DM9O3RY	Phase 1	NA	[3]
RP2-001-18	DMXYGG3	Phase 1	Oncolytic virus therapy	[1016]
RPTR-147	DMPCGY3	Phase 1	Cell therapy	[1017]
RSIFN-co	DMMRZOX	Phase 1	NA	[3]
RX108	DM4XETK	Phase 1	Small molecular drug	[1018]
RXDX-106	DM6NVTR	Phase 1	Small molecular drug	[1019]
SAR-405838	DMC1AZP	Phase 1	Small molecular drug	[1020]
SAR153192	DMUID83	Phase 1	NA	[992]
SAR428926	DMKIJRJ	Phase 1	NA	[6]
SAR439459	DM1YQS9	Phase 1	NA	[3]
SAR442720	DMTAOPC	Phase 1	Small molecular drug	[1021]
SAR444245	DM6UN42	Phase 1	Recombinant protein	[1022]
SB-1578	DMXTKYR	Phase 1	NA	[1023]
SB-639	DMSZIP5	Phase 1	Small molecular drug	[1024]
SBT6050	DMHBD3T	Phase 1	Antibody drug conjugate	[1025]
SC-002	DMZ3HD1	Phase 1	NA	[6]
SC-003	DMD5EFV	Phase 1	NA	[6]
SC-006	DMZ4NHG	Phase 1	NA	[6]
SCH-900353	DM19Y5O	Phase 1	NA	[1026]
SDX-7320	DMU0Q6L	Phase 1	Polymer drug conjugate	[3]
SEA-CD40	DM9OVYK	Phase 1	NA	[6]
SEA-TGT	DM7GUH3	Phase 1	Antibody	[1027]
Selicrelumab	DMCX2AB	Phase 1	NA	[3]
SGN-2FF	DMYVOGJ	Phase 1	NA	[3]
SGN-B6A	DMATJL9	Phase 1	Antibody drug conjugate	[1028]
SGN-CD228A	DMSVD2R	Phase 1	Antibody drug conjugate	[1029]
SGT-94	DMV8LWS	Phase 1	Gene therapy	[1030]
SGX523	DM3RSMF	Phase 1	Small molecular drug	[1031]
SI-B003	DMJW5R0	Phase 1	Antibody	[1032]
Simotaxel	DMFK7UR	Phase 1	Small molecular drug	[1033]
Simotinib	DM1JESE	Phase 1	Small molecular drug	[1034]
SL-052	DM6FEBX	Phase 1	NA	[1035]
SL-801	DMIVGYK	Phase 1	NA	[3]
SM08502	DM4KLNA	Phase 1	NA	[3]
SNDX-6352	DM8ZROW	Phase 1	NA	[3]
SNS-032	DMEITAS	Phase 1	Small molecular drug	[1036]
SNS-314	DMAC5F2	Phase 1	Small molecular drug	[1037]
SNX281	DMCGPU8	Phase 1	Small molecular drug	[1038]
SO-C101	DMAZAGJ	Phase 1	Recombinant protein	[1039]
SOR-C13	DMBKL6O	Phase 1	NA	[401]
SPYK04	DMPRNAB	Phase 1	NA	[1040]
SQZ-PBMC-HPV	DMXR61G	Phase 1	Vaccine	[1041]
SR13668	DMO5760	Phase 1	Small molecular drug	[1042]
SRF231	DM7F90R	Phase 1	NA	[3]
SRF388	DMQMO4N	Phase 1	Antibody	[1043]
SRF617	DMTK1BV	Phase 1	Antibody	[1044]
SRK-181	DM0EWMT	Phase 1	Antibody	[1045]
STA-5312	DMGPIV0	Phase 1	Small molecular drug	[1046]
StMN1 Lp	DM7TPW9	Phase 1	NA	[954]
STP1002	DMXCJP8	Phase 1	Small molecular drug	[1047]
SY-1365	DMK48PM	Phase 1	NA	[3]
SY-5609	DMNW3LH	Phase 1	Small molecular drug	[1048]
Sym021	DMVXLS5	Phase 1	Monoclonal antibody	[204]
Sym022	DMCK2YR	Phase 1	Antibody	[1049]
Sym023	DMV3L62	Phase 1	Antibody	[1050]
SYN004	DM0EZ69	Phase 1	NA	[6]
SYN125	DM4UVTO	Phase 1	Antibody	[1051]
T-0128	DMNE9Z0	Phase 1	Small molecular drug	[1052]
T3011	DMOAU54	Phase 1	NA	[1053]
Tafluposide	DMV8IQW	Phase 1	NA	[1054]
TAK-102	DMD79TX	Phase 1	CAR T Cell Therapy	[1055]
TAK-202	DMVYEFZ	Phase 1	NA	[3]
TAK-243	DM4GKV2	Phase 1	NA	[3]
TAK-252	DM1AKNI	Phase 1	Recombinant protein	[1056]
TAK-285	DM6KOBZ	Phase 1	Small molecular drug	[1057]
TAK-441	DM7DFBL	Phase 1	Small molecular drug	[1058]
TAK-593	DMNFZOT	Phase 1	Small molecular drug	[1059]
TAK-676	DMCKF5J	Phase 1	NA	[1060]
TAK-733	DMC4RNA	Phase 1	Small molecular drug	[1061]
TAK-931	DM1ALY9	Phase 1	NA	[3]
TAK-960	DMN4OGH	Phase 1	Small molecular drug	[1062]
Tapet	DMAIDEL	Phase 1	NA	[1063]
TAS-103	DM5WDKY	Phase 1	Small molecular drug	[1064]
TAS-116	DMRX530	Phase 1	NA	[3]
TAS-119	DMJXBVP	Phase 1	NA	[1065]
Tasidotin hydrochloride	DMKW4AJ	Phase 1	Small molecular drug	[1066]
TCD-717	DMJEBK8	Phase 1	NA	[1067]
Tecogalan sodium	DMOFH7A	Phase 1	NA	[1068]
Tefinostat	DMI9Q6L	Phase 1	Small molecular drug	[1069]
TEN010	DM4UOY5	Phase 1	NA	[26]
TGF-BR2 mab	DMWBQ2Z	Phase 1	Antibody	[1070]
Thiarabine	DMC1HRA	Phase 1	Small molecular drug	[1071]
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	DMO8SGD	Phase 1	NA	[1072]
TJ4309	DMM3U2Q	Phase 1	Antibody	[1073]
TJC4	DMLUOVS	Phase 1	Antibody	[1074]
TnMUC-1 CAR-T cell therapy	DMHD6PA	Phase 1	CAR T Cell Therapy	[1075]
TNO155	DMZ60X4	Phase 1	NA	[3]
TP-0184	DMJVZBC	Phase 1	Small molecular drug	[1076]
TP-1287	DM3Z07E	Phase 1	Small molecular drug	[1077]
TP-1454	DMBTL2M	Phase 1	NA	[1078]
TP-3654	DMBQ6XY	Phase 1	Small molecular drug	[1079]
TPST-1120	DMG4U32	Phase 1	NA	[1080]
TPST-1495	DM3GSB2	Phase 1	NA	[1081]
TPX-0022	DMC2IJN	Phase 1	Small molecular drug	[1082]
TR1801-ADC	DMGC2AT	Phase 1	Antibody drug conjugate	[1083]
TrasGEX	DMMRDUN	Phase 1	Antibody	[1084]
TRC093	DMLXP8X	Phase 1	NA	[1085]
TRIN-2755	DMV9HJ5	Phase 1	NA	[1086]
TRK-950	DMOABIP	Phase 1	NA	[3]
TRX-818	DMVGN42	Phase 1	NA	[3]
TRX518	DM9IDUH	Phase 1	Antibody	[1087]
TSR-022	DML22IV	Phase 1	NA	[3]
TSR-033	DMM26YN	Phase 1	NA	[3]
TSR-042	DM56PFL	Phase 1	Monoclonal antibody	[204]
TST-10088	DMT5AEF	Phase 1	NA	[1088]
TST001	DMZ9EMO	Phase 1	Antibody	[1089]
TT-00420	DMICE6I	Phase 1	Small molecular drug	[1090]
TTI-621	DMDNPAV	Phase 1	Recombinant protein	[3]
TTX-030	DM8H2AG	Phase 1	Antibody	[1091]
TTX-080	DM6GKYF	Phase 1	Antibody	[1092]
U3-1565	DMWOE62	Phase 1	NA	[1093]
UNBS-1450	DMR38M4	Phase 1	Small molecular drug	[1094]
Utomilumab	DMIKV9W	Phase 1	Antibody	[1095]
V930	DMB4KID	Phase 1	Vaccine	[1096]
V932	DMHDA24	Phase 1	Vaccine	[1097]
V935	DMFY5IA	Phase 1	NA	[1098]
V938	DMXTH2R	Phase 1	NA	[1099]
VGX-100	DM9GC4R	Phase 1	NA	[1100]
VIC-1911	DMDFC2Y	Phase 1	NA	[1101]
VLI-01B	DMMXJYJ	Phase 1	NA	[1102]
VLX600	DMOAOMY	Phase 1	NA	[3]
VM-206	DMB3I04	Phase 1	Vaccine	[1103]
VMD-928	DM4AXPT	Phase 1	Small molecular drug	[1104]
VS-4718	DMN9JCD	Phase 1	NA	[1105]
VS-5584	DMMO3G5	Phase 1	Small molecular drug	[1106]
VSV-IFN-beta-NIS	DMIWO2W	Phase 1	NA	[3]
VT1021	DM35LPE	Phase 1	NA	[3]
VX-970	DMR9PCT	Phase 1	NA	[3]
VXM-01	DMQZ5NF	Phase 1	NA	[1107]
W-198	DMJ2R69	Phase 1	Small molecular drug	[1108]
WT2725	DMUZDFR	Phase 1	NA	[1109]
XB-947	DM1UIOA	Phase 1	Small molecular drug	[1110]
XK-469	DMVYO41	Phase 1	Small molecular drug	[1111]
XL-888	DM3OMDV	Phase 1	Small molecular drug	[1112]
XL092	DM3LRAC	Phase 1	Small molecular drug	[1113]
XL418	DME0F5W	Phase 1	NA	[1114]
XmAb20717	DMJIH83	Phase 1	Antibody	[204]
XmAb22841	DMQB3HD	Phase 1	Antibody	[1115]
XmAb23104	DMK9XUQ	Phase 1	Antibody	[1116]
XmAB24306	DMZHL2T	Phase 1	Recombinant protein	[1117]
XMT-1001	DM4MDCH	Phase 1	NA	[1118]
XMT-1536	DMI1TY5	Phase 1	NA	[3]
YE-NEO-001	DMN91A2	Phase 1	Vaccine	[1119]
YM-116	DMW2HS8	Phase 1	NA	[1120]
Zemab	DM2S04R	Phase 1	Antibody	[1121]
ZL-1201	DMTNUA4	Phase 1	Antibody	[1122]
ZSTK474	DMVIMQX	Phase 1	Small molecular drug	[1123]
ZW49	DMAU8L9	Phase 1	Antibody drug conjugate	[1124]
PGF2alpha	DM4XAU7	Clinical trial	Small molecular drug	[1125]
TAK-070	DMCM5GK	Clinical trial	Small molecular drug	[1126]
tamatinib	DMGANIC	Clinical trial	Small molecular drug	[1127]

This Disease is Treated as An Indication in 2 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
AT-001	DML3HCN	Phase 2 Trial	Small molecular drug	[167]
LY3127804	DMAC457	Phase 2 Trial	Monoclonal antibody	[3]

This Disease is Treated as An Indication in 264 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1,2,4-oxadiazole derivative 1	DMESOA8	Patented	Small molecule immunotherapy	[1128]
1,2,4-oxadiazole derivative 2	DMA42SB	Patented	Small molecule immunotherapy	[1128]
1,2,4-oxadiazole derivative 4	DMT6EDP	Patented	Small molecule immunotherapy	[1128]
1,2,4-oxadiazole derivative 5	DM683R7	Patented	Small molecule immunotherapy	[1128]
1,2,4-oxadiazole derivative 6	DMFYKBJ	Patented	Small molecule immunotherapy	[1128]
1,2,4-oxadiazole derivative 7	DMBT4RJ	Patented	Small molecule immunotherapy	[1128]
1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1	DMRFXMB	Patented	Small molecular drug	[1129]
1,3,4-oxadiazole derivative 1	DMJMCNP	Patented	Small molecule immunotherapy	[1128]
1,3,4-oxadiazole derivative 2	DMH26EO	Patented	Small molecule immunotherapy	[1128]
1,3,4-oxadiazole derivative 3	DMSR0X6	Patented	Small molecule immunotherapy	[1128]
1,3,4-oxadiazole derivative 4	DM4GR2C	Patented	Small molecule immunotherapy	[1128]
1,3,4-oxadiazole derivative 5	DMI5VZN	Patented	Small molecule immunotherapy	[1128]
1,3,4-oxadiazole derivative 6	DMIEZ6L	Patented	Small molecule immunotherapy	[1128]
1,3,4-thiadiazole derivative 1	DMAB8QF	Patented	Small molecule immunotherapy	[1128]
1,3,4-thiadiazole derivative 2	DMXIG07	Patented	Small molecule immunotherapy	[1128]
1,3-dihydroxy phenyl derivative 1	DMUS7O3	Patented	Small molecule immunotherapy	[1128]
1,3-dihydroxy phenyl derivative 2	DM63NX5	Patented	Small molecule immunotherapy	[1128]
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Patented	NA	[1130]
3-substituted-1,2,4-oxadiazole derivative 1	DMWCT04	Patented	Small molecule immunotherapy	[1128]
3-substituted-1,2,4-oxadiazole derivative 2	DMB3806	Patented	Small molecule immunotherapy	[1128]
Antibodie derivative 7	DMJN37O	Patented	Antibody	[1131]
Antibodie derivative 9	DMDRJ31	Patented	Antibody	[1131]
Aromatic acetylene derivative 1	DMGR6X1	Patented	Small molecule immunotherapy	[1128]
Aromatic ethylene derivative 1	DMSRKON	Patented	Small molecule immunotherapy	[1128]
Benzimidazole and imidazopyridine derivative 1	DMIXERP	Patented	Small molecular drug	[1129]
Benzimidazole derivative 6	DMV7TMB	Patented	Small molecular drug	[1132]
Benzonaphthyridine derivative 1	DMM9J34	Patented	Small molecular drug	[1129]
Benzonaphthyridine derivative 2	DMB74LZ	Patented	Small molecular drug	[1129]
Benzyl phenyl ether derivative 1	DM6PTOX	Patented	Small molecule immunotherapy	[1128]
Benzyl phenyl ether derivative 2	DMMS4EI	Patented	Small molecule immunotherapy	[1128]
Biaryl compound 1	DMHEAJQ	Patented	Small molecule immunotherapy	[1128]
Biaryl compound 2	DMS8VYE	Patented	Small molecule immunotherapy	[1128]
Bicyclic heteroaryl benzamide derivative 1	DMTBWC9	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 2	DM5MT4R	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 3	DM54EV2	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 4	DMUBDYG	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 5	DMFOVPT	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 6	DMQGYWV	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 7	DMM1LKF	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 8	DMVBQJ1	Patented	NA	[1130]
Bicyclic heteroaryl benzamide derivative 9	DMGONY4	Patented	NA	[1130]
Bis-indolylmaleimide derivative 1	DMOR9ZA	Patented	Small molecular drug	[1129]
Bromo benzyl ether derivative 1	DMMXQJU	Patented	Small molecule immunotherapy	[1128]
Bromo benzyl ether derivative 2	DMVBAUC	Patented	Small molecule immunotherapy	[1128]
Cyclic compound 1	DMSVMUT	Patented	Small molecule immunotherapy	[1128]
Cyclic compound 2	DMGRBAJ	Patented	Small molecule immunotherapy	[1128]
Cyclic compound 3	DMVOEN7	Patented	Small molecule immunotherapy	[1128]
Cyclic peptidomimetic derivative 1	DMV2UQ5	Patented	Small molecule immunotherapy	[1128]
Cyclic peptidomimetic derivative 2	DMWH3FP	Patented	Small molecule immunotherapy	[1128]
Cyclic peptidomimetic derivative 3	DMI7KG4	Patented	Small molecule immunotherapy	[1128]
Dibenzo [c,f]-[2,7]naphthyridine derivative 1	DMRM5I1	Patented	Small molecular drug	[1129]
Five membered heterocyclic benzamide derivative 1	DMPFAST	Patented	NA	[1130]
Five membered heterocyclic benzamide derivative 2	DM4U63E	Patented	NA	[1130]
Five membered heterocyclic benzamide derivative 3	DMUS4Z0	Patented	NA	[1130]
Heteroaryl-carboxamide derivative 1	DMPRF1K	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 10	DMVTARK	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 2	DMGEFIW	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 3	DMBGTNM	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 4	DMHUIXR	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 5	DMMX6V4	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 6	DM9IPDU	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 7	DMOAYEV	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 8	DMJTN91	Patented	NA	[1129]
Heteroaryl-carboxamide derivative 9	DMI627Z	Patented	NA	[1129]
Heterocyclic derivative 10	DMN580F	Patented	NA	[1129]
Heterocyclic derivative 11	DMUOI92	Patented	NA	[1129]
Heterocyclic derivative 12	DMQJW9R	Patented	NA	[1129]
Heterocyclic derivative 13	DMWOBHM	Patented	NA	[1129]
Heterocyclic derivative 14	DMJ0WVR	Patented	NA	[1129]
Heterocyclic derivative 15	DMWZNDO	Patented	NA	[1129]
Heterocyclic derivative 16	DM6NJV7	Patented	NA	[1129]
Heterocyclic derivative 17	DMD1K7E	Patented	NA	[1129]
Heterocyclic derivative 18	DMFUEDL	Patented	NA	[1129]
Heterocyclic derivative 19	DMNG0WH	Patented	NA	[1129]
Heterocyclic derivative 4	DM7VP8M	Patented	NA	[1129]
Heterocyclic derivative 5	DMWJDEO	Patented	NA	[1129]
Heterocyclic derivative 6	DM6HWN3	Patented	NA	[1129]
Heterocyclic derivative 7	DMU6LS4	Patented	NA	[1129]
Heterocyclic derivative 8	DMKPSIA	Patented	NA	[1129]
Heterocyclic derivative 9	DMY4LB7	Patented	NA	[1129]
Heterocyclic-carboxamide derivative 1	DMA91IJ	Patented	Small molecular drug	[1129]
Heterocyclic-carboxamide derivative 2	DMSQK50	Patented	Small molecular drug	[1129]
Imidazo pyridine derivative 1	DMCXHGW	Patented	NA	[1130]
Imidazo quinoline derivative 1	DMGDMWA	Patented	Small molecular drug	[1129]
Imidazo[1,2-b]pyridazine derivative 1	DMULTAI	Patented	Small molecular drug	[1132]
Imidazo[1,2-b]pyridazine derivative 2	DM1JYNW	Patented	Small molecular drug	[1132]
Imidazo[1,2-b]pyridazine derivative 3	DMPDTG0	Patented	Small molecular drug	[1132]
Indazole derivative 1	DME8JTW	Patented	Small molecular drug	[1129]
Indolinone derivative 1	DMTC129	Patented	Small molecular drug	[1129]
Macrocycle derivative 1	DMN7I9C	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 2	DM5OEQZ	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 3	DMYGFTI	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 4	DMOQBN4	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 5	DMK3UJY	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 6	DMQ84KW	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 7	DMP2JF0	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 8	DMOMTBE	Patented	Small molecule immunotherapy	[1128]
Macrocycle derivative 9	DMARU0E	Patented	Small molecule immunotherapy	[1128]
Macrocyclic peptide analog 1	DMS65IT	Patented	Small molecule immunotherapy	[1128]
Macrocyclic peptide analog 2	DMOGLBZ	Patented	Small molecule immunotherapy	[1128]
Macrocyclic peptide analog 3	DMV172W	Patented	Small molecule immunotherapy	[1128]
N-(phenylpyrazolyl)benzamide derivative 1	DM0ZJX7	Patented	NA	[1130]
N-acylpiperidine ether derivative 1	DM5GCUR	Patented	NA	[1130]
N-acylpiperidine ether derivative 2	DM02RQ4	Patented	NA	[1130]
N-acylpiperidine ether derivative 3	DMXWE5R	Patented	NA	[1130]
N-acylpiperidine ether derivative 4	DMBUQDR	Patented	NA	[1130]
N-acylpiperidine ether derivative 5	DMQ2MKT	Patented	NA	[1130]
N-acylpiperidine ether derivative 6	DMAS01P	Patented	NA	[1130]
N-acylpiperidine ether derivative 7	DMCJR4N	Patented	NA	[1130]
N-acylpyrrolidine ether derivative 1	DMQ4ULC	Patented	NA	[1130]
N-acylpyrrolidine ether derivative 2	DMK4Y71	Patented	NA	[1130]
N-phenyl-pyridine-2-carboxamide derivative 1	DMMDYAV	Patented	Small molecule immunotherapy	[1128]
N-phenyl-pyridine-2-carboxamide derivative 2	DM6OG2Y	Patented	Small molecule immunotherapy	[1128]
Peptide analog 1	DMF3LIX	Patented	Peptide	[1128]
Peptide analog 2	DMYFUM6	Patented	Peptide	[1128]
Peptide analog 3	DMYMJV3	Patented	Peptide	[1128]
Peptide analog 4	DM5KEVG	Patented	Peptide	[1128]
Peptide analog 5	DM8B13I	Patented	Peptide	[1128]
Peptide analog 6	DM68M0G	Patented	Peptide	[1128]
Phenylate derivative 1	DMEO9QB	Patented	Small molecule immunotherapy	[1128]
Phenylate derivative 2	DMG0ZSY	Patented	Small molecule immunotherapy	[1128]
Piperazine urea derivative 3	DMNAJWQ	Patented	Small molecular drug	[1133]
Piperazine urea derivative 4	DM3K7IM	Patented	Small molecular drug	[1133]
Piperidine derivative 2	DMHXMB4	Patented	Small molecular drug	[1133]
Piperidine derivative 3	DM80XRM	Patented	Small molecular drug	[1133]
PMID25684022-Compound-EP20041486488	DMDZT7Y	Patented	Small molecular drug	[1129]
PMID25684022-Compound-US20120277229 39(1.1)	DMR4MSH	Patented	NA	[1129]
PMID25684022-Compound-US20120277229 40(1.2)	DMR3J9A	Patented	NA	[1129]
PMID25684022-Compound-US20120277229 41(1.3)	DM7V6E0	Patented	NA	[1129]
PMID25684022-Compound-US20120277229 44(1.4)	DMUQ04C	Patented	NA	[1129]
PMID25684022-Compound-US20120277229 45(1.5)	DMEIA6Y	Patented	NA	[1129]
PMID25684022-Compound-US20130053382 35(1-11)	DMDHJMU	Patented	NA	[1129]
PMID25684022-Compound-US20130053382 36(3-5)	DM40FVN	Patented	NA	[1129]
PMID25684022-Compound-US20130053382 37(4-6)	DMY7Z85	Patented	NA	[1129]
PMID25684022-Compound-US20130053382 38(5-7)	DMHLQ2T	Patented	NA	[1129]
PMID25684022-Compound-WO2004087707	DM809AX	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2006015124	DMV7PNF	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2008005457	DMDMJYL	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2008079988	DMKJ1HC	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2008107444	DM8L5JR	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2009153313	DMTP02Q	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2010127754	DM37FDV	Patented	Small molecular drug	[1129]
PMID25684022-Compound-WO2011137219 35(1-11)	DM3IZ0H	Patented	NA	[1129]
PMID25684022-Compound-WO2011137219 36(3-5)	DMAQHI5	Patented	NA	[1129]
PMID25684022-Compound-WO2011137219 37(4-6)	DMSQ5J8	Patented	NA	[1129]
PMID25684022-Compound-WO2011137219 38(5-7)	DM4NXBK	Patented	NA	[1129]
PMID25684022-Compound-WO2012135799 42(1.4)	DMSDRA4	Patented	NA	[1129]
PMID25684022-Compound-WO2012135799 43(1.5)	DMHI3O1	Patented	NA	[1129]
PMID27998201-Compound-19	DM67RMX	Patented	Small molecular drug	[1134]
PMID28270021-Compound-WO2010077680 103	DM437ZC	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 109	DMNUA21	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 201	DMQAZMC	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 481	DM6VAS2	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 495	DMQ9CBS	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 803	DM6TJU0	Patented	NA	[1130]
PMID28270021-Compound-WO2010077680 811	DM47FNS	Patented	NA	[1130]
PMID28270021-Compound-WO2013009582Example16	DMVS7CJ	Patented	NA	[1130]
PMID28270021-Compound-WO2013009582Example76	DMQK4IX	Patented	NA	[1130]
PMID28270021-Compound-WO2013161919Example85-117	DM2XKTB	Patented	NA	[1130]
PMID28270021-Compound-WO2014078408Example1	DMO02EL	Patented	NA	[1130]
PMID28270021-Compound-WO2014078408Example26	DMVCBSK	Patented	NA	[1130]
PMID28270021-Compound-WO2014129431Example8-1	DMKO4ZH	Patented	NA	[1130]
PMID28270021-Compound-WO2015042088Example11	DM16URY	Patented	NA	[1130]
PMID28270021-Compound-WO2015042088Example12	DMOZHGU	Patented	NA	[1130]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Patented	NA	[1130]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Patented	NA	[1130]
PMID28270021-Compound-WO2016054807Example112	DMW2ZRM	Patented	NA	[1130]
PMID28270021-Compound-WO2016054807Example71	DMREZ9I	Patented	NA	[1130]
PMID28270021-Compound-WO2016054807Example80	DMPI86D	Patented	NA	[1130]
PMID28270021-Compound-WO2016054807Example82	DM9ADSN	Patented	NA	[1130]
PMID28621580-Compound-WO2013036866C66	DMBTZ8I	Patented	Small molecular drug	[1131]
PMID30107136-Compound-Example1	DMY37VQ	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example11	DMD65GU	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example12	DMN2K10	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example13	DM4CN9K	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example14	DMAUFS7	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example15	DMYHQ0S	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example16	DM6EKIV	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example2	DM9HMB4	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example3	DMDCN43	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example4	DMRKLTE	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example41	DMQPIK4	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example42	DM95FIN	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example43	DMJSH0F	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example44	DM8KAIY	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example45	DMC075A	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example46	DMYFSAD	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example47	DM1TCBQ	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example48	DMH57FG	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example49	DM4D1WK	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example50	DMV15GM	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example51	DM08CBJ	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example52	DMJ1C0A	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example53	DM39FDV	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example54	DM9DL1E	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example57	DMZXC0D	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example58	DM3AY9K	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example59	DM6XWL9	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example60	DMUZ85A	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example7	DMS42KH	Patented	Small molecule immunotherapy	[1128]
PMID30107136-Compound-Example8	DMBIK28	Patented	Small molecule immunotherapy	[1128]
Pyrazole derivative 61	DMO6M1Q	Patented	Small molecular drug	[1129]
Pyrazolopyridines and imidazopyridine derivative 1	DMSR5FO	Patented	Small molecular drug	[1129]
Pyrazolo[1,5-a]pyridine derivative 1	DMH1W89	Patented	NA	[1130]
Pyrazolo[1,5-a]pyridine derivative 2	DMLS827	Patented	NA	[1130]
Pyrazolo[4,3-c]pyridine derivative 1	DMHRUIZ	Patented	NA	[1130]
Pyridine and pyrimidine derivative 1	DMGEYJW	Patented	Small molecular drug	[1135]
Pyridine derivative 4	DM6N8T3	Patented	Small molecular drug	[1131]
Pyridinone carboxamide derivative 1	DM3F4KS	Patented	Small molecular drug	[1129]
Pyrido[3,2-d]pyrimidine derivative 2	DMRHAU4	Patented	NA	[1130]
Pyrido[3,2-d]pyrimidine derivative 3	DM6D1XR	Patented	NA	[1130]
Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1	DMOTGEK	Patented	Small molecular drug	[1129]
Pyrimidine derivative 3	DMC3E8M	Patented	Small molecular drug	[1129]
Pyrimidinone derivative 1	DM1I7Z6	Patented	Small molecular drug	[1129]
Pyrrolo[2,3-b]pyridine derivative 1	DMVKCQU	Patented	NA	[1130]
Pyrrolo[2,3-b]pyridine derivative 2	DM7IPWB	Patented	NA	[1130]
Pyrrolo[2,3-b]pyridine derivative 3	DMCYOL7	Patented	NA	[1130]
Pyrrolo[2,3-d]pyrimidine derivative 16	DM1GYZQ	Patented	Small molecular drug	[1136]
Pyrrolo[2,3-d]pyrimidine derivative 17	DMXWVN2	Patented	Small molecular drug	[1136]
Pyrrolo[2,3-d]pyrimidine derivative 3	DMTX1G4	Patented	NA	[1130]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Patented	NA	[1130]
Pyrrolo[3,2-c]pyridine derivative 1	DMKF8HI	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 1	DMYFK85	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 2	DMX6AKV	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 3	DMEGVD4	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 4	DMB0D1H	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 5	DM0GTUH	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 6	DMZU96C	Patented	NA	[1130]
Six-membered heterocyclic benzamide derivative 7	DM15AFI	Patented	NA	[1130]
Thiazole carboxamide derivative 1	DMW62LX	Patented	NA	[1129]
Thiazole carboxamide derivative 10	DMWKI89	Patented	NA	[1129]
Thiazole carboxamide derivative 11	DM0Q3HF	Patented	NA	[1129]
Thiazole carboxamide derivative 12	DMG0H73	Patented	NA	[1129]
Thiazole carboxamide derivative 13	DMHQCEJ	Patented	NA	[1129]
Thiazole carboxamide derivative 14	DMMKNP7	Patented	NA	[1129]
Thiazole carboxamide derivative 15	DMCH1DL	Patented	NA	[1129]
Thiazole carboxamide derivative 16	DMJQBVH	Patented	NA	[1129]
Thiazole carboxamide derivative 17	DMPMN92	Patented	NA	[1129]
Thiazole carboxamide derivative 18	DM987MK	Patented	NA	[1129]
Thiazole carboxamide derivative 19	DMW59Q4	Patented	NA	[1129]
Thiazole carboxamide derivative 2	DMLIRGM	Patented	NA	[1129]
Thiazole carboxamide derivative 20	DMORSH9	Patented	NA	[1129]
Thiazole carboxamide derivative 21	DMTJBCG	Patented	NA	[1129]
Thiazole carboxamide derivative 22	DM6WTR2	Patented	NA	[1129]
Thiazole carboxamide derivative 23	DMMO6JY	Patented	NA	[1129]
Thiazole carboxamide derivative 24	DMZ6YB0	Patented	NA	[1129]
Thiazole carboxamide derivative 25	DMLRTFX	Patented	NA	[1129]
Thiazole carboxamide derivative 26	DM8DHZ4	Patented	NA	[1129]
Thiazole carboxamide derivative 27	DMV30QO	Patented	NA	[1129]
Thiazole carboxamide derivative 28	DMGEIZV	Patented	NA	[1129]
Thiazole carboxamide derivative 29	DMCRVO5	Patented	NA	[1129]
Thiazole carboxamide derivative 3	DMLRA3C	Patented	NA	[1129]
Thiazole carboxamide derivative 30	DMEOKCB	Patented	NA	[1129]
Thiazole carboxamide derivative 4	DMI3X14	Patented	NA	[1129]
Thiazole carboxamide derivative 5	DM2H95E	Patented	NA	[1129]
Thiazole carboxamide derivative 6	DMWHCOE	Patented	NA	[1129]
Thiazole carboxamide derivative 7	DMLBK8V	Patented	NA	[1129]
Thiazole carboxamide derivative 8	DMVOTKN	Patented	NA	[1129]
Thiazole carboxamide derivative 9	DM5P04R	Patented	NA	[1129]
Thieno[3,2-c]pyridine-7-carboxamide derivative 1	DM1C8MA	Patented	Small molecular drug	[1129]
Thieno[3,2-c]pyridine-7-carboxamide derivative 2	DMOWFA5	Patented	Small molecular drug	[1129]
Tri-substituted urea derivative 1	DMHGRTX	Patented	NA	[1130]
Tri-substituted urea derivative 2	DMUVPR8	Patented	NA	[1130]
Triazolo[4,3-b]pyridazine derivative 2	DMMJ1FN	Patented	NA	[1130]

This Disease is Treated as An Indication in 287 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hexylcarbamoyl fluorouracil	DMYNPK8	Withdrawn from market	Small molecular drug	[1]
EF-13	DMZTC44	Discontinued in Preregistration	NA	[1137]
EMITEFUR	DMKQI7S	Discontinued in Preregistration	Small molecular drug	[1138]
Rubratin	DMUAWLH	Discontinued in Preregistration	NA	[1139]
Acecainide	DMKM543	Discontinued in Phase 3	Small molecular drug	[1140]
ARANOSE	DM8XO3B	Discontinued in Phase 3	Small molecular drug	[1141]
BECATECARIN	DMRQV8I	Discontinued in Phase 3	Small molecular drug	[1142]
CBT-1	DM097UP	Discontinued in Phase 3	NA	[3]
Crisnatol	DM9V1LR	Discontinued in Phase 3	Small molecular drug	[1143]
Diaziquone	DM7T9PO	Discontinued in Phase 3	Small molecular drug	[1144]
Dofequidar fumarate	DMWMHU7	Discontinued in Phase 3	Small molecular drug	[1145]
Epothilone B	DMM5ZX6	Discontinued in Phase 3	Small molecular drug	[1146]
Galocitabine	DMNSE2I	Discontinued in Phase 3	Small molecular drug	[1147]
KW-2149	DMQZ6SE	Discontinued in Phase 3	Small molecular drug	[1148]
Miproxifene	DMMZO8X	Discontinued in Phase 3	Small molecular drug	[1149]
Sepimostat mesylate	DMRBYH8	Discontinued in Phase 3	Small molecular drug	[1150]
Transferrin CRM-107	DMG7KXT	Discontinued in Phase 3	NA	[1151]
99mTc-Hynic-Annexin V	DMVDQ58	Discontinued in Phase 2	NA	[1152]
ADOZELESIN	DMJ8ZFR	Discontinued in Phase 2	Small molecular drug	[1153]
Angiozyme	DMBQLS5	Discontinued in Phase 2	NA	[1154]
BISNAFIDE MESILATE	DMBIQL2	Discontinued in Phase 2	Small molecular drug	[1155]
BW-773U82	DMI2LFG	Discontinued in Phase 2	Small molecular drug	[1156]
Caracemide	DMNOLHT	Discontinued in Phase 2	Small molecular drug	[1157]
CARZELESIN	DM5DI1G	Discontinued in Phase 2	Small molecular drug	[1158]
CB1954	DMVP4YK	Discontinued in Phase 2	Small molecular drug	[1159]
CDP-850	DMWHQM3	Discontinued in Phase 2	Antibody	[1160]
CDP-860	DMEI0LJ	Discontinued in Phase 2	NA	[1161]
CEMADOTIN HYDROCHLORIDE	DMIR4FB	Discontinued in Phase 2	Small molecular drug	[1162]
CLOTURIN	DMKFMYR	Discontinued in Phase 2	Small molecular drug	[1163]
Dexniguldipine	DMLZIT2	Discontinued in Phase 2	Small molecular drug	[1164]
Didox	DM64CAS	Discontinued in Phase 2	Small molecular drug	[1165]
ELINAFIDE MESILATE	DMBCYRG	Discontinued in Phase 2	NA	[1166]
Ellipravin	DMPNQZG	Discontinued in Phase 2	NA	[1167]
ERBULOZOLE	DM03I7V	Discontinued in Phase 2	Small molecular drug	[1168]
FK-317	DMX839R	Discontinued in Phase 2	Small molecular drug	[1169]
FO-152	DM3PXLZ	Discontinued in Phase 2	Small molecular drug	[1170]
Galarubicin	DMTNYSF	Discontinued in Phase 2	Small molecular drug	[1171]
GlycoPEGylated erythropoietin	DM5JKCL	Discontinued in Phase 2	NA	[1172]
INX-3280	DM1DAEP	Discontinued in Phase 2	NA	[1173]
KRX-0403	DMWZ82U	Discontinued in Phase 2	NA	[1174]
L-4-OXALYSINE	DM7JZ53	Discontinued in Phase 2	Small molecular drug	[1175]
LANIQUIDAR	DM3YABD	Discontinued in Phase 2	Small molecular drug	[1176]
Lexacalcitol	DMJ3ZT8	Discontinued in Phase 2	Small molecular drug	[1177]
LG-1550	DM8W31H	Discontinued in Phase 2	Small molecular drug	[1178]
Lomeguatrib	DMW9MOK	Discontinued in Phase 2	Small molecular drug	[1179]
LP-2307	DMDD0Q8	Discontinued in Phase 2	NA	[1180]
Mitonafide	DMW59FE	Discontinued in Phase 2	Small molecular drug	[1181]
MIVOBULIN ISETHIONATE	DMSBZGI	Discontinued in Phase 2	Small molecular drug	[1182]
NB-506	DMGVYXB	Discontinued in Phase 2	NA	[1183]
NC-190	DMGEBUQ	Discontinued in Phase 2	Small molecular drug	[1184]
NIM-811	DMERJ2Z	Discontinued in Phase 2	NA	[1185]
NK-611	DM5OVGH	Discontinued in Phase 2	Small molecular drug	[1186]
Oncopurge	DMEG20L	Discontinued in Phase 2	NA	[1187]
P53	DM2ZUS9	Discontinued in Phase 2	NA	[1188]
Panomifene	DME4RSI	Discontinued in Phase 2	Small molecular drug	[1189]
PAZELLIPTINE TRIHYDROCHLORIDE	DM186ZV	Discontinued in Phase 2	Small molecular drug	[1190]
Perillyl alcohol	DMFWC3O	Discontinued in Phase 2	Small molecular drug	[1191]
PIBROZELESIN HYDROCHLORIDE	DMJKN0B	Discontinued in Phase 2	Small molecular drug	[1192]
RhLT28-171	DMOY7ON	Discontinued in Phase 2	NA	[1193]
RK-28	DMSC16Q	Discontinued in Phase 2	Small molecular drug	[1194]
S-12363	DMS6NAK	Discontinued in Phase 2	NA	[1195]
S-16020-2	DM51WJN	Discontinued in Phase 2	Small molecular drug	[1196]
S-9788	DMER3I9	Discontinued in Phase 2	Small molecular drug	[1197]
Spirogermanium hydrochloride	DMXN05A	Discontinued in Phase 2	Small molecular drug	[1198]
SRI-62-834	DMRKE9G	Discontinued in Phase 2	Small molecular drug	[1199]
SUPER-LEU-DOX	DM19Y0T	Discontinued in Phase 2	NA	[1200]
T-506	DM7XGJY	Discontinued in Phase 2	Small molecular drug	[1201]
Tacedinaline	DM1Z74X	Discontinued in Phase 2	Small molecular drug	[1202]
Tallimustine	DMWVPEU	Discontinued in Phase 2	Small molecular drug	[1203]
Theradigm-Melanoma	DMBO0UP	Discontinued in Phase 2	NA	[1204]
Titanocene dichloride	DMIP9M4	Discontinued in Phase 2	Small molecular drug	[1205]
TNP-351	DMW05DS	Discontinued in Phase 2	Small molecular drug	[1206]
TNP-470	DMT0QK8	Discontinued in Phase 2	Small molecular drug	[1207]
Tridolgosir	DMUZNF0	Discontinued in Phase 2	Small molecular drug	[1208]
Trimelamol	DMLTG2Q	Discontinued in Phase 2	Small molecular drug	[1209]
Vitaxin	DMHCLVQ	Discontinued in Phase 2	NA	[1210]
Zilascorb (2H)	DM3IRES	Discontinued in Phase 2	Small molecular drug	[1211]
ALKASAR-18	DM06U6R	Discontinued in Phase 1/2	Small molecular drug	[1212]
AP5280	DMUOPYN	Discontinued in Phase 1/2	NA	[1213]
AZD8055	DM7L8SG	Discontinued in Phase 1/2	Small molecular drug	[1214]
RhApo2L/TRAIL	DMIAZJ9	Discontinued in Phase 1/2	NA	[1215]
WX-UK1	DM8Q2ZR	Discontinued in Phase 1/2	Small molecular drug	[1216]
7U85	DM640U0	Discontinued in Phase 1	NA	[1217]
A-216546	DMHT84I	Discontinued in Phase 1	Small molecular drug	[1218]
ABJ-879	DMJTIUP	Discontinued in Phase 1	NA	[1219]
ABT-518	DMA2RM3	Discontinued in Phase 1	Small molecular drug	[1220]
AG-331	DMCEM0L	Discontinued in Phase 1	Small molecular drug	[1221]
Antineoplaston-A3	DM4SWHY	Discontinued in Phase 1	NA	[1222]
Antineoplaston-A5	DMGTNOU	Discontinued in Phase 1	NA	[1223]
Autologous dendritic cell therapy	DMFID97	Discontinued in Phase 1	NA	[1224]
AZD4769	DMA3OWI	Discontinued in Phase 1	Small molecular drug	[1225]
AZD8330	DMUKNQ5	Discontinued in Phase 1	Small molecular drug	[1226]
BAY-61-2116	DMK4WEN	Discontinued in Phase 1	NA	[1227]
BEPH	DMQI2F4	Discontinued in Phase 1	Small molecular drug	[1228]
BIM-26226	DM9F4LP	Discontinued in Phase 1	NA	[1229]
CA9-ADC	DMSTN6W	Discontinued in Phase 1	Antibody	[1230]
CEP-2563	DMH1PQ0	Discontinued in Phase 1	NA	[1231]
CGP-55847	DMY9Y98	Discontinued in Phase 1	NA	[1232]
Clomet	DMYPFLR	Discontinued in Phase 1	NA	[1233]
D-1927	DM5D8JW	Discontinued in Phase 1	NA	[1234]
DE-310	DMAOZH3	Discontinued in Phase 1	NA	[1235]
Denibulin	DM5G43H	Discontinued in Phase 1	Small molecular drug	[1236]
Elacridar	DMURVE8	Discontinued in Phase 1	Small molecular drug	[1237]
Enoticumab	DM70QT3	Discontinued in Phase 1	Monoclonal antibody	[1238]
ES-285	DMW9LHG	Discontinued in Phase 1	NA	[1239]
Ether lipid	DMZLQ50	Discontinued in Phase 1	NA	[1240]
FCE-28161	DMSFA7L	Discontinued in Phase 1	NA	[1241]
Fibrovax	DMVJBV0	Discontinued in Phase 1	NA	[1242]
FK-973	DMB5HMS	Discontinued in Phase 1	Small molecular drug	[1243]
Giracodazole	DMGN8FI	Discontinued in Phase 1	Small molecular drug	[1244]
HGS-TR2J	DM0W2TA	Discontinued in Phase 1	Antibody	[1245]
HuMV833	DM9LY4Q	Discontinued in Phase 1	Antibody	[1246]
IGN301	DM8RQV2	Discontinued in Phase 1	NA	[1247]
IMC-1C11	DMQIXD2	Discontinued in Phase 1	Antibody	[1248]
INOC-002	DMGCUTI	Discontinued in Phase 1	NA	[1249]
INOC-003	DMOC4FD	Discontinued in Phase 1	NA	[1250]
KU-2285	DMXK150	Discontinued in Phase 1	Small molecular drug	[1251]
LAF-389	DMRL900	Discontinued in Phase 1	NA	[1252]
LBY-135	DMSRD5U	Discontinued in Phase 1	Antibody	[1253]
LOR-2501	DMSL0Y5	Discontinued in Phase 1	Antisense drug	[1254]
MBI 1121	DMP19KT	Discontinued in Phase 1	Antisense drug	[1255]
MK-6592	DMB5NOI	Discontinued in Phase 1	NA	[1256]
Mofarotene	DMKHEQL	Discontinued in Phase 1	Small molecular drug	[1257]
NAMI-A	DMYRC70	Discontinued in Phase 1	NA	[1258]
NV-18	DM4O7DA	Discontinued in Phase 1	NA	[1259]
ONT-093	DMB8T5U	Discontinued in Phase 1	Small molecular drug	[1260]
PF-04605412	DMYNEBJ	Discontinued in Phase 1	NA	[1261]
Phytosel	DMZ8H1S	Discontinued in Phase 1	NA	[1262]
PLD-147	DMAPD6M	Discontinued in Phase 1	Small molecular drug	[1263]
PTL-68001	DM31P7H	Discontinued in Phase 1	Small molecular drug	[1264]
Pyroxamide	DM4LNBQ	Discontinued in Phase 1	Small molecular drug	[1265]
RB-6145	DM3V5O2	Discontinued in Phase 1	Small molecular drug	[1266]
RC-8800	DMR6QMJ	Discontinued in Phase 1	NA	[1267]
RDEA-436	DM0ILRU	Discontinued in Phase 1	NA	[1268]
RG-7167	DMGLRK0	Discontinued in Phase 1	NA	[1269]
RG-7594	DMSX752	Discontinued in Phase 1	NA	[1270]
RG7212	DM9GHH8	Discontinued in Phase 1	NA	[1271]
Rhenex	DM2T3BC	Discontinued in Phase 1	NA	[1272]
RO-4987655	DMMF0OP	Discontinued in Phase 1	Small molecular drug	[1269]
S-23906-1	DM6SON1	Discontinued in Phase 1	NA	[1273]
SDZ-62-434	DMU3TQJ	Discontinued in Phase 1	Small molecular drug	[1274]
SGN-10	DMRZJOH	Discontinued in Phase 1	NA	[1275]
SR-271425	DM6X9M8	Discontinued in Phase 1	Small molecular drug	[1276]
SS1(dsFv)-PE38	DM3O4ST	Discontinued in Phase 1	Antibody	[1277]
SSR-97225	DMWMPD8	Discontinued in Phase 1	NA	[1278]
SULOFENUR	DM5DBE4	Discontinued in Phase 1	Small molecular drug	[1279]
SURADISTA	DM1Z42H	Discontinued in Phase 1	NA	[1280]
SW-33377	DMY3FES	Discontinued in Phase 1	Small molecular drug	[1281]
TAK165	DMBE5OF	Discontinued in Phase 1	Small molecular drug	[1282]
TALTOBULIN	DM1ZYCA	Discontinued in Phase 1	Small molecular drug	[1283]
Teloxantrone	DMDT5HZ	Discontinued in Phase 1	Small molecular drug	[1284]
TG-1024	DM9KYVQ	Discontinued in Phase 1	NA	[1285]
TG-4023	DMSX5RO	Discontinued in Phase 1	NA	[1286]
XL844	DMHTG38	Discontinued in Phase 1	Small molecular drug	[1287]
XR-9051	DMCK210	Discontinued in Phase 1	Small molecular drug	[1288]
ZD-2767	DM7JUCI	Discontinued in Phase 1	NA	[1289]
1D09C3	DMZHLMV	Terminated	NA	[1355]
21-AMINOEPOTHILONE B	DMTH52F	Terminated	Small molecular drug	[1356]
ABT-100	DMPFLS5	Terminated	Small molecular drug	[1357]
AG-3296	DMF2ME4	Terminated	NA	[1358]
ALS-769	DMGBT9Z	Terminated	NA	[1359]
AN-1006	DMZO9NV	Terminated	Small molecular drug	[1360]
Anticancer glycosaminoglycans	DM72YFD	Terminated	Small molecular drug	[1361]
AS-1405	DMTYXY2	Terminated	NA	[1362]
AS-1406	DMRYQBE	Terminated	NA	[1363]
AstaFactor	DMIEU26	Terminated	Small molecular drug	[1364]
AZD-9935	DMFE3CD	Terminated	NA	[1365]
AZD3409	DM3WFB5	Terminated	Small molecular drug	[1366]
B-428	DME6OFU	Terminated	NA	[1367]
B-581	DM5EKPM	Terminated	Small molecular drug	[1368]
B-956	DM1IO9X	Terminated	NA	[1369]
BB-3644	DM7YRFE	Terminated	Small molecular drug	[1370]
BCH-2051	DMN1RQD	Terminated	NA	[1371]
BE-13793C	DM6WQ8F	Terminated	Small molecular drug	[1372]
BhCG vaccine	DMCNRW0	Terminated	NA	[1373]
BIBW-22	DMXIH3Q	Terminated	Small molecular drug	[1374]
Bisbenzimide (Hoechst 33258)	DMKRBL2	Terminated	Small molecular drug	[1375]
Bivatuzumab mertansine	DM0DO4S	Terminated	Antibody	[1376]
BL-1893	DM87864	Terminated	NA	[1377]
BMS-182566	DMO7C09	Terminated	NA	[1378]
BMS-185857	DMTA7O8	Terminated	NA	[1379]
BN-80245	DMMZ9DY	Terminated	Small molecular drug	[1380]
BW-A502U	DMF6OY8	Terminated	Small molecular drug	[1381]
CB-30865	DMOLVWF	Terminated	Small molecular drug	[1382]
CDP-845	DMGMS2D	Terminated	NA	[1383]
CEP-5214	DMFRW0G	Terminated	Small molecular drug	[1384]
CGP-52411	DMIWUFC	Terminated	Small molecular drug	[1385]
CGP-53716	DMJ325M	Terminated	NA	[1386]
CGP-60474	DM4TGY0	Terminated	Small molecular drug	[1387]
CL-329753	DMZO9RS	Terminated	NA	[1388]
CM-101	DM9A9C9	Terminated	NA	[1389]
CP-471358	DMDEPKM	Terminated	NA	[1390]
CP-663427	DMIZMJD	Terminated	NA	[1391]
CP-79328	DM4EWUA	Terminated	NA	[1392]
CT-2412	DMI63ER	Terminated	NA	[1393]
CTA-002	DM00H0C	Terminated	NA	[1394]
CVS-3083	DMEK2EQ	Terminated	NA	[1395]
CYC-103	DM17NYA	Terminated	NA	[1396]
CZ-112	DMF8TCI	Terminated	NA	[1397]
D-21775	DME07ML	Terminated	NA	[1398]
D-21805	DM9K8OT	Terminated	NA	[1399]
D-26344	DMBJAUC	Terminated	NA	[1400]
DMPDDF	DMLBS83	Terminated	NA	[1401]
DW-2282	DMOMZ80	Terminated	Small molecular drug	[1402]
EC-154	DM5ITJF	Terminated	NA	[1403]
Ecomustine	DMOWC6Z	Terminated	Small molecular drug	[1404]
ED-110	DMJN7MY	Terminated	Small molecular drug	[1405]
Elmustine	DM32ZGK	Terminated	Small molecular drug	[1406]
Endovion	DMJU39N	Terminated	Small molecular drug	[1407]
EP-2060	DMZA5Q4	Terminated	NA	[1408]
EPD-clofarabine	DM149HL	Terminated	NA	[1409]
EPICOAT cancer vaccine	DM71L0O	Terminated	NA	[1410]
EPTALOPROST	DM2NHLW	Terminated	Small molecular drug	[1411]
ERIC-1	DM08XS2	Terminated	NA	[1412]
FD-891	DMT1L7I	Terminated	Small molecular drug	[1413]
FR-118487	DM5N03U	Terminated	Small molecular drug	[1414]
FR-182877	DMRKJ4Y	Terminated	Small molecular drug	[1415]
Glyfoline	DMDM994	Terminated	Small molecular drug	[1416]
GM-CSF-expressing oncolytic adenovirus	DMX3UFN	Terminated	NA	[1417]
GS-438	DMEB8UU	Terminated	NA	[1418]
GSK-923295	DMMYUWT	Terminated	Small molecular drug	[1419]
HuCD40L	DMTGCA6	Terminated	NA	[1420]
ICA-1	DM1C4IG	Terminated	NA	[1421]
IGN-311	DMBKZ4R	Terminated	Antibody	[1422]
IGN-312	DMDMJZ2	Terminated	NA	[1423]
INGN-007	DME4FDL	Terminated	NA	[1424]
INGN-402	DMRHGL2	Terminated	NA	[1425]
IPH-3102	DMY3BMC	Terminated	NA	[1426]
IPH-3201	DM7J8IO	Terminated	NA	[1427]
KIN-806	DMVFJWL	Terminated	Small molecular drug	[1428]
KYN-54	DM9CC8A	Terminated	Small molecular drug	[1429]
L-731735	DM1XBKC	Terminated	Small molecular drug	[1430]
L-739749	DMAUG0L	Terminated	Small molecular drug	[1431]
L-745631	DM4UP7R	Terminated	Small molecular drug	[1432]
LC-9018	DMWPZDW	Terminated	NA	[1433]
LK-410	DM5LM6B	Terminated	NA	[1434]
LN-020	DM8CMW3	Terminated	NA	[1435]
MEDI-542	DM4G0D5	Terminated	Antibody	[1436]
Mitoflaxone	DMO06JV	Terminated	Small molecular drug	[1437]
MKC-1313	DMAITRL	Terminated	NA	[1438]
MX-7065	DMP26BW	Terminated	NA	[1439]
MX-7091	DMWPJA8	Terminated	NA	[1439]
NK-109	DMI4J48	Terminated	NA	[1440]
OC104-26	DM1SXNX	Terminated	NA	[1441]
OC42-92	DMVW2F8	Terminated	NA	[1442]
Omniferon	DMSKAGP	Terminated	NA	[1443]
ON-09300	DMMLXRG	Terminated	NA	[1444]
Oncomer	DMB8FYB	Terminated	NA	[1445]
ONYX-411	DM5QW8E	Terminated	NA	[1446]
Org-6632	DMB5BXJ	Terminated	NA	[1447]
Oxamflatin	DM1TG3C	Terminated	Small molecular drug	[1448]
PI-083	DM6P7RM	Terminated	Small molecular drug	[1449]
PIROXANTRONE	DMR87MO	Terminated	Small molecular drug	[1450]
PJ-3505	DMJBHVP	Terminated	NA	[1451]
QG-AGC1	DMGHPWC	Terminated	NA	[1452]
R-253	DMOJBRR	Terminated	Small molecular drug	[1453]
RemeStim-CEA	DM5YSXN	Terminated	NA	[1454]
RG-83852	DM2PGCA	Terminated	NA	[1455]
RPK-739	DMUCP8K	Terminated	NA	[1456]
S-1286	DM064OE	Terminated	NA	[1457]
SC-102	DM1MQ6Z	Terminated	Small molecular drug	[1458]
SC-236	DMO1URE	Terminated	Small molecular drug	[1459]
Sch-207758	DM037SB	Terminated	NA	[1460]
Sch-49209	DMBTADI	Terminated	Small molecular drug	[1461]
Sch-49210	DM4CYNI	Terminated	Small molecular drug	[1462]
SCR-44001	DMFZNUA	Terminated	NA	[1463]
SDZ-280-446	DM3SL5V	Terminated	NA	[1464]
SDZ-62-826	DMAT657	Terminated	NA	[1465]
Sebriplatin	DMHR3N9	Terminated	NA	[1466]
SKI-2034R	DM5RCZ0	Terminated	NA	[1467]
SR-11237	DMQG3CK	Terminated	Small molecular drug	[1468]
TAN-1496	DMU3BDY	Terminated	NA	[1469]
TAR-1	DM197D0	Terminated	Antibody	[1470]
TES-23-NCS	DMK5TWE	Terminated	NA	[1471]
TPI-273	DMMWZLG	Terminated	NA	[1472]
TRK-710	DMPIJJ8	Terminated	Small molecular drug	[1473]
TZ-93	DMZS509	Terminated	NA	[1474]
VB2-011	DMC321N	Terminated	NA	[1475]
VG-106	DMY0V6J	Terminated	NA	[1476]
XL-541	DM965P4	Terminated	NA	[1477]
XR-3054	DMXI39O	Terminated	NA	[1478]
XR-5118	DMIK72F	Terminated	Small molecular drug	[1479]
YP-004	DMK1UJM	Terminated	NA	[1480]
YP-009	DMPXLG2	Terminated	NA	[1481]
ZD-4190	DMVWRU9	Terminated	Small molecular drug	[1482]
ZD-6003	DMU2F6Q	Terminated	NA	[1483]
ZD-9063P	DMQ43Y9	Terminated	NA	[1484]

This Disease is Treated as An Indication in 100 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rintatolimid	DM574C8	Application submitted	NA	[3]
1-methyl-L-tryptophan	DMT8SFV	Preclinical	Small molecular drug	[1290]
1954U89	DM503DN	Preclinical	NA	[1291]
212Pb-labelled aTEM1	DM1H15W	Preclinical	Radiopharmaceutical therapy agent	[1292]
212Pb-labelled PLEa	DML1K7Z	Preclinical	Radiopharmaceutical therapy agent	[1292]
227Th-labelled HER2-TTC	DM1O2C3	Preclinical	Radiopharmaceutical therapy agent	[1292]
4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine	DM57GL1	Preclinical	Small molecular drug	[1290]
4SC-202	DMXFC3W	Preclinical	Small molecular drug	[529]
680C91	DMCDTIG	Preclinical	Small molecular drug	[1290]
9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile	DMEKMV0	Preclinical	Small molecular drug	[1293]
A-366	DM1H45U	Preclinical	Small molecular drug	[1294]
ABI-013	DMQ0NU1	Preclinical	Antibody	[1295]
ADC-01	DM19R28	Preclinical	Small molecular drug	[1296]
ADC-03	DM21I35	Preclinical	Small molecular drug	[1296]
AEZS-127	DM0JYBU	Preclinical	Small molecular drug	[1297]
ATA3271	DMXQVBT	Preclinical	CAR T Cell Therapy	[1298]
AVR-147	DMVGYG2	Preclinical	NA	[1299]
AVR-168	DM4988W	Preclinical	NA	[1299]
AZ505	DMKQ20J	Preclinical	Small molecular drug	[1294]
AZD-5180	DMTK3FX	Preclinical	NA	[1300]
AZD-6495	DM0OLP9	Preclinical	Small molecular drug	[1301]
BAP-15	DMOW07D	Preclinical	Small molecular drug	[1302]
BMS-695735	DMQG39T	Preclinical	Small molecular drug	[1303]
BN-108	DM6SCTF	Preclinical	NA	[1304]
BN-AM-206	DMYPGFR	Preclinical	NA	[1304]
BN-OD-026	DM8WDAL	Preclinical	NA	[1305]
BNC-102	DMM1O0P	Preclinical	Antibody	[1306]
BST-1005	DM3WHB2	Preclinical	Antibody	[1307]
CB7993113	DMJUQ6E	Preclinical	Small molecular drug	[1290]
CCT-018159	DM065ZH	Preclinical	Small molecular drug	[1308]
Chlamydocin	DM89DQP	Preclinical	Small molecular drug	[1309]
CPH-102	DMQGRC8	Preclinical	NA	[1310]
CS-00028	DMB4FWX	Preclinical	NA	[1311]
CYC-800	DMA1MK5	Preclinical	Small molecular drug	[1312]
DAP-81	DMUWRIF	Preclinical	NA	[1313]
Depudecin	DMD0T1U	Preclinical	Small molecular drug	[1314]
DX-2802	DM8YSW7	Preclinical	Antibody	[1315]
EGFR/IGFR tandem adnectin	DMZ3YP6	Preclinical	NA	[1316]
EndoAngio-GT	DMYBQQ0	Preclinical	NA	[1317]
EP-128504	DMJEKQM	Preclinical	NA	[1318]
EP-2167	DMERKYO	Preclinical	NA	[1318]
EPL-1410	DM5K17C	Preclinical	Small molecular drug	[1290]
EPZ028862	DM2TESM	Preclinical	Small molecular drug	[1294]
EPZ031686	DM8UKL0	Preclinical	Small molecular drug	[1319]
EPZ032597	DMHU742	Preclinical	Small molecular drug	[1294]
EPZ033294	DMDO6NZ	Preclinical	Small molecular drug	[1294]
FAP5-DM1	DMYFVZ3	Preclinical	Antibody	[1320]
FGFR2-ADC	DMQPMM5	Preclinical	NA	[1321]
GSK2643943A	DM5AOI3	Preclinical	Small molecular drug	[1296]
GSK2807	DMAZROV	Preclinical	Small molecular drug	[1322]
HBX-41108	DMW78BX	Preclinical	Small molecular drug	[1296]
HBX19818	DM6GSI1	Preclinical	Small molecular drug	[1323]
HC-Toxin	DMPLZ7E	Preclinical	Small molecular drug	[1324]
INOC-005	DMBQGZ9	Preclinical	NA	[1325]
JT07	DMHBWOP	Preclinical	Antibody	[1326]
JT08	DM8OAZ6	Preclinical	Antibody	[1326]
KOS-1803	DMFLIC0	Preclinical	NA	[1327]
KOS-1815	DMCGFY6	Preclinical	NA	[1328]
KOS-2484	DMXY81K	Preclinical	NA	[1329]
LDN-57444	DM1982I	Preclinical	Small molecular drug	[1296]
LLY-507	DMNOE1M	Preclinical	Small molecular drug	[1294]
LM10	DMXYDMP	Preclinical	Small molecular drug	[1290]
M-carboxycinnamic acid bishydroxamide	DMHJLPS	Preclinical	Small molecular drug	[1330]
MEDI-543	DM7Q1PF	Preclinical	Vaccine	[1331]
ML323	DMY91A3	Preclinical	Small molecular drug	[1296]
MNLP-462a	DMMMAX1	Preclinical	NA	[1332]
MOR-203	DMWVNT9	Preclinical	NA	[1333]
MS2177	DMDEJBQ	Preclinical	Small molecular drug	[1294]
MX-76629	DMKXM5H	Preclinical	NA	[1318]
Nemorubicin	DMX7Q3H	Preclinical	Small molecular drug	[1334]
NKP-46	DMK8UD0	Preclinical	Antibody	[1335]
NP-50501	DMK1WBU	Preclinical	Small molecular drug	[1336]
NPS-1034	DMOGRWB	Preclinical	Small molecular drug	[1337]
NSC-207895	DMO5MUY	Preclinical	Small molecular drug	[1302]
NSC632839	DMQRZ4T	Preclinical	Small molecular drug	[1302]
NVP-2	DMO5EXL	Preclinical	Small molecular drug	[1338]
OBP-401	DM098Y6	Preclinical	NA	[1339]
ON-01135	DMEXLU5	Preclinical	NA	[1340]
P5091	DMGIR3F	Preclinical	Small molecular drug	[1296]
PBI-1393	DMYIQVW	Preclinical	NA	[1341]
Piperlongumine	DMIZCOE	Preclinical	Small molecular drug	[1342]
PYN-7	DM6QLL6	Preclinical	NA	[1343]
RG70099	DM7JH0K	Preclinical	Small molecular drug	[1290]
RO-26-2853	DM3ZE5A	Preclinical	NA	[1344]
Salicylihalamide A	DMGXVRZ	Preclinical	Small molecular drug	[1345]
Saliphenylhalamide	DMLMRGH	Preclinical	Small molecular drug	[1345]
Scriptaid	DM9JZ21	Preclinical	Small molecular drug	[1346]
SK-7041	DM7DNOG	Preclinical	Small molecular drug	[1347]
SK-7068	DMCI371	Preclinical	Small molecular drug	[1347]
SL-11093	DMQ77WJ	Preclinical	Small molecular drug	[1348]
SMER3	DMKETFV	Preclinical	Small molecular drug	[1302]
SR9009	DM8SKU1	Preclinical	Small molecular drug	[1349]
SR9011	DMZ9BO8	Preclinical	Small molecular drug	[1349]
Tosyl-l-arginine methyl ester	DMONGIR	Preclinical	Small molecular drug	[1302]
Trimidox	DMY8GDA	Preclinical	Small molecular drug	[1350]
VER-155008	DMIQAY4	Preclinical	Small molecular drug	[222]
Viraplex	DMRJVOK	Preclinical	NA	[1351]
XL-388	DMRBOJL	Preclinical	Small molecular drug	[1352]
XL-499	DMINSA5	Preclinical	NA	[1353]
ZK-thiazolidinone	DMNG84V	Preclinical	Small molecular drug	[1354]

This Disease is Treated as An Indication in 925 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
(S)-8-Hydroxy palmitic acid	DMGEES8	Investigative	NA	[222]
14F7 humanized mab	DM8O98F	Investigative	Monoclonal antibody	[222]
177Lu-labelled RM2	DMLC2VE	Investigative	Radiopharmaceutical therapy agent	[1292]
18F labeled ethanolamine derivative	DMWTSXC	Investigative	NA	[222]
18F-fluoromethylallylcholine	DMVX02Y	Investigative	NA	[222]
18F-SMIBR-K5	DM2VZMC	Investigative	NA	[1485]
209-342	DM4ECOW	Investigative	NA	[222]
213Bi DOTA-PESIN	DMDZ9O7	Investigative	NA	[222]
227Th-rituximab	DMHJM0F	Investigative	Antibody	[1486]
227Th-trastuzumab	DMSK8MX	Investigative	Monoclonal antibody	[222]
3-CLA	DM0DRI4	Investigative	NA	[222]
31.1Chi	DMDMHDT	Investigative	NA	[222]
3C23K	DM1NSGX	Investigative	NA	[222]
4-iodo-6-phenylpyrimidine	DMYNVLZ	Investigative	Small molecular drug	[222]
4SC-207	DMK0RJF	Investigative	NA	[222]
58-1066	DMPEXG5	Investigative	NA	[222]
6-azacytidine	DMKLJQ4	Investigative	Small molecular drug	[222]
68Ga-DOTA-AE-105	DMPNHE9	Investigative	NA	[222]
6F4	DME2UI7	Investigative	NA	[222]
A-620223	DM9SXDI	Investigative	Small molecular drug	[1487]
A-928605	DM4FU7S	Investigative	NA	[222]
A35566-A	DMFNR3Y	Investigative	NA	[1488]
ABC-4	DMA01OF	Investigative	Antibody	[1489]
ABC-7	DM2AIE9	Investigative	Antibody	[1490]
ABD-035	DM7I5MC	Investigative	NA	[222]
AbGn-100	DMVL44Z	Investigative	NA	[222]
ABI-010	DMRB0R8	Investigative	NA	[222]
ABI-2088	DMMKS5I	Investigative	NA	[222]
ABX-101	DMK1NF2	Investigative	Small molecular drug	[222]
ABX-102	DMMDYF4	Investigative	Small molecular drug	[222]
ABX-103	DMM501T	Investigative	Small molecular drug	[222]
AC-03-636	DMBDM4K	Investigative	NA	[222]
ACTB-1003	DMPHSU8	Investigative	NA	[1491]
AD-0027	DM3IDCS	Investigative	NA	[222]
AD5-10	DMV48L3	Investigative	Antibody	[1492]
Adarotene ester derivative back-up compounds	DMVMYXD	Investigative	NA	[222]
ADC-1012	DMJQM7H	Investigative	NA	[1493]
ADMDD-15	DMQ7M51	Investigative	NA	[222]
ADRIAC-36	DMXMUOR	Investigative	NA	[222]
Adva-27a	DMC60T0	Investigative	NA	[222]
Adva-33c	DM8LNKZ	Investigative	NA	[222]
Adva-R46	DMLWDO5	Investigative	NA	[222]
AE-298p	DMZ2D07	Investigative	NA	[222]
AEH-10p	DM1VS4D	Investigative	NA	[222]
AEZS-115	DMULWOG	Investigative	NA	[1494]
AEZS-126	DMM52FD	Investigative	NA	[1495]
AEZS-131	DMN9RE5	Investigative	NA	[1496]
AF-11	DM5154F	Investigative	NA	[222]
AFM-20	DM36K9E	Investigative	NA	[222]
AFM-21	DM8U1IW	Investigative	Antibody	[1497]
AG-122005	DM55RP8	Investigative	NA	[222]
AGX-1053	DM6TTSR	Investigative	NA	[222]
AGX-51	DMBO5DA	Investigative	NA	[222]
AK-1	DMVMI1Q	Investigative	Small molecular drug	[222]
AL-6802	DM3JNRC	Investigative	NA	[1497]
ALD-805	DMQXO5G	Investigative	Antibody	[1498]
ALD-806	DMWBKH1	Investigative	Antibody	[1498]
ALERT	DMAMIJW	Investigative	NA	[222]
ALM-301	DMY1OG7	Investigative	NA	[122]
Alpha-C-galactosyl ceramide	DM1T4KX	Investigative	NA	[222]
ALT-802	DMUDVO0	Investigative	NA	[222]
ALT-804	DMVI5RQ	Investigative	NA	[222]
AMBAZONE	DMAVC9T	Investigative	Small molecular drug	[1499]
AMG-429	DME04BH	Investigative	NA	[1500]
AMP-423	DM27UZ8	Investigative	NA	[222]
AN-207	DMRS0LA	Investigative	NA	[1494]
ANA-011	DM3EZES	Investigative	NA	[222]
ANG-1007	DMPPE5G	Investigative	NA	[222]
ANG-2864	DMQ2TNL	Investigative	NA	[1487]
Angeloxin	DMUDGC5	Investigative	NA	[222]
ANT-429	DMZ66P9	Investigative	NA	[222]
Anti-CD326 humanized mab	DMPW1XP	Investigative	Monoclonal antibody	[222]
Anti-CD5 humanized mab	DMLYJS3	Investigative	Monoclonal antibody	[222]
Anti-DLL-4 mab	DMLQIR5	Investigative	Monoclonal antibody	[222]
Anti-EGFR humanized mabs	DMWLMV2	Investigative	Antibody	[1497]
Anti-Fas mabs	DMXWHDC	Investigative	Antibody	[1501]
Anti-FGFR1 mab program	DMP5VZQ	Investigative	Antibody	[1502]
Anti-FGFR2 humanized mab	DMMQ3WX	Investigative	Antibody	[1503]
Anti-GD2 mab	DMPDM5G	Investigative	Monoclonal antibody	[222]
Anti-GP88 mabs	DMGC8R1	Investigative	Monoclonal antibody	[222]
Anti-heparanase mabs	DM29GMS	Investigative	Monoclonal antibody	[222]
Anti-Her-2 mab	DMR8ZG5	Investigative	Monoclonal antibody	[222]
Anti-HER-2 mab-FcgR2- FcgR4 fusion proteins	DMADQL2	Investigative	Monoclonal antibody	[222]
Anti-HER2 bi-specific mabs	DMY60GE	Investigative	Monoclonal antibody	[222]
Anti-hTfR IgG3-Av	DMNBSZR	Investigative	NA	[222]
Anti-Neu5Gc mabs	DMJXPQI	Investigative	Monoclonal antibody	[222]
Anti-Notch-1 mabs	DMJC07U	Investigative	Monoclonal antibody	[222]
Anti-Notch-1 receptor mabs	DMH2WUU	Investigative	Monoclonal antibody	[222]
Anti-PECAM-1 mab	DMAXBKR	Investigative	Monoclonal antibody	[222]
Anti-PrP mabs	DM00SA0	Investigative	Monoclonal antibody	[222]
Anti-RON receptor mabs	DMXACM2	Investigative	Antibody	[1490]
Anti-TAG-72 antibody	DMWAI26	Investigative	NA	[222]
Anti-tubulin agents	DMLKN9P	Investigative	NA	[222]
Anti-VEGF human mabs	DMQS4QM	Investigative	Monoclonal antibody	[222]
AP-10295	DMDDQHX	Investigative	NA	[222]
AP-11014	DM76WRQ	Investigative	NA	[222]
AP-15012	DM1CSGW	Investigative	NA	[222]
APC-001	DMXHACA	Investigative	NA	[222]
APC-0013	DMPRP64	Investigative	NA	[222]
APC-003	DMJ29T5	Investigative	NA	[222]
APC-004	DMZS4BW	Investigative	NA	[222]
APCK-110	DMNQ9M1	Investigative	NA	[1504]
APG-201	DM0BVJN	Investigative	NA	[1505]
APG-232	DMG0YMT	Investigative	NA	[222]
APH-0911	DMYGKW7	Investigative	NA	[1506]
Apicidin	DM83WVF	Investigative	Small molecular drug	[1507]
APIT	DMXD5I1	Investigative	NA	[222]
APN-501	DMC9KSK	Investigative	NA	[222]
Apogossypol	DM7OPCH	Investigative	Small molecular drug	[1508]
Apomab	DMAMY5G	Investigative	Small molecular drug	[222]
Aposense probe-cytotoxic agent conjugates	DMVYCG7	Investigative	NA	[222]
APS-3010	DM8DOBG	Investigative	NA	[1498]
APX-009	DM0CX58	Investigative	NA	[222]
APY29	DMCOMLS	Investigative	Small molecular drug	[1509]
AR-00341677	DMK2XB7	Investigative	Small molecular drug	[1510]
AR-54	DMROCVS	Investigative	NA	[222]
AR-mTOR-26	DM24MKI	Investigative	NA	[1511]
ARC-200	DMAZV5D	Investigative	NA	[1506]
ARNAX	DM4EH68	Investigative	Vaccine	[1512]
ARO 087	DMNAJQY	Investigative	NA	[1513]
ARRY-575	DMIRTF5	Investigative	NA	[1514]
ARRY-770	DMHX7K8	Investigative	NA	[222]
AstraStim	DMOBKGU	Investigative	NA	[222]
AT-003	DMZ6FNZ	Investigative	NA	[222]
AT-004	DMHISC0	Investigative	NA	[222]
AT-006	DM0V1AK	Investigative	NA	[222]
AT-009	DMCO2S4	Investigative	NA	[1515]
AT-012	DM01GOR	Investigative	NA	[222]
AT-027	DMGAWUK	Investigative	NA	[222]
ATI-0810	DMU0QDE	Investigative	NA	[222]
ATI-1150	DMN5VDB	Investigative	NA	[1488]
ATN-658	DMR2M7L	Investigative	NA	[1516]
Atpenin B	DMD5CXA	Investigative	Small molecular drug	[222]
Atu-195	DM5ZYVP	Investigative	NA	[222]
ATX-S10	DM1OQ39	Investigative	Small molecular drug	[222]
Augmab	DMY3NLA	Investigative	NA	[222]
AV-370	DMF1VS9	Investigative	Antibody	[1517]
Avicin D	DM4XPYJ	Investigative	NA	[222]
AVP-4	DMGGUFI	Investigative	NA	[222]
AVP-7	DMN4MF6	Investigative	NA	[222]
AX-13057	DMT4C8V	Investigative	NA	[222]
AZ-05	DMW9A3Z	Investigative	NA	[222]
AZ-23	DM59UDI	Investigative	Small molecular drug	[222]
AZ-628	DMEWQHP	Investigative	Small molecular drug	[1518]
AZD-7507	DMLJPDW	Investigative	NA	[1519]
Azole	DML30LO	Investigative	Small molecular drug	[222]
B-06	DMUGTS4	Investigative	NA	[222]
BA-016	DMFQ8QU	Investigative	NA	[222]
BAL-27862	DM0ZOOT	Investigative	NA	[222]
BAY-85-3474	DMW625B	Investigative	NA	[1498]
BB-15600	DM56Q3L	Investigative	NA	[222]
BB-16000	DM051WZ	Investigative	NA	[222]
BBI-8000	DM7JB62	Investigative	NA	[222]
BBT-012	DMZGGG0	Investigative	NA	[222]
BBT-046	DMQQT7K	Investigative	NA	[222]
BC-822	DMPLI2S	Investigative	NA	[222]
BE-14106	DMZID6K	Investigative	Small molecular drug	[222]
BIM-46187	DMA05KX	Investigative	NA	[222]
BIOO-1	DMJ6B6C	Investigative	NA	[222]
BIOO-2	DMK3S1W	Investigative	NA	[222]
BIOO-3	DMA2FR4	Investigative	NA	[222]
BIOO-5	DMQAA1J	Investigative	NA	[222]
BIOO-6	DMW5J6D	Investigative	NA	[222]
Bisplatinum complexes	DM4430R	Investigative	NA	[222]
BKT-120	DMWCBIX	Investigative	NA	[222]
BL-Angiostatin	DMNKVQB	Investigative	NA	[222]
BLV-0801	DMGB9PN	Investigative	NA	[1520]
Bmab-100	DMP6EEL	Investigative	Monoclonal antibody	[222]
Bmab-200	DM8AEQX	Investigative	Antibody	[1497]
BMS-739562	DMFODQV	Investigative	NA	[1521]
BN-82002	DMXY574	Investigative	NA	[1522]
BND-002	DMA0VA6	Investigative	NA	[222]
BO-0742	DMENLQ0	Investigative	Small molecular drug	[222]
BO-110	DMTCQE5	Investigative	NA	[222]
Botulinum toxin	DMZF393	Investigative	NA	[222]
BP-9906	DMC3ETC	Investigative	NA	[222]
BPI-704001	DMGQXTR	Investigative	NA	[1487]
BPKDi	DM5OHIY	Investigative	NA	[1523]
BPR-DC-2	DMFRIOT	Investigative	NA	[222]
BPR1K-0224	DMJPN8Z	Investigative	NA	[1521]
BQS-481	DM7J740	Investigative	NA	[222]
BRD1240	DMIZ9ON	Investigative	Small molecular drug	[1524]
Breceptin	DM21ZBU	Investigative	NA	[1525]
BRX-1002	DM94XTD	Investigative	NA	[222]
BS-194	DMLXFHD	Investigative	Small molecular drug	[1526]
BSI-302	DM0Y4ZB	Investigative	NA	[222]
BST-204	DMFMTWX	Investigative	NA	[222]
BT-D005	DMRIZ1W	Investigative	NA	[222]
BU-32	DMZ1H76	Investigative	NA	[222]
Buthionine sulfoximine	DMJ46CB	Investigative	Small molecular drug	[1527]
BVB-808	DM10UHA	Investigative	NA	[1528]
C-5304	DMF7HUX	Investigative	Small molecular drug	[222]
CAB-051	DM7GZA6	Investigative	NA	[222]
CAB-103	DMON95A	Investigative	NA	[222]
Calcium nanoparticles	DM0DNZ3	Investigative	NA	[222]
CAP-3.2	DMPITRT	Investigative	NA	[222]
Cardiotoxin	DMJFRNX	Investigative	NA	[222]
CBI-006	DM91V5G	Investigative	NA	[222]
CBI-008	DM4KZU0	Investigative	NA	[222]
CBLC-4H10	DMZQTQA	Investigative	NA	[222]
CC-0101	DMNTQIU	Investigative	NA	[222]
CC-0651	DMLJTOF	Investigative	NA	[222]
CCT-241533	DMZXFT9	Investigative	Small molecular drug	[1529]
CCX-662	DM6WX1A	Investigative	NA	[1530]
CD19xCD3 DART	DMB16TG	Investigative	NA	[222]
CEL-1000	DMRYX1P	Investigative	Vaccine	[1531]
CEN-209	DM8F97U	Investigative	NA	[222]
Centanamycin	DM3PXHO	Investigative	Small molecular drug	[222]
CEP-28122	DMAY04M	Investigative	Small molecular drug	[1532]
CEP-37249	DMUZYCQ	Investigative	NA	[222]
CG-103065	DMGW9QL	Investigative	Small molecular drug	[1533]
CG-1521	DMN3YEQ	Investigative	Small molecular drug	[1534]
CG-701338	DMIWOA6	Investigative	NA	[222]
CGEN-25008	DMWQ71H	Investigative	NA	[222]
CGEN-671	DM1S06Y	Investigative	NA	[222]
CH-223191	DMMJZYC	Investigative	Small molecular drug	[1535]
CH-4938056	DMC2JHW	Investigative	NA	[222]
CH-5015765	DM60H9X	Investigative	Small molecular drug	[222]
CHAP1	DMBZ0QY	Investigative	Small molecular drug	[1536]
CHAP31	DMOXRID	Investigative	Small molecular drug	[1536]
Chk1-A	DMLCZ3D	Investigative	NA	[1514]
Chloromethylpyrrolindolines	DM2TXC4	Investigative	NA	[222]
CHR-4125	DMXKU73	Investigative	NA	[1537]
CID755673	DMSHIQA	Investigative	Small molecular drug	[1523]
CIGB-166	DMADBMZ	Investigative	NA	[222]
CIGB-247	DMY1GYY	Investigative	NA	[222]
CIGB-370	DMRP5MS	Investigative	NA	[222]
CIGB-552	DMSTL75	Investigative	NA	[222]
CIGB-598a	DMPTU9F	Investigative	NA	[222]
CIP-137401	DMZ2WS9	Investigative	NA	[1538]
CJX-1	DMRNVKG	Investigative	NA	[222]
CK-37	DMTCRJ9	Investigative	NA	[222]
CKBP-004	DMCA797	Investigative	NA	[222]
CKD-10101	DMLBMEY	Investigative	NA	[222]
CKD-403	DM77U20	Investigative	NA	[222]
CL-5343	DM9AFZ3	Investigative	Small molecular drug	[1539]
CLT-010	DMMHHJB	Investigative	NA	[222]
CME-548	DMOH1YB	Investigative	NA	[222]
CMET Avimer polypeptides	DM6PFG0	Investigative	NA	[1498]
CMUS-100	DM9YIPR	Investigative	NA	[222]
CNDO-113	DM3T8QF	Investigative	NA	[222]
CNX-1351	DMFUN0Q	Investigative	NA	[222]
COG-112	DML2ZEX	Investigative	NA	[222]
Conjugated-trastuzumab	DMZ7MQW	Investigative	Monoclonal antibody	[222]
CP-4033	DMWOKF7	Investigative	NA	[1]
CP-4200	DMZMKAQ	Investigative	NA	[1540]
CP51-2705	DMAMFDZ	Investigative	NA	[222]
CPA-7	DMI8ISK	Investigative	NA	[222]
CPC-410	DMWVC2A	Investigative	NA	[222]
CPD-VO	DMK051D	Investigative	NA	[222]
Cripto-1 mabs	DMXVGWK	Investigative	Monoclonal antibody	[222]
CRL-37212	DMERKU2	Investigative	NA	[1532]
CRT-0004592	DMVYSAZ	Investigative	NA	[1541]
CRT0066101	DMX09KI	Investigative	Small molecular drug	[1542]
CSP-9222	DMWIPRG	Investigative	NA	[222]
CST-104	DMOY57S	Investigative	NA	[222]
CT-10	DMIVNMJ	Investigative	NA	[1543]
CT-400	DM3IMJ3	Investigative	NA	[222]
CTA-001	DMSND8G	Investigative	NA	[222]
CTP-conjugated WT1 peptide	DM44J7O	Investigative	NA	[222]
CTT-54	DMQ5JX8	Investigative	NA	[1544]
CU-906	DMY1WEM	Investigative	NA	[1495]
CUV-3	DMUZVVH	Investigative	NA	[222]
CVA-21 DAF	DMZ4KZ5	Investigative	NA	[222]
CX-02	DMXMIT4	Investigative	Antibody	[1515]
CX-1001	DM7293Q	Investigative	NA	[1545]
CX-5011	DMXD1IN	Investigative	Small molecular drug	[1546]
CX-5461	DMQKNLN	Investigative	Small molecular drug	[222]
CX-7000	DMNTAV8	Investigative	NA	[1546]
CX-9051	DM526C9	Investigative	NA	[1547]
CX-99	DMTN2N3	Investigative	Small molecular drug	[222]
CYC-4068	DM8ITFX	Investigative	NA	[222]
Cytoreg	DM2S3YL	Investigative	NA	[222]
Cytoros	DMBRJCS	Investigative	Small molecular drug	[222]
CZ-775	DMTJN4W	Investigative	NA	[222]
CZ-ON002	DMLYJV0	Investigative	NA	[222]
D-11B	DMX8AQE	Investigative	NA	[222]
D-699126	DMWTT6C	Investigative	NA	[222]
D-81050	DM881B4	Investigative	NA	[222]
DAF-3	DM1IDWF	Investigative	NA	[222]
DasKloster 0014-01	DMHSHTI	Investigative	NA	[222]
Debio-0617	DM34QYB	Investigative	NA	[222]
Debio-0826	DMJMRAB	Investigative	NA	[222]
Debio-0929	DM6H2NB	Investigative	NA	[222]
Debio-1142	DMDZ06B	Investigative	NA	[222]
Del 60 tetramer	DMGZ2H5	Investigative	Aptamer	[1548]
Dendrogenin A	DMQBP7I	Investigative	Small molecular drug	[222]
Deuteroporphyrin	DMULQV4	Investigative	Small molecular drug	[222]
DHF-18	DMPZE50	Investigative	NA	[222]
Dibenzoylmethane	DMU8TH5	Investigative	Small molecular drug	[222]
DISBA-01	DMMBE7N	Investigative	NA	[222]
Dismutase mimetics	DMR3Y71	Investigative	NA	[222]
DM-204	DMSXI6W	Investigative	Antibody	[1549]
DM-PIT-1	DMEAMLN	Investigative	NA	[222]
DMB mabs	DMDI2OA	Investigative	Monoclonal antibody	[222]
DNX-3000	DM72GKY	Investigative	NA	[222]
DP-266	DMWNFUK	Investigative	NA	[222]
DP-3590	DMFZML9	Investigative	NA	[1498]
DPK-DTSM-02	DM2H8SV	Investigative	NA	[222]
DR-5/DR-4 cross reactive mabs	DMX2TZD	Investigative	Antibody	[1550]
DSLIM	DM8N112	Investigative	NA	[222]
DT-310	DMENH4I	Investigative	NA	[222]
DT-320	DM69GTR	Investigative	NA	[222]
DT-330	DM2HN8J	Investigative	NA	[222]
DTS-108	DM7PNOK	Investigative	NA	[1488]
DVD-Ig	DMWF9GQ	Investigative	NA	[1551]
DWJ-424	DM73ZSZ	Investigative	NA	[222]
DWP-438	DMP8DB5	Investigative	NA	[222]
DX-2400	DMF9M06	Investigative	NA	[1552]
DZ-13	DMU5TKU	Investigative	NA	[222]
E-003	DMA9CZV	Investigative	NA	[1553]
E-758	DMY6DM5	Investigative	NA	[1554]
E12/DP3-117	DMUEL91	Investigative	NA	[222]
EBC-46	DMA5I64	Investigative	Small molecular drug	[222]
EC-0531	DMI6T5J	Investigative	NA	[222]
EC-0565	DMIC372	Investigative	NA	[1511]
EC-70124	DM5M7O5	Investigative	NA	[222]
EC-8042	DMOLKS5	Investigative	NA	[222]
EDP-08	DM6CKNS	Investigative	NA	[222]
EDP-13	DMLSMBI	Investigative	NA	[1497]
EDP-17	DM4GZFM	Investigative	NA	[222]
EDP-20	DMDMKG3	Investigative	NA	[222]
EDP-23	DM6F92W	Investigative	NA	[222]
EDP-24	DMYL4SR	Investigative	NA	[222]
EG-Vac	DMIB9WZ	Investigative	NA	[222]
EHT-107	DM0ATGJ	Investigative	NA	[222]
EM-101	DMQ63J2	Investigative	Small molecular drug	[1555]
EM-6110a	DMEP4PB	Investigative	NA	[222]
ENDG-4010	DMUCZPJ	Investigative	NA	[1556]
Engineered toxin bodies	DMWQN22	Investigative	NA	[222]
Enkastim-iv	DMH8CS1	Investigative	NA	[222]
EP-200	DMAURX5	Investigative	NA	[1557]
EP-342	DM1M95Z	Investigative	NA	[222]
EP-400	DME5937	Investigative	NA	[222]
EphB4-131	DM3F427	Investigative	Antibody	[1558]
EPI-0030	DM72DO1	Investigative	NA	[1500]
EPI-2221	DMV0AFC	Investigative	NA	[222]
EPI-288	DMILK4U	Investigative	NA	[222]
Epitinib	DM1C8FW	Investigative	Small molecular drug	[1497]
EQ-818-1	DMJQ8GF	Investigative	NA	[222]
EU-517	DMZ1FCJ	Investigative	NA	[1559]
Evatak	DMNMEAW	Investigative	NA	[1560]
EVIRNA	DMDRD2W	Investigative	NA	[222]
EZN-3889	DM5N5L3	Investigative	NA	[222]
EZN-3920	DMXV5PM	Investigative	NA	[1561]
EZN-4150	DMHEY3D	Investigative	NA	[222]
EZN-4482	DMNRRU4	Investigative	NA	[222]
F-1013	DM5YNRI	Investigative	Small molecular drug	[222]
F-12458	DMXHKE3	Investigative	NA	[1562]
F-80002-RR	DMPEYO6	Investigative	NA	[222]
F61F12	DMD7HO8	Investigative	Antibody	[1563]
FAS-031	DMRMI0V	Investigative	NA	[1501]
Fc-IFN alpha 2b	DML7G6O	Investigative	NA	[222]
FE-999040	DM3UCWM	Investigative	NA	[1564]
Fenbunafide	DMU1XSK	Investigative	NA	[222]
FG-020318	DM2GJBM	Investigative	Small molecular drug	[222]
Fluoroglycoconjugates	DMJUQD1	Investigative	NA	[222]
Forskolin	DM6ITNG	Investigative	Small molecular drug	[222]
FRAX-120	DMRWD63	Investigative	NA	[222]
Fsn-0306	DMBC9AS	Investigative	NA	[222]
Fsn-0503	DM2KUEV	Investigative	Antibody	[1565]
Fusion toxin protein	DMO5NIZ	Investigative	NA	[222]
G-573	DMC54UG	Investigative	Small molecular drug	[1538]
G6976	DMEZO4M	Investigative	Small molecular drug	[1523]
Gadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates	DMP3E0B	Investigative	NA	[222]
Galectin-3C	DMGTEES	Investigative	NA	[222]
GB-2542	DME23ZB	Investigative	NA	[222]
GD2 ganglioside peptide mimics	DMUPCET	Investigative	NA	[222]
GF-15	DM3GT5Y	Investigative	NA	[222]
GFC-003	DMIFL9Q	Investigative	NA	[222]
GFC-012	DMI06PJ	Investigative	NA	[222]
GFP-bacterial methioninase/selenomethionine GDEPT	DMTIO7Y	Investigative	NA	[222]
GIT27-NO	DMUYDDW	Investigative	NA	[222]
GivaRex	DMMU0KH	Investigative	NA	[222]
GLG-101	DMW8FP5	Investigative	NA	[222]
Glionitrin A	DM98CSW	Investigative	Small molecular drug	[1566]
GR-ARA1	DMFLCJU	Investigative	NA	[222]
GS-156 mab	DMZAWNE	Investigative	Monoclonal antibody	[222]
GSK-2334470	DM3BI7R	Investigative	Small molecular drug	[1567]
GTx-027	DM315VL	Investigative	NA	[1568]
GTx-134	DMTN5CI	Investigative	NA	[222]
GTx-186	DMX3S83	Investigative	NA	[222]
GTx-230	DMUFLPK	Investigative	NA	[222]
GUT-70	DMBA2CR	Investigative	NA	[222]
GW-559768X	DMGRKT4	Investigative	NA	[1569]
GW-788388	DMIBUW5	Investigative	Small molecular drug	[1570]
GX-51	DM0J587	Investigative	NA	[222]
HAP aniline mustard	DM6RT0P	Investigative	NA	[222]
HBDt.Fc	DMFEB6K	Investigative	NA	[222]
HC-15	DMFYGMX	Investigative	NA	[222]
HD-148	DM2HB64	Investigative	NA	[222]
HG-1068	DMHYRH1	Investigative	NA	[222]
HG-1070	DM0RGBG	Investigative	NA	[222]
HG-1071	DM7AJ9G	Investigative	NA	[222]
HG-1072	DMU9ICZ	Investigative	NA	[222]
HG-1076	DMNT9C1	Investigative	NA	[222]
HG-1077	DMX6CB4	Investigative	NA	[222]
HG-1078	DMC0U95	Investigative	NA	[222]
HG-1097	DM25T8M	Investigative	NA	[222]
HG-1109	DMC2411	Investigative	NA	[222]
HG-1141	DM17THK	Investigative	NA	[222]
HG-1143	DM4EVN6	Investigative	NA	[222]
HG-1144	DMX8R9W	Investigative	NA	[222]
HG-1164	DM0PRSB	Investigative	NA	[222]
HG-1177	DMFIQZR	Investigative	NA	[222]
HG-1179	DMRGORV	Investigative	NA	[222]
HG-1182	DMM59YX	Investigative	NA	[222]
HG-1202	DM3PC64	Investigative	NA	[222]
HG-1209	DMY2HT2	Investigative	NA	[222]
HG-1220	DMHQI90	Investigative	NA	[222]
HG-1226	DM4YM3U	Investigative	NA	[222]
HG-1245	DMUQ6ZO	Investigative	NA	[222]
HG-1246	DMO0M4W	Investigative	NA	[222]
HG-1300	DMBY24H	Investigative	NA	[222]
HG-1338	DMDIZK4	Investigative	NA	[222]
HG-1343	DMGCC8T	Investigative	NA	[222]
HG-1438	DMJQTI1	Investigative	NA	[222]
Histidase-PEG-20	DM8SVP1	Investigative	NA	[222]
HKI-46F08	DMU0XJL	Investigative	NA	[222]
HL-020	DMZCWVR	Investigative	NA	[222]
HL-021	DMZOR4S	Investigative	NA	[222]
HL-022	DMPJEBS	Investigative	NA	[222]
HL-023	DMSW4C6	Investigative	NA	[222]
HL-024	DMRCRCL	Investigative	NA	[222]
HL-1172	DMG6W0K	Investigative	NA	[222]
HL-146	DMCE4WR	Investigative	NA	[222]
HL-160	DMU4V6B	Investigative	NA	[222]
HLL1-Fab-A3B3	DM2URWO	Investigative	Vaccine	[1571]
HLM-008182	DMVW4JB	Investigative	NA	[222]
HM-5016699	DMKHVUE	Investigative	NA	[1495]
HM-61713B	DMNOFTX	Investigative	NA	[1497]
HM-90822	DMSUVSE	Investigative	NA	[222]
HO-4073	DMHG5S6	Investigative	NA	[222]
HOO-IFOS	DM3FHXM	Investigative	NA	[222]
HP-161	DMD7B8E	Investigative	NA	[222]
HPMA-docetaxel conjugate	DMVHM0M	Investigative	NA	[222]
HPMA-gemcitabine conjugate	DM2BZ7B	Investigative	NA	[222]
HRGP	DM5KDMP	Investigative	Small molecular drug	[222]
HS-113	DM4DBAD	Investigative	NA	[222]
HS-1183	DMQLSIT	Investigative	NA	[222]
HS-7	DM9BUM5	Investigative	Small molecular drug	[222]
HuGAL-F2	DMF82SS	Investigative	NA	[222]
Human embryonic stem cell-derived vascular progenitors	DMQQAGV	Investigative	NA	[222]
HuMax-CD38b	DM4FIZJ	Investigative	NA	[1572]
HuMax-CD74	DMKPXDG	Investigative	NA	[222]
HuMax-cMet	DM8AG5R	Investigative	Antibody	[1498]
HuMax-Her2	DMQCSAH	Investigative	NA	[222]
HuMax-VEGF	DME2T5M	Investigative	NA	[222]
HuMax-Wnt	DM2W7WC	Investigative	NA	[222]
HX-01	DMZ7HSA	Investigative	NA	[222]
HZ-08	DMFJURN	Investigative	NA	[222]
I-387	DMXLHKN	Investigative	NA	[222]
IAI-100	DMOQIDG	Investigative	Small molecular drug	[1573]
IB-06F259	DMR2F9D	Investigative	NA	[222]
Ibulocydine	DMEGEV8	Investigative	NA	[222]
ICGD	DMA18DV	Investigative	NA	[222]
ICT-037	DMPH8E9	Investigative	Antibody	[1571]
ICT-111	DMRB13T	Investigative	NA	[222]
IDN-13389	DMU40WY	Investigative	NA	[222]
IDN-5174	DMNS9KW	Investigative	NA	[1488]
IDN-5390	DM1OMSW	Investigative	Small molecular drug	[1506]
IDN-6384	DM6TEWZ	Investigative	NA	[1488]
IDN-6439	DMLYXK5	Investigative	NA	[222]
IDR-803	DMZZ8WX	Investigative	NA	[222]
IFN-beta	DM1I5AP	Investigative	NA	[1574]
IGFBP 2 variants	DMITCMQ	Investigative	NA	[222]
IKH-02	DM7R7GU	Investigative	NA	[222]
IKH-25	DM94AIL	Investigative	NA	[1575]
IKI-1	DM8GQ9X	Investigative	NA	[1576]
IKS-04	DM90MYL	Investigative	NA	[222]
IL-2 mimetic peptides	DMDEQYH	Investigative	NA	[222]
Imab-468	DM8Z9C6	Investigative	Monoclonal antibody	[222]
ImBryon	DMDTC9F	Investigative	NA	[222]
IMD-015213	DMANWVC	Investigative	NA	[222]
IMD-026260	DMRBL78	Investigative	NA	[222]
IMGN-007	DM351AA	Investigative	NA	[222]
IMGN-009	DMH5S2Y	Investigative	NA	[222]
ImmuneFx	DM2NFLN	Investigative	NA	[222]
IMP-111	DMEG38J	Investigative	NA	[222]
IMT-504	DMHS71X	Investigative	NA	[222]
INK4a	DMWE9FC	Investigative	NA	[222]
INO-1002	DMZEXY9	Investigative	NA	[1487]
INP-04	DM5HFH0	Investigative	NA	[222]
Interferon beta	DMXU6IJ	Investigative	NA	[222]
Interferon-alpha dimers	DMP3PVN	Investigative	NA	[222]
IPC-003	DM699LV	Investigative	NA	[222]
IPI-194	DM4SZT8	Investigative	NA	[222]
IPS-01003	DM0T8ZU	Investigative	NA	[1497]
IRC-083927	DMWKGIH	Investigative	Small molecular drug	[222]
ISC-4	DMH6YVD	Investigative	NA	[1577]
ISF-120	DM8O1FH	Investigative	NA	[222]
ISIS 13920	DM4PM1G	Investigative	Antisense drug	[1578]
ISIS 15770	DMJCXHM	Investigative	Antisense drug	[1578]
ISIS 16507	DMK69ZR	Investigative	Antisense drug	[1579]
ISIS 16518	DM24L0S	Investigative	Antisense drug	[1579]
ISIS 18078	DMHZPJ0	Investigative	Antisense drug	[1578]
ITE	DMA9GH2	Investigative	Small molecular drug	[222]
IVV-001	DMECB27	Investigative	NA	[222]
J-30	DMBYBJV	Investigative	Small molecular drug	[222]
JBD-401	DMA6N87	Investigative	NA	[222]
JBP-1	DM0KMPN	Investigative	NA	[1580]
JIN-2011	DM9JU63	Investigative	NA	[222]
JIN-2019	DMFY8UL	Investigative	NA	[222]
JP-1201	DM8KCCP	Investigative	NA	[222]
JP-8019	DMO5T3R	Investigative	NA	[222]
JX-1395	DMNHUG6	Investigative	NA	[222]
K-454	DMYSMWI	Investigative	NA	[1528]
K252a	DMT68RG	Investigative	Small molecular drug	[1581]
KA-10X	DM4GSHY	Investigative	NA	[1582]
KA-40X	DM7LKY1	Investigative	NA	[222]
Karomab	DM2V3P2	Investigative	Monoclonal antibody	[222]
KB-9520	DMCQRA3	Investigative	NA	[1583]
KC-7F2	DMEMR45	Investigative	NA	[222]
KI-0001	DM1GKD6	Investigative	NA	[222]
KI-0003	DMZ50P1	Investigative	NA	[222]
KI-0803	DMLT9BE	Investigative	NA	[222]
KI-0804	DMNC8QM	Investigative	NA	[222]
KI-0901	DML56LS	Investigative	NA	[222]
KI-0904	DMFVOMW	Investigative	NA	[222]
Ki-23057	DMPPZP6	Investigative	NA	[222]
KIN-4064	DMTX4V3	Investigative	NA	[222]
KM-3413	DMNT1R4	Investigative	NA	[222]
KM-3900	DMQK4UF	Investigative	NA	[222]
KM-4056	DMK17GN	Investigative	Antibody	[1584]
KNW-001	DML1FUP	Investigative	NA	[222]
KOSN1559	DM1SKNP	Investigative	NA	[1585]
KP-27	DM8C2KG	Investigative	NA	[222]
KPC-34	DM96ZV7	Investigative	NA	[222]
KRH-102053	DMXFBER	Investigative	NA	[1586]
KST-213	DMN25K2	Investigative	NA	[222]
KST-301	DMKAC48	Investigative	NA	[222]
KST-401	DMBTDOW	Investigative	NA	[222]
KT-105	DMYL4I7	Investigative	NA	[222]
KU-135	DMV0GE9	Investigative	NA	[222]
KU-55933	DMDT42X	Investigative	Small molecular drug	[1587]
Kuzbanian	DMA80V3	Investigative	NA	[222]
KYS-05050	DMXR3V4	Investigative	Small molecular drug	[1588]
LA-480	DMP1V8Y	Investigative	Antibody	[1498]
LA22-radioimmunoconjugates	DMY6K2A	Investigative	NA	[1497]
LC-445	DMYONVF	Investigative	Small molecular drug	[1313]
LD-101	DMD5GO0	Investigative	NA	[122]
LG-911	DMPPKB2	Investigative	NA	[222]
LHD-4	DMKI70D	Investigative	NA	[1589]
Liposomal disintergrin	DMIEYHT	Investigative	NA	[222]
LIV-1205	DMRO8BG	Investigative	NA	[222]
LIV-2008	DMIPJ2T	Investigative	NA	[222]
LJJ-10	DM8R845	Investigative	NA	[222]
LLL-12	DMNZS97	Investigative	NA	[222]
Low toxic paclitaxel derivative	DML9MTI	Investigative	NA	[222]
LP-10218	DMCECC8	Investigative	NA	[222]
LP-20104	DMH8LGU	Investigative	NA	[222]
LP-205A1	DMUIS92	Investigative	NA	[222]
LP-226A1	DMJOIOW	Investigative	NA	[222]
LP-30171	DM598WZ	Investigative	NA	[222]
LQB-118	DMFAP8V	Investigative	Small molecular drug	[222]
LT-0301	DM5S5JX	Investigative	NA	[222]
LY-GSK-3i	DMMTR71	Investigative	NA	[222]
M-402	DM9YEMU	Investigative	NA	[222]
mab 224G11	DM1ICOW	Investigative	Antibody	[1498]
mab 37.1	DM3DHH9	Investigative	Monoclonal antibody	[222]
Macbecin	DMDLF0J	Investigative	Small molecular drug	[1585]
MB-312	DM8IGNX	Investigative	NA	[222]
MB-314	DMUT3HU	Investigative	NA	[222]
MCT-465	DMR4IEH	Investigative	NA	[222]
MCT-485	DMWLL3E	Investigative	NA	[222]
MDC-917	DMKHQXM	Investigative	NA	[222]
MDC-922	DMX791J	Investigative	NA	[222]
MDP-01	DM8ZK12	Investigative	NA	[1497]
MDX-1140	DMLELJ2	Investigative	NA	[222]
MDX-1204	DM4RGCZ	Investigative	NA	[222]
MDX-1414	DMM0T1Y	Investigative	NA	[222]
MDX-1459	DMSZS4L	Investigative	NA	[222]
MEN-14295	DMEIRDX	Investigative	NA	[1488]
Metallo-SAHA	DM4XAF1	Investigative	NA	[222]
MG-1110	DMRNXWG	Investigative	NA	[222]
MG-28	DMN1F7Z	Investigative	NA	[1501]
MG-401	DMYZD8R	Investigative	NA	[222]
Mi-TUMEX	DMU17K7	Investigative	NA	[222]
MIP-1231	DM2IGD1	Investigative	NA	[1564]
MIP-1267	DME83MI	Investigative	NA	[222]
MIRNA-Rx07	DM8YBO7	Investigative	NA	[222]
ML-436	DMQKHP5	Investigative	NA	[222]
ML-721	DM5TR7N	Investigative	NA	[222]
MM-131	DMLTVH3	Investigative	NA	[222]
MMPT	DMCL7CM	Investigative	NA	[222]
MN-7105	DM4OBGE	Investigative	NA	[222]
MNX-200	DMLW7R9	Investigative	NA	[222]
MOR-205	DMX2O7Z	Investigative	NA	[222]
MOR-206	DMCW0SR	Investigative	NA	[222]
MP-529	DMV5T1I	Investigative	NA	[1521]
MP-AA-1	DMJ6MXN	Investigative	NA	[222]
MP-PN-1	DM2JB4B	Investigative	NA	[222]
MP-PN-2	DMLYKR0	Investigative	NA	[222]
MP-RM-1	DMFKG7C	Investigative	Antibody	[1590]
MPC-0767	DMCX9T8	Investigative	NA	[222]
MPC-9528	DMR5F4W	Investigative	NA	[222]
mRNA-046	DMIOEA0	Investigative	NA	[222]
MST-400	DMUKWJ2	Investigative	NA	[1591]
MT-101	DMEWKER	Investigative	Small molecular drug	[222]
MT-119	DMB5U42	Investigative	NA	[1592]
MT-503	DMYJGJA	Investigative	NA	[222]
MTC-220	DMXC4IT	Investigative	NA	[222]
MTD-102	DMTQFCO	Investigative	NA	[222]
MTKi-328	DMRJZDN	Investigative	NA	[222]
MTL-003	DM4QVR7	Investigative	NA	[222]
MTL-004	DMK7ALT	Investigative	NA	[222]
MTL-005	DMCUT8Q	Investigative	NA	[222]
MTL-007	DMOAKMA	Investigative	NA	[222]
MTL-102	DMABVL2	Investigative	NA	[222]
MTL-104	DM0RT44	Investigative	NA	[222]
MTX-25251	DMZ7G6R	Investigative	NA	[222]
N-885	DMWLY45	Investigative	NA	[222]
N-acetylardeemin	DMKJBX5	Investigative	NA	[222]
NBM-HD-1	DML3X8T	Investigative	NA	[222]
NBRI-16716a	DM16EGY	Investigative	NA	[222]
NC-0604	DM3QKWP	Investigative	NA	[222]
NCL-00016149	DMR5G9Q	Investigative	NA	[222]
NCTX	DMORXH5	Investigative	NA	[222]
NDC-1022	DM7NJI2	Investigative	NA	[1583]
NDC-1187	DM2LSFL	Investigative	NA	[222]
NDC-KM	DMAQ3SR	Investigative	NA	[222]
Nh-125	DMJIAVA	Investigative	NA	[222]
NKP-3752	DM523A3	Investigative	NA	[222]
NKTT-320	DMBZVO7	Investigative	NA	[222]
NLCQ-1	DMKR489	Investigative	NA	[222]
NLP-83	DMILGQ8	Investigative	NA	[222]
NM-006-MENK	DM9A8VP	Investigative	NA	[222]
NMB-T-BMX-OS01	DM5Q9FG	Investigative	NA	[1593]
NMS-1	DMX4ZGL	Investigative	NA	[1313]
NMS-E973	DMCKM6D	Investigative	Small molecular drug	[222]
NMS-P626	DMEIGJJ	Investigative	NA	[222]
NMS-P715	DMGJ7D3	Investigative	NA	[222]
NOD factors	DMLVQ83	Investigative	NA	[222]
NOPPI	DME5KJW	Investigative	NA	[222]
NOX-S91	DMVS6DW	Investigative	NA	[1594]
NPB-2	DMUUGDU	Investigative	NA	[222]
NPS-1	DM3OERD	Investigative	NA	[222]
NPS-2	DMSDX94	Investigative	NA	[222]
NRC-2694	DMXP03H	Investigative	NA	[1497]
NSC-134754	DMXAHF2	Investigative	Small molecular drug	[222]
NSC-73306	DM4R02J	Investigative	Small molecular drug	[222]
NSC-88915	DM9WIHJ	Investigative	Small molecular drug	[1595]
NU-1001-41	DMEHMOK	Investigative	Antibody	[122]
NVP-LDE276	DMJX1MO	Investigative	NA	[222]
NVX-144	DMEF540	Investigative	NA	[222]
NVX-188	DMJ67VQ	Investigative	NA	[222]
NVX-207	DMBQRA8	Investigative	NA	[1596]
NVX-272	DMY8RK5	Investigative	NA	[222]
NXD-30001	DM552GS	Investigative	NA	[222]
OB-24	DMY5V1O	Investigative	NA	[222]
OB-28	DM19YH0	Investigative	NA	[222]
OCID-4681	DM6E6CT	Investigative	NA	[222]
Octahydrocurcumin	DMUFDR6	Investigative	Small molecular drug	[1597]
OG-232	DMNYOL7	Investigative	NA	[222]
OG-9	DM6EOB9	Investigative	NA	[222]
OM-197-MP-AC	DME8RNV	Investigative	NA	[1598]
OM-294-DP	DML5AWQ	Investigative	NA	[1598]
ON-044580	DMWOHDV	Investigative	NA	[1599]
ON-123	DMHLEGT	Investigative	NA	[1600]
ON-128	DMTNKBW	Investigative	NA	[1497]
ON-24160	DMSFQHO	Investigative	NA	[1506]
Onco-D	DMQ0OWL	Investigative	NA	[222]
OP-02	DM3TDO0	Investigative	NA	[222]
OP-06	DMWBHK1	Investigative	NA	[222]
OPI-1100	DMQZO04	Investigative	NA	[222]
OpsoVac	DM2JZMY	Investigative	NA	[222]
Orazamide orotate	DM0NHJ8	Investigative	NA	[222]
OSU-2S	DMDYETD	Investigative	NA	[222]
OVI-117	DMAV9PS	Investigative	NA	[1601]
OXA-01	DMCFM2E	Investigative	NA	[1511]
P-3378	DMKTG3F	Investigative	NA	[222]
P-6915	DMJDI7O	Investigative	NA	[1495]
P2B-002	DMIV3T8	Investigative	NA	[222]
P2B-003	DMXOGAD	Investigative	NA	[222]
P2B-004	DMTUGHF	Investigative	NA	[222]
P31-Protein	DM9P8QW	Investigative	NA	[222]
P53 mdm-2-binding domain peptides	DM4EAG0	Investigative	NA	[222]
PAN-622	DMKS7KJ	Investigative	NA	[222]
PAT-CM-1	DMTWY1X	Investigative	Small molecular drug	[222]
PAT-CSL1	DMWGY5N	Investigative	NA	[222]
PAT-NM-1	DM0RRFW	Investigative	NA	[222]
PAT-SM3	DM591XV	Investigative	NA	[222]
PAT-SM4	DMPCOLF	Investigative	NA	[222]
PAT-SM5	DMYL3SJ	Investigative	NA	[222]
PB-102	DMC542F	Investigative	NA	[222]
PBOX-15	DMHH4D9	Investigative	NA	[222]
PC-22	DMOPPQ5	Investigative	NA	[222]
PC-24	DMUZFIB	Investigative	NA	[222]
PC-8608	DMSZ3G6	Investigative	NA	[222]
PCI-34051	DMIMPDL	Investigative	Small molecular drug	[1593]
PEG-LPA-2	DMY293M	Investigative	NA	[1602]
PEG-PLA-TNP-470	DM14CN9	Investigative	NA	[222]
PEGylated recombinant IFN-alpha2b	DM5UNML	Investigative	NA	[222]
PF-00212062	DMRHIMC	Investigative	Small molecular drug	[1603]
PF-00614435	DMWL9CU	Investigative	NA	[1498]
PF-03772304	DMJ0936	Investigative	NA	[1604]
PF-05094037	DMZAE97	Investigative	NA	[1511]
PF-3475952	DMF7TBC	Investigative	NA	[222]
PF-3823863	DMOTURH	Investigative	NA	[222]
PF-4989216	DMSG6F1	Investigative	NA	[1495]
PF-5177624	DMUOFT0	Investigative	NA	[1605]
PFK-015	DMO3QVP	Investigative	NA	[222]
PG-11144	DMC6UD4	Investigative	NA	[222]
PGGA-PTX	DM56QB3	Investigative	NA	[222]
PH sensitive micelles	DM21BQV	Investigative	NA	[222]
PHA-647A	DMPB3ZV	Investigative	NA	[222]
PHA-665752	DMCGX9U	Investigative	Small molecular drug	[1606]
PHA-690509	DMNS70E	Investigative	Small molecular drug	[1607]
Phospho-aspirins	DMQUUHK	Investigative	NA	[222]
PHY-626	DM0QBZJ	Investigative	NA	[222]
PHY-777	DMSOTG9	Investigative	NA	[222]
PHY-808	DME19W6	Investigative	NA	[222]
PJJ-34	DMP7LBJ	Investigative	NA	[222]
PKI-402	DM6NX4H	Investigative	Small molecular drug	[1608]
PLX-ORI3	DMZG1L5	Investigative	NA	[1609]
PM-72G	DMVPMCV	Investigative	NA	[222]
PMA-104R	DM68PWJ	Investigative	NA	[222]
PMA-109R	DM7QTFV	Investigative	NA	[222]
PMA-406	DMIC2JN	Investigative	NA	[222]
PMA-BB10	DMVEDMA	Investigative	NA	[222]
PMX-500	DM4NZ42	Investigative	NA	[222]
PMX-900	DMS6IME	Investigative	NA	[222]
PN-203	DM390ZS	Investigative	NA	[222]
PNH-192	DMIS7G4	Investigative	NA	[222]
PNT-200	DMKQPS4	Investigative	NA	[222]
PNT-300	DM8WJQ0	Investigative	NA	[1610]
PNT-400	DM1O34R	Investigative	NA	[222]
PNT-500	DMIEKVB	Investigative	NA	[1611]
PNT-600	DMS9I9C	Investigative	NA	[222]
PNU-248686A	DM43K1D	Investigative	NA	[1612]
Polymer-tubulysin A prodrug conjugate	DMAJYG8	Investigative	NA	[222]
POP-1	DMVTKCX	Investigative	NA	[1580]
PP-200	DMC61ZI	Investigative	NA	[222]
PP-405	DMJKPBU	Investigative	NA	[222]
PPMX-2017	DMLCR8E	Investigative	NA	[222]
PQ-1	DMXLPO6	Investigative	NA	[1613]
Pretubulysin	DMS00KQ	Investigative	NA	[222]
ProLindaun	DMNXBBM	Investigative	NA	[222]
Protease activated prodrug	DMFGSQA	Investigative	NA	[222]
PRS-110	DMB923H	Investigative	NA	[1498]
PSP-D-CD40L	DMNYUGD	Investigative	NA	[222]
PSP-D-GITRL	DMNAWCV	Investigative	NA	[222]
PTL-43401	DMK1XS7	Investigative	NA	[222]
PTX-001	DM4JIHW	Investigative	NA	[222]
PTX-008	DM01MY4	Investigative	NA	[222]
PU24S	DMHAJC1	Investigative	NA	[1585]
PV-1019	DMRI1LF	Investigative	NA	[1614]
PV-921	DMPC2LN	Investigative	NA	[222]
Pyridocarbazole	DM6RFTK	Investigative	NA	[222]
Pyriplatin	DM8E4Z0	Investigative	Small molecular drug	[222]
QBI-206	DMHRMXN	Investigative	NA	[222]
R-84	DM1MIRJ	Investigative	Antibody	[1500]
Rad51	DMDQA7C	Investigative	NA	[222]
Radiolabeled onartuzumab	DMT8KHO	Investigative	Monoclonal antibody	[222]
RBT-401	DM3Z6B4	Investigative	NA	[222]
REACTA	DM46YFK	Investigative	NA	[222]
Recombinant interleukin-2	DMDN494	Investigative	NA	[222]
Recombinant opticin	DMEIRII	Investigative	NA	[222]
Recombinant therapeutic proteins	DMWVPP4	Investigative	NA	[222]
Recombinant Wolinella (rWS) asparaginase	DMQ141Z	Investigative	NA	[222]
RepliVec	DM9Z6BP	Investigative	NA	[222]
RESP-4000	DMAQR2Y	Investigative	NA	[222]
RG6061	DM06PX3	Investigative	NA	[222]
RGel-Adnectin	DM5GAPD	Investigative	NA	[222]
RHAMLET	DMF8LGM	Investigative	NA	[222]
RIG-I adjuvant	DM3TE2F	Investigative	NA	[222]
RO-4920506	DMD9SCI	Investigative	NA	[1538]
Ro-5287373	DMMVMDE	Investigative	NA	[222]
RP-1040	DMP2EDX	Investigative	NA	[1498]
RP-525	DMASW8E	Investigative	NA	[222]
RP-656	DM6MBV6	Investigative	NA	[222]
RP-701	DMUUB9B	Investigative	NA	[222]
RR-1	DMR6LVV	Investigative	NA	[222]
RTA-301	DMLY4C9	Investigative	Small molecular drug	[1506]
RVLYSIN	DMS7QWZ	Investigative	NA	[222]
RX-0201N	DMTBYCY	Investigative	NA	[222]
RX-1792	DMKYNGE	Investigative	NA	[1497]
S-024	DMT36AB	Investigative	NA	[1514]
S-070	DMANSCK	Investigative	NA	[1514]
S-111	DMRVUCY	Investigative	NA	[1487]
S109	DM2JYQA	Investigative	Small molecular drug	[1615]
SA3C	DMTC3X9	Investigative	NA	[222]
Salinosporamide B	DMM9BAO	Investigative	Small molecular drug	[222]
Salmonella typhimurium A1-R	DMSZLLX	Investigative	NA	[222]
SapC-DOPS	DMFFXF6	Investigative	NA	[222]
SAR-131675	DMSYE4W	Investigative	Small molecular drug	[1616]
SARMs	DMILBO9	Investigative	NA	[222]
SB-101	DMM8A9Q	Investigative	NA	[222]
SB-2280	DMIBS95	Investigative	NA	[1511]
SB-41947	DM6UCFR	Investigative	NA	[222]
SCH-1450206	DMMSRWT	Investigative	NA	[222]
SCH-1595241	DM1U5B5	Investigative	NA	[222]
SCH-546909	DMMXIB4	Investigative	Small molecular drug	[1617]
SCIB-2	DMD020B	Investigative	NA	[222]
SDX-7400	DML1FOR	Investigative	NA	[222]
SEL-120	DM9NITG	Investigative	NA	[222]
Sensor linked micelle	DMFUZLZ	Investigative	NA	[222]
SER-201	DMG95EP	Investigative	NA	[222]
SER-203	DMIKT7W	Investigative	NA	[1488]
SER-207	DMZZD9A	Investigative	NA	[222]
SERMs	DM4ZYKV	Investigative	NA	[1618]
SG-2274	DMDNP2S	Investigative	NA	[222]
SGI-1252	DMZ20A5	Investigative	NA	[1528]
SIL-43	DMWDNPU	Investigative	NA	[222]
SIM-010603	DMDT8C9	Investigative	NA	[222]
SIM-0702	DMGIRLF	Investigative	NA	[222]
SIM-0710	DM98QMX	Investigative	NA	[222]
SJ-3249	DMA4LK9	Investigative	NA	[222]
SJ-8002	DMEQBU2	Investigative	NA	[1619]
SL-201	DM7R12F	Investigative	NA	[222]
SL-301	DM2IUPT	Investigative	NA	[222]
SMNT-1	DM3K1VJ	Investigative	NA	[222]
SMOi2-17	DMABIX1	Investigative	NA	[1620]
SMT-A07	DMOAX8N	Investigative	NA	[222]
SMTP-0	DM9SF48	Investigative	NA	[1621]
SN-28049	DMVOK5R	Investigative	Small molecular drug	[222]
SNG-163	DMOLQNK	Investigative	NA	[1618]
SNX-9	DMQJJAC	Investigative	NA	[222]
Soluble ErbB3 theragnostics	DMJXN1G	Investigative	NA	[1590]
SOM-0002	DMU78W0	Investigative	NA	[222]
SOM-0777	DM3R3N5	Investigative	NA	[222]
Sophorolipid isoforms	DM6FHSG	Investigative	NA	[222]
SP-1031C	DMI6F2O	Investigative	NA	[222]
SPL-2101	DMX3HBZ	Investigative	NA	[222]
SPVF-2801-10	DMHA263	Investigative	NA	[222]
SPVF-2801-30	DMB8ANZ	Investigative	NA	[222]
SR-3850	DM3Y09Z	Investigative	NA	[1622]
SRI-21009	DMKQ765	Investigative	NA	[222]
SST-0001	DMMY8K9	Investigative	NA	[222]
ST-2987	DMWXTM8	Investigative	Small molecular drug	[1623]
STA-9584	DMJCM23	Investigative	NA	[222]
STAT-3 DECOY (NSC-741763)	DM8EL0X	Investigative	NA	[222]
STF-31	DM488R2	Investigative	NA	[222]
Sulforaphane	DMQY3L0	Investigative	NA	[1624]
SWA11-ZZ-PE38	DMNA70Y	Investigative	NA	[222]
SX-RDS1	DMBA6XH	Investigative	NA	[222]
SYM-005	DM80ZIM	Investigative	NA	[222]
SYM-007	DMXB5KM	Investigative	NA	[222]
SYM-011	DMKIDRY	Investigative	NA	[1590]
Synthetic peptide	DM86CNO	Investigative	NA	[222]
T-115	DM3TJ72	Investigative	NA	[222]
T-oligos	DM9BFZP	Investigative	NA	[222]
T1-IR	DMAXCTM	Investigative	NA	[222]
TA-103	DMIPURX	Investigative	Small molecular drug	[222]
Taxotere-mab	DMZEBFL	Investigative	Monoclonal antibody	[222]
TB-09	DM5K6VP	Investigative	NA	[222]
TCR-transduced T-cell immunotherapy	DMP55O1	Investigative	NA	[222]
TEM-8-Fc	DM27T6U	Investigative	NA	[222]
Terpenoid schweinfurthins	DMIWRPL	Investigative	NA	[222]
TG-3003	DMHTEMP	Investigative	Antibody	[1519]
TG-6002	DM3X5MH	Investigative	NA	[222]
TGC-9	DM4J21P	Investigative	NA	[222]
TGF-beta Shield	DMUP34S	Investigative	NA	[1625]
TGN-208	DMY2ZF6	Investigative	NA	[222]
TH-1011	DMGNEYK	Investigative	NA	[222]
TH-1320	DMLC8PX	Investigative	NA	[1488]
TH-337	DM8U4H9	Investigative	NA	[222]
Theliatinib	DMRVXFN	Investigative	NA	[1497]
THZ531	DMBZ2MF	Investigative	Small molecular drug	[1626]
TL-1836	DMEGBDJ	Investigative	NA	[222]
TL-1892	DMAHG9E	Investigative	NA	[1506]
TNF-PEG-20	DMO89WS	Investigative	NA	[222]
TP-801	DM4WTCE	Investigative	NA	[1498]
Tr-2	DM4GK89	Investigative	Small molecular drug	[1627]
Tr-3	DMDAH3O	Investigative	NA	[222]
TR-4	DM20L31	Investigative	NA	[222]
TRAIL-R Atrimer	DMXHK6J	Investigative	NA	[222]
Transcobalamin (vitamin B12) receptor-targeting mabTCR23-saporin conjugate	DMVJ9KY	Investigative	NA	[222]
Trichostatin A	DM9C8NX	Investigative	Small molecular drug	[1628]
Trunkamide	DMLB167	Investigative	Small molecular drug	[222]
TRX-585	DMYM9RC	Investigative	NA	[222]
TSRI-265	DMXFMI8	Investigative	NA	[222]
TT-310	DMVTO00	Investigative	NA	[222]
TTL-1177	DMDM7C6	Investigative	NA	[1629]
Tumor vascular thrombogen	DMIRQ65	Investigative	NA	[1630]
Tumor-associated macrophage immunotherapy	DMX1A95	Investigative	NA	[222]
Tyrophostins	DMWJ6PT	Investigative	NA	[222]
UAI-201	DMJBPYW	Investigative	NA	[222]
UCB-1350883	DMZ9Y0T	Investigative	NA	[222]
UltraGITRL	DMDRHYJ	Investigative	NA	[222]
UMN-01	DMWGZM2	Investigative	NA	[222]
UPA-targeted oncolytic Sendai virus	DMR46C8	Investigative	NA	[1516]
UPAR-lock	DMANNR4	Investigative	NA	[222]
V-1810	DMM1T7Q	Investigative	NA	[222]
VAL-101	DMWIU6T	Investigative	NA	[222]
VBY- 825	DMRBPTC	Investigative	NA	[222]
VE-04051645	DM3GADP	Investigative	NA	[1630]
VE-821	DM0UXNF	Investigative	Small molecular drug	[1631]
VEGF kinoid	DMANX2H	Investigative	NA	[222]
VER-54505	DMYD7P5	Investigative	NA	[1617]
VER-82160	DMCQFBZ	Investigative	NA	[222]
VG-102	DM6F7FW	Investigative	NA	[222]
VGX-200	DMKU5XT	Investigative	NA	[222]
Vivia-007	DMC4M9B	Investigative	NA	[222]
Vivia-008	DMBGWUT	Investigative	NA	[222]
Vivia-009	DMF3Z65	Investigative	NA	[222]
Vivia-1615	DMIR31H	Investigative	NA	[222]
Vivia-577	DMMTLF5	Investigative	NA	[222]
VK-12	DMRQBEW	Investigative	NA	[1632]
VL-01	DMU1SPO	Investigative	NA	[222]
VPC-51299	DMTMF6I	Investigative	NA	[222]
VPC-8	DM84R48	Investigative	NA	[222]
VS1-011	DMM0FZU	Investigative	NA	[222]
WAY-255348	DMSLNWA	Investigative	Small molecular drug	[1633]
WBI-2000	DMZSTZK	Investigative	NA	[222]
WBZ-7	DME10AL	Investigative	NA	[1504]
WEHI-0103122	DMK0OVE	Investigative	NA	[1553]
WL-276	DM8SEHO	Investigative	NA	[1634]
WT2527	DMHX22B	Investigative	NA	[222]
WTC-01	DMP58OS	Investigative	NA	[222]
WX-037	DM6J7OQ	Investigative	NA	[1495]
WYE-130600	DMMIVNM	Investigative	NA	[222]
X-387	DMZ0TDL	Investigative	NA	[1511]
XB-05	DMYT5DI	Investigative	NA	[1540]
XGP-210	DMDVIGK	Investigative	NA	[222]
XGP-215	DM19I8N	Investigative	NA	[222]
XN-05	DMQJPXL	Investigative	NA	[222]
XN-0502	DMXH6DL	Investigative	Small molecular drug	[1506]
YK-3237	DMU0NHX	Investigative	NA	[1635]
ZG-451	DMV0NNQ	Investigative	NA	[222]
ZIO-102	DMMM4S9	Investigative	NA	[222]
ZP-10395	DMXQYM6	Investigative	NA	[222]
ZP-2571	DMMNRLO	Investigative	NA	[222]
[111In]B3	DMASJGH	Investigative	NA	[222]
[99mTc]Met	DMMB13F	Investigative	NA	[222]

This Disease is Treated as An Indication in 1 Investigative Agents

Drug Name	Drug ID	Highest Status	Drug Type	REF
Silvestrol	DM5JKNF	Investigative	Small molecular drug	[222]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT00633087) A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7955).
• [5] ClinicalTrials.gov (NCT00571168) Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy. U.S. National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3860).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7709).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7589).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5343).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
• [13] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050682.
• [14] Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
• [15] The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
• [18] ClinicalTrials.gov (NCT04589845) Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. U.S. National Institutes of Health.
• [19] New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
• [20] ClinicalTrials.gov (NCT03210714) Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial). U.S. National Institutes of Health.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4801).
• [23] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [24] ClinicalTrials.gov (NCT02314819) A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients RESCO). U.S. National Institutes of Health.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5483).
• [26] Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
• [29] Clinical pipeline report, company report or official report of Teva.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5984).
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024778)
• [32] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7877).
• [35] Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56.
• [36] Recent natural products based drug development: a pharmaceutical industry perspective. J Nat Prod. 1998 Aug;61(8):1053-71.
• [37] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001292)
• [38] Drug information of Lucanthone, 2008. eduDrugs.
• [39] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7382).
• [40] Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for ... Trials. 2015 Mar 4;16:77.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6945).
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8274).
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
• [44] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2509).
• [45] ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [46] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8394).
• [47] Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463.
• [48] ClinicalTrials.gov (NCT01982955) MSC2156119J With Gefitinib in Subjects With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [49] De novo synthesis of two new cytotoxic tiazofurin analogues with modified sugar moieties. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3167-70.
• [50] Plant-derived compounds in clinical trials. Drug Discov Today. 2008 Feb;13(3-4):161-71.
• [51] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2774).
• [52] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1177).
• [54] Clinical pipeline report, company report or official report of Taiho Pharmaceutical.
• [55] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
• [56] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2054).
• [57] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
• [58] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7105).
• [59] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7974).
• [60] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8305).
• [61] ClinicalTrials.gov (NCT00604890) Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma. U.S. National Institutes of Health.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040945)
• [63] ClinicalTrials.gov (NCT01394679) A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer. U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT03628677) A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies. U.S. National Institutes of Health.
• [65] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5657).
• [66] ClinicalTrials.gov (NCT01580397) Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.
• [67] ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [68] ClinicalTrials.gov (NCT01752920) Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [69] ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
• [70] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7949).
• [71] Phase III clinical study of a new anticancer drug atofluding. Ai Zheng. 2002 Dec;21(12):1350-3.
• [72] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7942).
• [73] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8445).
• [74] Clinical pipeline report, company report or official report of Revance Therapeutics.
• [75] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8360).
• [76] Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
• [77] Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78.
• [78] Clinical pipeline report, company report or official report of Circassia.
• [79] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2339).
• [80] A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies. Anticancer Res. 2007 May-Jun;27(3B):1593-600.
• [81] ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health.
• [82] ClinicalTrials.gov (NCT02087306) Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection. U.S. National Institutes of Health.
• [83] ClinicalTrials.gov (NCT01106599) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [84] Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13.
• [85] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000).
• [86] ClinicalTrials.gov (NCT00824161) Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer. U.S. National Institutes of Health.
• [87] Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol. 2008 Jun;87(3):326-30.
• [88] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [89] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7649).
• [90] ClinicalTrials.gov (NCT00023972) Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [91] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7794).
• [92] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031868)
• [93] ClinicalTrials.gov (NCT01991184) A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT00019682) Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma. U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT02405442) Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease. U.S. National Institutes of Health.
• [96] Clinical pipeline report, company report or official report of Panagin Pharmaceuticals Inc.
• [97] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 422).
• [98] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8221).
• [99] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013516)
• [100] ClinicalTrials.gov (NCT01630733) A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [101] ClinicalTrials.gov (NCT00163319) Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101). U.S. National Institutesof Health.
• [102] A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015 Mar;51(4):522-32.
• [103] ClinicalTrials.gov (NCT01450228) Efficacy and Safety of KI1001 in 55 Years Old Insomnia Patients. U.S. National Institutes of Health.
• [104] The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther. 1991 Jun;257(3):967-71.
• [105] ClinicalTrials.gov (NCT00112554) Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [106] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7383).
• [107] Clinical pipeline report, company report or official report of Triphase Accelerator .
• [108] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7985).
• [109] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7790).
• [110] ClinicalTrials.gov (NCT01200992) Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer. U.S. National Institutes of Health.
• [111] First-in-Class Cancer Stemness Inhibitor Shows Promising Results in Advanced Colorectal Cancer. 2016 ASCO GI Conference. January 26, 2016.
• [112] ClinicalTrials.gov (NCT00012324) Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer. U.S. National Institutes of Health.
• [113] ClinicalTrials.gov (NCT02068339) Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis. U.S. National Institutes of Health.
• [114] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7423).
• [115] ClinicalTrials.gov (NCT01674855) Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT02031991) A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01). U.S. National Institutes of Health.
• [117] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7833).
• [118] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [119] ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [120] ClinicalTrials.gov (NCT02127710) A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC). U.S. National Institutes of Health.
• [121] ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.
• [122] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [123] ClinicalTrials.gov (NCT00931008) Study to Evaluate SID 530 Compared to Taxotere. U.S. National Institutes of Health.
• [124] ClinicalTrials.gov (NCT00139282) A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration. U.S. National Institutes of Health.
• [125] ClinicalTrials.gov (NCT02133157) Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [126] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [127] ClinicalTrials.gov (NCT02525536) A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [128] Flows and flaws in primary central nervous system lymphoma. Nat Rev Clin Oncol. 2010 Aug;7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2.
• [129] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7971).
• [130] ClinicalTrials.gov (NCT00918138) Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg ComparedTo Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg. U.S. National Institutes of Health.
• [131] ClinicalTrials.gov (NCT01741038) Study of AlloStim In-Situ Vaccine in Pre-Treated Metastatic Breast Cancer. U.S. National Institutes of Health.
• [132] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7707).
• [133] ClinicalTrials.gov (NCT00057382) T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients. U.S. National Institutes of Health.
• [134] ClinicalTrials.gov (NCT00442533) Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors. U.S. National Institutes of Health.
• [135] ClinicalTrials.gov (NCT01442636) Drug Eluting Stents In The Critically Ischemic Lower Leg 2. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT04887870) Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study. U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT00420888) ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. U.S. National Institutes of Health.
• [138] ClinicalTrials.gov (NCT00368173) IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome. U.S. National Institutes of Health.
• [139] ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health.
• [140] ClinicalTrials.gov (NCT01898273) Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma. U.S. National Institutes of Health.
• [141] ClinicalTrials.gov (NCT03724253) [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NeoFIND). U.S. National Institutes of Health.
• [142] ClinicalTrials.gov (NCT02502786) Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma.
• [143] ClinicalTrials.gov (NCT00978250) A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU). U.S. National Institutes of Health.
• [144] ClinicalTrials.gov (NCT04239092) 9-ING-41 in Pediatric Patients With Refractory Malignancies.. U.S. National Institutes of Health.
• [145] ClinicalTrials.gov (NCT02494570) A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa.
• [146] ClinicalTrials.gov (NCT00602199) ABT-510 in Treating Patients With Metastatic Melanoma. U.S. National Institutes of Health.
• [147] ClinicalTrials.gov (NCT00436852) ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment. U.S. National Institutes of Health.
• [148] ClinicalTrials.gov (NCT00740441) A Phase II Study of AS1411 in Renal Cell Carcinoma. U.S. National Institutes of Health.
• [149] ClinicalTrials.gov (NCT03544723) Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.. U.S. National Institutes of Health.
• [150] Clinical pipeline report, company report or official report of Adaptimmune.
• [151] ClinicalTrials.gov (NCT04592653) A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment (ARTISTRY-3). U.S. National Institutes of Health.
• [152] ClinicalTrials.gov (NCT02384954) ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab. U.S. National Institutes of Health.
• [153] ClinicalTrials.gov (NCT02420587) AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.
• [154] ClinicalTrials.gov (NCT02110355) A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma. U.S. National Institutes of Health.
• [155] ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health.
• [156] ClinicalTrials.gov (NCT00687596) Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy. U.S. National Institutes ofHealth.
• [157] ClinicalTrials.gov (NCT03926143) A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies. U.S. National Institutes of Health.
• [158] ClinicalTrials.gov (NCT00612664) Phase II, 2nd Line Melanoma - RAND Monotherapy. U.S. National Institutes of Health.
• [159] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7741).
• [160] A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50(12):1958-63.
• [161] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246)
• [162] ClinicalTrials.gov (NCT03375086) A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330). U.S. National Institutes of Health.
• [163] ClinicalTrials.gov (NCT00043199) A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies. U.S. National Institutes of Health.
• [164] ClinicalTrials.gov (NCT01473095) Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma. U.S. National Institutes of Health.
• [165] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020571)
• [166] ClinicalTrials.gov (NCT01989325) A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma. U.S. National Institutes of Health.
• [167] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4371).
• [168] ClinicalTrials.gov (NCT00163280) Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis. U.S. National Institutes of Health.
• [169] ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health.
• [170] ClinicalTrials.gov (NCT00932724) CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer. U.S. National Institutes of Health.
• [171] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7873).
• [172] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7699).
• [173] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021605)
• [174] ClinicalTrials.gov (NCT02448225) 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules. U.S. National Institutes of Health.
• [175] ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health.
• [176] ClinicalTrials.gov (NCT04819373) BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors. U.S. National Institutes of Health.
• [177] ClinicalTrials.gov (NCT00538343) RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases. U.S. National Institutes of Health.
• [178] Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42.
• [179] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7950).
• [180] Clinical pipeline report, company report or official report of BeiGene.
• [181] Clinical pipeline report, company report or official report of Morphosys.
• [182] ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
• [183] Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005 Apr;16(4):597-601.
• [184] A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. Br J Cancer. 2006 Jan 16;94(1):79-84.
• [185] ClinicalTrials.gov (NCT00359450) Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer). U.S. National Institutes of Health.
• [186] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7647).
• [187] ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health.
• [188] The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018 Jul;17(7):509-527.
• [189] ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
• [190] ClinicalTrials.gov (NCT01781429) Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [191] ClinicalTrials.gov (NCT02094560) CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors. U.S. National Institutes of Health.
• [192] SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral. Antiviral Res. 2012 Jan;93(1):69-77.
• [193] ClinicalTrials.gov (NCT02129075) CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma. U.S. National Institutes of Health.
• [194] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034210)
• [195] Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
• [196] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015700)
• [197] ClinicalTrials.gov (NCT00430144) Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix. U.S. National Institutes of Health.
• [198] ClinicalTrials.gov (NCT01778088) Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma. U.S. National Institutes of Health.
• [199] ClinicalTrials.gov (NCT00659334) Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation. U.S. National Institutes of Health.
• [200] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7881).
• [201] ClinicalTrials.gov (NCT01803269) Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.
• [202] Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9.
• [203] ClinicalTrials.gov (NCT00061659) Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma. U.S. National Institutes of Health.
• [204] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [205] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8126).
• [206] Results of phase II clinical trial of cycloplatam in refractory solid tumors. Vopr Onkol. 2001;47(6):752-6.
• [207] Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer. 1998 Feb;34(3):422-3.
• [208] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031447)
• [209] ClinicalTrials.gov (NCT03834220) Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial). U.S. National Institutes of Health.
• [210] ClinicalTrials.gov (NCT00128544) Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B. U.S. National Institutes of Health.
• [211] A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5922-8.
• [212] ClinicalTrials.gov (NCT00080015) Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC). U.S. National Institutes of Health.
• [213] ClinicalTrials.gov (NCT03368859) A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab. U.S. National Institutes of Health.
• [214] ClinicalTrials.gov (NCT00003677) Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [215] Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
• [216] Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol. 2007 Feb 15;73(4):469-80.
• [217] ClinicalTrials.gov (NCT00507741) Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02). U.S. National Institutes of Health.
• [218] Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.
• [219] Clinical pipeline report, company report or official report of Rogosin Institute.
• [220] Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604.
• [221] ClinicalTrials.gov (NCT00949559) Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [222] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [223] Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer. 2013 Jun;80(3):313-8.
• [224] ClinicalTrials.gov (NCT00264433) A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent. U.S. National Institutes of Health.
• [225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031837)
• [226] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000888)
• [227] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7886).
• [228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004717)
• [229] ClinicalTrials.gov (NCT02454010) A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer. U.S. National Institutes of Health.
• [230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032798)
• [231] ClinicalTrials.gov (NCT00485563) A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma. U.S. National Institutes of Health.
• [232] Clinical pipeline report, company report or official report of Five Prime Therapeutics.
• [233] ClinicalTrials.gov (NCT01777594) Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [234] ClinicalTrials.gov (NCT04632992) A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC). U.S. National Institutes of Health.
• [235] Clinical pipeline report, company report or official report of Genentech (2011).
• [236] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5682).
• [237] ClinicalTrials.gov (NCT01519817) Open Label Study to Evaluate the Safety and Tolerability of GI-6301 (Whole Heat-Killed Recombinant Yeast Modified to Express Brachyury Protein) in Adults With Solid Tumors. U.S. National Institutes of Health.
• [238] A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas. Journal of Clinical Oncology, Vol 25, No 18S (June 20 Supplement), 2007: 3010.
• [239] ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [240] ClinicalTrials.gov (NCT01531894) Continuation Study of the Oral AKT Inhibitor GSK2110183. U.S. National Institutes of Health.
• [241] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023682)
• [242] Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
• [243] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027035)
• [244] ClinicalTrials.gov (NCT02358889) Study Evaluating Intravitreal hI-con1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration. U.S. National Institutes of Health.
• [245] Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004 Jul 15;22(14):2800-7.
• [246] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7903).
• [247] ClinicalTrials.gov (NCT00060268) Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors. U.S. National Institutes of Health.
• [248] ClinicalTrials.gov (NCT00992732) Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders. U.S. National Institutes of Health.
• [249] ClinicalTrials.gov (NCT02420873) A Study of Lorvotuzumab Mertansine. U.S. National Institutes of Health.
• [250] ClinicalTrials.gov (NCT01303172) A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer. U.S. National Institutes of Health.
• [251] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [252] ClinicalTrials.gov (NCT03277352) INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. U.S. National Institutes of Health.
• [253] ClinicalTrials.gov (NCT04629339) Study of INCB086550 in Select Solid Tumors. U.S. National Institutes of Health.
• [254] ClinicalTrials.gov (NCT00116363) Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma. U.S. National Institutes of Health.
• [255] A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol. 2011 May 8;3:25.
• [256] Iodostearic acid in the treatment of advanced gastrointestinal carcinoma. Eur J Surg Oncol. 1992 Aug;18(4):357-61.
• [257] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [258] ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
• [259] Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014 Jan;13(1):39-62.
• [260] Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol. 1999 Dec;17(12):3822-7.
• [261] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
• [262] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028294)
• [263] ClinicalTrials.gov (NCT04891198) ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [264] ClinicalTrials.gov (NCT01063907) A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [265] Clinical pipeline report, company report or official report of Immunomedics.
• [266] Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72.
• [267] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7912).
• [268] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6925).
• [269] Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr Opin Mol Ther. 2006 Dec;8(6):539-46.
• [270] ClinicalTrials.gov (NCT01900652) A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants. U.S. National Institutes of Health.
• [271] Clinical pipeline report, company report or official report of Eli Lilly.
• [272] ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health.
• [273] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8104).
• [274] ClinicalTrials.gov (NCT02549989) Study of LY3023414 for the Treatment of Recurrent.
• [275] ClinicalTrials.gov (NCT00482976) Effect of LY333531 on Vascular and Neural Functions. U.S. National Institutes of Health.
• [276] ClinicalTrials.gov (NCT01652482) A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. U.S. National Institutes of Health.
• [277] ClinicalTrials.gov (NCT02008929) to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell). U.S. National Institutes of Health.
• [278] ClinicalTrials.gov (NCT01828021) Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer. U.S. National Institutes of Health.
• [279] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7008).
• [280] ClinicalTrials.gov (NCT00685204) An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma. U.S. National Institutes of Health.
• [281] Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21.
• [282] ClinicalTrials.gov (NCT02399137) A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [283] Clinical pipeline report, company report or official report of MetronomX.
• [284] Fourth-quarter biotech job picture. Nat Biotechnol. 2014 Feb;32(2):199.
• [285] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7932).
• [286] Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience. Expert Rev Vaccines. 2009 Oct;8(10):1399-413.
• [287] J Clin Oncol 30, 2012 (suppl, abstr 2577).
• [288] A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother. 2000 Sep;49(7):347-60.
• [289] ClinicalTrials.gov (NCT00004033) Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma. U.S. National Institutes of Health.
• [290] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026542)
• [291] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [292] ClinicalTrials.gov (NCT00562315) FACBC PET/CT for Recurrent Prostate Cancer. U.S. National Institutes of Health.
• [293] ClinicalTrials.gov (NCT00036660) SarCNU in Treating Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
• [294] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027019)
• [295] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [296] ClinicalTrials.gov (NCT03592264) This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
• [297] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
• [298] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5268).
• [299] Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9.
• [300] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032966)
• [301] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032967)
• [302] Biotechnology in Comparative Perspective, Gerhard Fuchs. Page(82).
• [303] ClinicalTrials.gov (NCT01899599) PankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer. U.S. National Institutes of Health.
• [304] ClinicalTrials.gov (NCT02329717) Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
• [305] A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
• [306] ClinicalTrials.gov (NCT00078468) Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment. U.S. National Institutes of Health.
• [307] ClinicalTrials.gov (NCT00002634) Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma. U.S. National Institutes of Health.
• [308] ClinicalTrials.gov (NCT01620970) PF-03446962 in Relapsed or Refractory Urothelial Cancer. U.S. National Institutes of Health.
• [309] ClinicalTrials.gov (NCT03092856) Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
• [310] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7940).
• [311] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7476).
• [312] ClinicalTrials.gov (NCT00268593) Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer. U.S. National Institutes of Health.
• [313] Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
• [314] ClinicalTrials.gov (NCT00900562) Clinical Trial of PM00104 (Zalypsis) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy. U.S. National Institutes of Health.
• [315] ClinicalTrials.gov (NCT01733238) Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [316] ClinicalTrials.gov (NCT00291837) CT-2106 for the Second Line Treatment of Ovarian Cancer. U.S. National Institutes of Health.
• [317] ClinicalTrials.gov (NCT00746590) Study of Anti-tumour Effects and Safety of Prolarix in Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [318] ClinicalTrials.gov (NCT00797940) Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1). U.S. National Institutes of Health.
• [319] ClinicalTrials.gov (NCT00911248) PTC299 for Treatment of Neurofibromatosis Type 2. U.S. National Institutes of Health.
• [320] ClinicalTrials.gov (NCT01718899) Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma. U.S. National Institutes of Health.
• [321] The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med. 2006 Feb;147(2):83-90.
• [322] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7941).
• [323] ClinicalTrials.gov (NCT02160730) Treatment of Cushing's Disease With R-roscovitine. U.S. National Institutes of Health.
• [324] ClinicalTrials.gov (NCT00625586) Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [325] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6183).
• [326] Technology evaluation: AVI-4126, AVI BioPharma. Curr Opin Mol Ther. 2004 Oct;6(5):551-8.
• [327] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035593)
• [328] A phase 2 study of oral MKC-1, an inhibitor of importin-beta, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20.
• [329] ClinicalTrials.gov (NCT02407509) Phase I Trial of RO5126766. U.S. National Institutes of Health.
• [330] ClinicalTrials.gov (NCT01622764) 89Zr-RO5323441 PET Imaging in Glioblastoma. U.S. National Institutes of Health.
• [331] ClinicalTrials.gov (NCT01463956) Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT). U.S. National Institutes of Health.
• [332] ClinicalTrials.gov (NCT01028495) A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
• [333] ClinicalTrials.gov (NCT02030067) Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies. U.S. National Institutes of Health.
• [334] ClinicalTrials.gov (NCT02003092) RX-5902 Treatment of Subjects With Solid Tumors. U.S. National Institutes of Health.
• [335] ClinicalTrials.gov (NCT00027781) MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy. U.S. National Institutes of Health.
• [336] Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601.
• [337] ClinicalTrials.gov (NCT02435121) A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification. U.S. National Institutes of Health.
• [338] ClinicalTrials.gov (NCT01156870) First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor. U.S. National Institutes of Health.
• [339] ClinicalTrials.gov (NCT01936363) Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer. U.S. National Institutes of Health.
• [340] Clinical pipeline report, company report or official report of Merrimack Pharmaceuticals.
• [341] ClinicalTrials.gov (NCT02984683) Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [342] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
• [343] ClinicalTrials.gov (NCT00343564) A Study of SB-743921 in Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [344] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
• [345] ClinicalTrials.gov (NCT01642342) Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors. U.S. National Institutes of Health.
• [346] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026065)
• [347] ClinicalTrials.gov (NCT00099255) Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma. U.S. National Institutes of Health.
• [348] ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
• [349] ClinicalTrials.gov (NCT00064220) Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma. U.S. National Institutes of Health.
• [350] Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
• [351] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3886).
• [352] ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
• [353] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036387)
• [354] Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
• [355] Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(13):1991-7.
• [356] ClinicalTrials.gov (NCT00014547) BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment. U.S. National Institutes of Health.
• [357] ClinicalTrials.gov (NCT02160106) First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors. U.S. National Institutes of Health.
• [358] Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.
• [359] ClinicalTrials.gov (NCT00730262) Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme. U.S. National Institutes of Health.
• [360] NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21.
• [361] ClinicalTrials.gov (NCT01851369) TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [362] ClinicalTrials.gov (NCT00129948) Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
• [363] ClinicalTrials.gov (NCT01057342) Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer. U.S. National Institutes of Health.
• [364] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705).
• [365] ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health.
• [366] ClinicalTrials.gov (NCT04504916) A Study of VLS-101 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [367] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7910).
• [368] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5718).
• [369] ClinicalTrials.gov (NCT00493441) AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer. U.S. National Institutes of Health.
• [370] Clinical pipeline report, company report or official report of Tyrogenex.
• [371] ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health.
• [372] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7963).
• [373] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5679).
• [374] ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth.
• [375] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [376] ClinicalTrials.gov (NCT03872778) [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay). U.S. National Institutes of Health.
• [377] ClinicalTrials.gov (NCT02509546) 8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia.
• [378] ClinicalTrials.gov (NCT03602079) Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene. U.S. National Institutes of Health.
• [379] ClinicalTrials.gov (NCT04775680) Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma. U.S. National Institutes of Health.
• [380] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7643).
• [381] ClinicalTrials.gov (NCT00768339) A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas. U.S. National Institutes of Health.
• [382] ClinicalTrials.gov (NCT04259450) Study to Assess AFM24 in Advanced Solid Cancers. U.S. National Institutes of Health.
• [383] ClinicalTrials.gov (NCT04503265) A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [384] ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
• [385] ClinicalTrials.gov (NCT03745326) Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients. U.S. National Institutes of Health.
• [386] ClinicalTrials.gov (NCT03190941) Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients. U.S. National Institutes of Health.
• [387] ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health.
• [388] ClinicalTrials.gov (NCT03834948) AO-176 in Multiple Solid Tumor Malignancies. U.S. National Institutes of Health.
• [389] ClinicalTrials.gov (NCT03520075) Study of ASTX029 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [390] ClinicalTrials.gov (NCT03975387) Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53. U.S. National Institutes of Health.
• [391] ClinicalTrials.gov (NCT01302015) Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease. U.S. National Institutes of Health.
• [392] ClinicalTrials.gov (NCT03907969) A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.. U.S. National Institutes of Health.
• [393] ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors.
• [394] ClinicalTrials.gov (NCT01092091) Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002). U.S. National Institutes of Health.
• [395] ClinicalTrials.gov (NCT04278144) A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors. U.S. National Institutes of Health.
• [396] ClinicalTrials.gov (NCT04209465) A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (MasterKey-01). U.S. National Institutes of Health.
• [397] ClinicalTrials.gov (NCT03905148) Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors. U.S. National Institutes of Health.
• [398] ClinicalTrials.gov (NCT03379259) Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
• [399] ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
• [400] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7951).
• [401] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [402] Clinical pipeline report, company report or official report of Humanetics.
• [403] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2641).
• [404] ClinicalTrials.gov (NCT02061761) Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM. U.S. National Institutes of Health.
• [405] ClinicalTrials.gov (NCT02419417) Study of BMS-986158 in Subjects With Select Advanced Cancers (BET). U.S. National Institutes of Health.
• [406] ClinicalTrials.gov (NCT02913313) An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread. U.S. National Institutes of Health.
• [407] ClinicalTrials.gov (NCT04785287) Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies. U.S. National Institutes of Health.
• [408] ClinicalTrials.gov (NCT03994601) An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers. U.S. National Institutes of Health.
• [409] ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [410] ClinicalTrials.gov (NCT02034227) Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [411] ClinicalTrials.gov (NCT04180371) Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression. U.S. National Institutes of Health.
• [412] ClinicalTrials.gov (NCT04561362) Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies. U.S. National Institutes of Health.
• [413] ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
• [414] ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
• [415] ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
• [416] ClinicalTrials.gov (NCT00912899) A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [417] ClinicalTrials.gov (NCT01177397) Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma. U.S. NationalInstitutes of Health.
• [418] ClinicalTrials.gov (NCT03568656) Study to Evaluate CCS1477 in Advanced Tumours. U.S. National Institutes of Health.
• [419] ClinicalTrials.gov (NCT04592484) A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors. U.S. National Institutes of Health.
• [420] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7880).
• [421] ClinicalTrials.gov (NCT02908906) A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers. U.S. National Institutes of Health.
• [422] ClinicalTrials.gov (NCT04521413) Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [423] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8391).
• [424] Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
• [425] ClinicalTrials.gov (NCT01516905) PET/CT Imaging of Malignant Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue 124I-NM404. U.S. National Institutes of Health.
• [426] ClinicalTrials.gov (NCT01520558) CNDO-109-AANK for AML in First Complete Remission (CR1). U.S. National Institutes of Health.
• [427] ClinicalTrials.gov (NCT02028117) Phase I / II Study Of ColoAd1 Intraperitoneally in Ovarian Cancer Patients. U.S. National Institutes of Health.
• [428] ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
• [429] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025455)
• [430] ClinicalTrials.gov (NCT00906243) RNActive-Derived Therapeutic Vaccine. U.S. National Institutes of Health.
• [431] Clinical pipeline report, company report or official report of CovX (2011).
• [432] ClinicalTrials.gov (NCT03997968) A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors. U.S. National Institutes of Health.
• [433] ClinicalTrials.gov (NCT03069469) Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor. U.S. National Institutes of Health.
• [434] ClinicalTrials.gov (NCT04143711) Study of DF1001 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [435] ClinicalTrials.gov (NCT04423029) Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications. U.S. National Institutes of Health.
• [436] ClinicalTrials.gov (NCT04471415) First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [437] ClinicalTrials.gov (NCT04145622) Study of DS-7300a in Participants With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
• [438] ClinicalTrials.gov (NCT03416335) A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile. U.S. National Institutes of Health.
• [439] ClinicalTrials.gov (NCT04440735) A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [440] ClinicalTrials.gov (NCT04092673) Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin). U.S. National Institutes of Health.
• [441] ClinicalTrials.gov (NCT02988817) Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors. U.S. National Institutes of Health.
• [442] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032624)
• [443] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026777)
• [444] ClinicalTrials.gov (NCT02661542) Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [445] ClinicalTrials.gov (NCT03674567) Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab. U.S. National Institutes of Health.
• [446] ClinicalTrials.gov (NCT04130516) Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab. U.S. National Institutes of Health.
• [447] ClinicalTrials.gov (NCT03633110) Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine. U.S. National Institutes of Health.
• [448] ClinicalTrials.gov (NCT04049617) Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [449] ClinicalTrials.gov (NCT00499239) A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). U.S. National Institutes of Health.
• [450] ClinicalTrials.gov (NCT04198818) A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors. U.S. National Institutes of Health.
• [451] ClinicalTrials.gov (NCT03872206) Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression. U.S. National Institutes of Health.
• [452] ClinicalTrials.gov (NCT01721018) Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.. U.S. National Institutes of Health.
• [453] ClinicalTrials.gov (NCT02001623) HuMax-TF-ADC Safety Study in Patients With Solid Tumors. U.S. National Institutes of Health.
• [454] ClinicalTrials.gov (NCT02045368) Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. U.S. National Institutes of Health.
• [455] ClinicalTrials.gov (NCT02054351) Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR). U.S. National Institutes of Health.
• [456] ClinicalTrials.gov (NCT04262466) Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors. U.S. National Institutes of Health.
• [457] ClinicalTrials.gov (NCT04020185) Safety and Efficacy Study of IMSA101 in Refractory Malignancies. U.S. National Institutes of Health.
• [458] ClinicalTrials.gov (NCT03837509) INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [459] ClinicalTrials.gov (NCT02431260) An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [460] ClinicalTrials.gov (NCT02711137) Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [461] ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health.
• [462] ClinicalTrials.gov (NCT01563302) Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers. U.S. National Institutes of Health.
• [463] ClinicalTrials.gov (NCT04121442) Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors. U.S. National Institutes of Health.
• [464] ClinicalTrials.gov (NCT04720976) JAB-3312 Activity in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [465] ClinicalTrials.gov (NCT03829501) Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer. U.S. National Institutes of Health.
• [466] ClinicalTrials.gov (NCT00987753) Study Evaluating the Safety and Tolerability of L-377202. U.S. National Institutes of Health.
• [467] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024869)
• [468] ClinicalTrials.gov (NCT02057887) Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A). U.S. National Institutes of Health.
• [469] ClinicalTrials.gov (NCT03947385) Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions. U.S. National Institutes of Health.
• [470] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
• [471] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035260)
• [472] ClinicalTrials.gov (NCT02632448) A Study of LY2880070 in Participants With Advanced or Metastatic Cancer. U.S. National Institutes of Health.
• [473] ClinicalTrials.gov (NCT01722292) A Study of LY2940680 in Small Cell Lung Cancer. U.S. National Institutes of Health.
• [474] ClinicalTrials.gov (NCT02784795) A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [475] ClinicalTrials.gov (NCT03092934) A Study of AK-01 (LY3295668) in Solid Tumors. U.S. National Institutes of Health.
• [476] ClinicalTrials.gov (NCT04165031) A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation. U.S. National Institutes of Health.
• [477] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7961).
• [478] ClinicalTrials.gov (NCT01862900) Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions. U.S. National Institutes of Health.
• [479] Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558.
• [480] ClinicalTrials.gov (NCT03729596) MGC018 With or Without MGA012 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [481] ClinicalTrials.gov (NCT03179436) Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001). U.S. National Institutes of Health.
• [482] ClinicalTrials.gov (NCT02393209) Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [483] ClinicalTrials.gov (NCT04300556) A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRalpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types. U.S. National Institutes of Health.
• [484] ClinicalTrials.gov (NCT04441099) NBE-002 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [485] ClinicalTrials.gov (NCT04408599) A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [486] ClinicalTrials.gov (NCT04143789) Evaluation of AP-002 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [487] ClinicalTrials.gov (NCT03435640) A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL). U.S. National Institutes of Health.
• [488] ClinicalTrials.gov (NCT04474470) A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer. U.S. National Institutes of Health.
• [489] ClinicalTrials.gov (NCT03573544) This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health.
• [490] ClinicalTrials.gov (NCT04084366) Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [491] ClinicalTrials.gov (NCT03035591) ODM-207 in Patients With Advance Solid Tumours (BETIDES). U.S. National Institutes of Health.
• [492] ClinicalTrials.gov (NCT01598129) ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers. U.S. National Institutes of Health.
• [493] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7743).
• [494] ClinicalTrials.gov (NCT04585750) The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation. U.S. National Institutes of Health.
• [495] ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health.
• [496] ClinicalTrials.gov (NCT04432597) HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers. U.S. National Institutes of Health.
• [497] ClinicalTrials.gov (NCT01695590) Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma. U.S. National Institutes of Health.
• [498] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028412)
• [499] ClinicalTrials.gov (NCT04497116) Study of RP-3500 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [500] ClinicalTrials.gov (NCT04372706) RTX-240 Monotherapy. U.S. National Institutes of Health.
• [501] ClinicalTrials.gov (NCT00078390) Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [502] Clinical pipeline report, company report or official report of Inovio.
• [503] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158).
• [504] ClinicalTrials.gov (NCT01073384) A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer. U.S. National Institutes of Health.
• [505] ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
• [506] ClinicalTrials.gov (NCT04246671) Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients. U.S. National Institutes of Health.
• [507] ClinicalTrials.gov (NCT00112060) A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health.
• [508] ClinicalTrials.gov (NCT02224599) Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies. U.S. National Institutes of Health.
• [509] ClinicalTrials.gov (NCT03410927) A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities. U.S. National Institutes of Health.
• [510] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [511] Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 Dec;2(6):e00076.
• [512] ClinicalTrials.gov (NCT02191878) Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma. U.S. National Institutes ofHealth.
• [513] ClinicalTrials.gov (NCT00100256) Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy. U.S. National Institutes of Health.
• [514] ClinicalTrials.gov (NCT04161391) Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations. U.S. National Institutes of Health.
• [515] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5920).
• [516] ClinicalTrials.gov (NCT01690468) Triciribine and Carboplatin in Ovarian Cancer. U.S. National Institutes of Health.
• [517] ClinicalTrials.gov (NCT02280317) Dose Finding Safety Study of VAL201 in Cancer Patients. U.S. National Institutes of Health.
• [518] ClinicalTrials.gov (NCT04208958) Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO). U.S. National Institutes of Health.
• [519] NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial. Breast Cancer (Auckl). 2012;6:151-7.
• [520] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7972).
• [521] ClinicalTrials.gov (NCT01581060) Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours. U.S. National Institutes of Health.
• [522] ClinicalTrials.gov (NCT03321981) MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. U.S. National Institutes of Health.
• [523] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8202).
• [524] Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer. 1997;75(4):608-13.
• [525] A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009 Jul 1;15(13):4484-92.
• [526] ClinicalTrials.gov (NCT00961831) Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers andPatients. U.S. National Institutes of Health.
• [527] ClinicalTrials.gov (NCT01384253) Safety Study of b-TCMC-Trastuzumab Radio Immunotherapy. U.S. National Institutes of Health.
• [528] ClinicalTrials.gov (NCT03746431) A Phase 1 Study of [225Ac]-FPI-1434 Injection. U.S. National Institutes of Health.
• [529] 2011 Pipeline of 4SC AG.
• [530] Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991 Nov;34(11):3280-4.
• [531] ClinicalTrials.gov (NCT03950297) Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A. U.S. National Institutes of Health.
• [532] ClinicalTrials.gov (NCT04508179) A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects. U.S. National Institutes of Health.
• [533] ClinicalTrials.gov (NCT01099644) Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum. U.S. NationalInstitutes of Health.
• [534] ClinicalTrials.gov (NCT00199875) Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250. U.S. National Institutes of Health.
• [535] In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
• [536] ClinicalTrials.gov (NCT03821935) Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [537] ClinicalTrials.gov (NCT03595059) A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors. U.S. National Institutes of Health.
• [538] ClinicalTrials.gov (NCT02099058) A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors. U.S. National Institutes of Health.
• [539] ClinicalTrials.gov (NCT04417465) First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors. U.S. National Institutes of Health.
• [540] ClinicalTrials.gov (NCT01466569) An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [541] ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [542] ClinicalTrials.gov (NCT04190628) Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [543] ClinicalTrials.gov (NCT04192344) A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK021 in Patients With Advanced Solid Tumor. U.S. National Institutes of Health.
• [544] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035144)
• [545] ClinicalTrials.gov (NCT01339650) Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. U.S. National Institutes of Health.
• [546] ClinicalTrials.gov (NCT02379741) ADC-1013 First-in-Human Study. U.S. National Institutes of Health.
• [547] ClinicalTrials.gov (NCT04501276) ADG116 in Patients With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
• [548] More Than 800 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer. Pharmaceutical Research and Manufacturers of America report. 2009.
• [549] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [550] Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
• [551] ClinicalTrials.gov (NCT03860272) Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer. U.S. National Institutes of Health.
• [552] ClinicalTrials.gov (NCT04156100) A Study in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [553] ClinicalTrials.gov (NCT04121676) Anti-CD137 Monoclonal Antibody in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [554] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034170)
• [555] ClinicalTrials.gov (NCT02175433) A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies. U.S. National Institutes of Health.
• [556] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032164)
• [557] Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
• [558] ClinicalTrials.gov (NCT00724100) A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [559] ClinicalTrials.gov (NCT04186637) An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1). U.S. National Institutes of Health.
• [560] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040094)
• [561] ClinicalTrials.gov (NCT02437916) Safety Study of AMG 228 to Treat Solid Tumors. U.S. National Institutes of Health.
• [562] ClinicalTrials.gov (NCT04362748) Study of AMG 256 in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [563] ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [564] ClinicalTrials.gov (NCT04049903) Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [565] ClinicalTrials.gov (NCT04293094) Study of AMG 650 in Adult Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [566] Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.
• [567] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031593)
• [568] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8060).
• [569] ClinicalTrials.gov (NCT01352884) Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [570] ClinicalTrials.gov (NCT03536728) Oral AMXT 1501 Dicaprate in Combination With DFMO. U.S. National Institutes of Health.
• [571] 2nd Generation Anti-CEA Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines and Exhibit Superior Anti-Tumor Activity In Vivo: A Preclinical Evaluation. Clin Cancer Res. 2008 December 15; 14(24): 8112-8122.
• [572] ClinicalTrials.gov (NCT01455103) Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma. U.S. National Institutes of Health.
• [573] ClinicalTrials.gov (NCT03053466) APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors. U.S. National Institutes of Health.
• [574] ClinicalTrials.gov (NCT02267863) A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health.
• [575] ClinicalTrials.gov (NCT01225536) Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations. U.S. National Institutes of Health.
• [576] ClinicalTrials.gov (NCT00398840) A Study of ARQ 171 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [577] ClinicalTrials.gov (NCT02761694) Vevorisertib (ARQ 751) (4440-001) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations. U.S. National Institutes of Health.
• [578] ClinicalTrials.gov (NCT00828165) A Safety Study of ARRY-300 in Healthy Subjects. U.S. National Institutes of Health.
• [579] ClinicalTrials.gov (NCT01921335) ARRY-380 + Trastuzuamab for Breast w/ Brain Mets. U.S. National Institutes of Health.
• [580] 2011 Pipeline of Seattle Genetics.
• [581] ClinicalTrials.gov (NCT04094506) Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [582] ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [583] ClinicalTrials.gov (NCT03954067) A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors. U.S. National Institutes of Health.
• [584] Clinical pipeline report, company report or official report of Astellas Pharma.
• [585] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032292)
• [586] Clinical pipeline report, company report or official report of Affitech (2011).
• [587] ClinicalTrials.gov (NCT01585701) Phase I Study of AT13148, a Novel AGC Kinase Inhibitor. U.S. National Institutes of Health.
• [588] ClinicalTrials.gov (NCT02503709) Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery in National Cancer Institute (NCI).
• [589] ClinicalTrials.gov (NCT01041235) Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies. U.S. National Institutes of Health.
• [590] ClinicalTrials.gov (NCT04244552) A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [591] ClinicalTrials.gov (NCT00938574) Study With Atu027 in Patients With Advanced Solid Cancer. U.S. National Institutes of Health.
• [592] Clinical pipeline report, company report or official report of Tella Inc.
• [593] Clinical pipeline report, company report or official report of Dana-Farber Cancer Institute Inc.
• [594] ClinicalTrials.gov (NCT01603979) A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [595] ClinicalTrials.gov (NCT03834662) A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies. U.S. National Institutes of Health.
• [596] ClinicalTrials.gov (NCT03238027) A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors. U.S. National Institutes of Health.
• [597] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8472).
• [598] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8473).
• [599] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7698).
• [600] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7713).
• [601] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8527).
• [602] ClinicalTrials.gov (NCT04504669) First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours. U.S. National Institutes of Health.
• [603] GM-CSF-Secreting Vaccines for Solid Tumors: Moving Forward. Discov Med. 2010 July; 10(50): 52-60.
• [604] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017003)
• [605] ClinicalTrials.gov (NCT01728311) Open Label Study of BAY1082439 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [606] ClinicalTrials.gov (NCT03596372) Study of BAY1834942 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [607] ClinicalTrials.gov (NCT03666273) A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254. U.S. National Institutes of Health.
• [608] ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [609] ClinicalTrials.gov (NCT04147819) A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein. U.S. National Institutes of Health.
• [610] ClinicalTrials.gov (NCT01028755) To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [611] ClinicalTrials.gov (NCT01297530) Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [612] ClinicalTrials.gov (NCT01439152) Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [613] ClinicalTrials.gov (NCT00975299) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers. U.S. National Institutes of Health.
• [614] ClinicalTrials.gov (NCT01205321) PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers. U.S. National Institutes of Health.
• [615] ClinicalTrials.gov (NCT01089998) PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations. U.S. National Institutes of Health.
• [616] ClinicalTrials.gov (NCT01915576) Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients. U.S. National Institutes of Health.
• [617] ClinicalTrials.gov (NCT02134197) Dose-escalation Study of BAY1129980. U.S. National Institutes of Health.
• [618] ClinicalTrials.gov (NCT02345382) Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia. U.S. National Institutes of Health.
• [619] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040625)
• [620] ClinicalTrials.gov (NCT01881217) First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors. U.S. National Institutes of Health.
• [621] ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [622] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [623] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
• [624] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018110)
• [625] ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
• [626] ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [627] ClinicalTrials.gov (NCT04215978) Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [628] ClinicalTrials.gov (NCT04835714) A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (KRAS). U.S. National Institutes of Health.
• [629] ClinicalTrials.gov (NCT04742556) A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive). U.S. National Institutes of Health.
• [630] ClinicalTrials.gov (NCT04653142) A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors). U.S. National Institutes of Health.
• [631] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038828)
• [632] ClinicalTrials.gov (NCT03604445) This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours). U.S. National Institutes of Health.
• [633] ClinicalTrials.gov (NCT04147247) A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread. U.S. National Institutes of Health.
• [634] ClinicalTrials.gov (NCT04137289) A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer. U.S. National Institutes of Health.
• [635] ClinicalTrials.gov (NCT03449381) This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors). U.S. National Institutes of Health.
• [636] ClinicalTrials.gov (NCT01195688) Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects. U.S. National Institutes of Health.
• [637] ClinicalTrials.gov (NCT01343719) Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.. U.S. National Institutes of Health.
• [638] ClinicalTrials.gov (NCT00756223) Phase I Study of BI 831266 in Patients With Advanced Solid Tumours. U.S. National Institutes of Health.
• [639] ClinicalTrials.gov (NCT02145741) Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours. U.S. National Institutes of Health.
• [640] ClinicalTrials.gov (NCT01324830) Monotherapy Dose Finding With BI 847325 in Solid Tumours. U.S. National Institutes of Health.
• [641] ClinicalTrials.gov (NCT01905111) A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer. U.S. National Institutes of Health.
• [642] An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.
• [643] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020039)
• [644] Clinical pipeline report, company report or official report of Baxter Healthcare.
• [645] ClinicalTrials.gov (NCT02204046) Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast. U.S. National Institutes of Health.
• [646] ClinicalTrials.gov (NCT04294576) Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH). U.S. National Institutes of Health.
• [647] In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82.
• [648] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7968).
• [649] ClinicalTrials.gov (NCT03956680) An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers. U.S. National Institutes of Health.
• [650] ClinicalTrials.gov (NCT03871348) A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [651] ClinicalTrials.gov (NCT03780517) Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors. U.S. National Institutes of Health.
• [652] ClinicalTrials.gov (NCT02478866) Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [653] ClinicalTrials.gov (NCT02168725) Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors. U.S. National Institutes of Health.
• [654] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037548)
• [655] Clinical pipeline report, company report or official report of Bayer HealthCare Pharmaceuticals.
• [656] ClinicalTrials.gov (NCT03616574) First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [657] ClinicalTrials.gov (NCT00689065) Safety Study of CALAA-01 to Treat Solid Tumor Cancers. U.S. National Institutes of Health.
• [658] ClinicalTrials.gov (NCT03684785) Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors. U.S. National Institutes of Health.
• [659] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004602)
• [660] ClinicalTrials.gov (NCT00458159) A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes. U.S. National Institutes of Health.
• [661] ClinicalTrials.gov (NCT01421524) Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma. U.S. National Institutes of Health.
• [662] ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health.
• [663] Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute. Curr Opin Mol Ther. 2003 Aug;5(4):428-32.
• [664] ClinicalTrials.gov (NCT02284971) Pilot Study of SBRT and CDX-1127 in Prostate Cancer. U.S. National Institutes of Health.
• [665] ClinicalTrials.gov (NCT04440943) A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [666] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
• [667] ClinicalTrials.gov (NCT01922752) To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [668] ClinicalTrials.gov (NCT02792465) A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [669] ClinicalTrials.gov (NCT01226407) Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile. U.S. National Institutes of Health.
• [670] ClinicalTrials.gov (NCT01760525) A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors. U.S. National Institutes of Health.
• [671] ClinicalTrials.gov (NCT01437280) GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers. U.S. National Institutes of Health.
• [672] ClinicalTrials.gov (NCT04475523) Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies. U.S. National Institutes of Health.
• [673] ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health.
• [674] ClinicalTrials.gov (NCT00481936) Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin. U.S. National Institutes of Health.
• [675] ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health.
• [676] HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008 Oct;20(10):1839-47.
• [677] ClinicalTrials.gov (NCT00537368) First Study of the Safety of CNTO 888 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [678] ClinicalTrials.gov (NCT03667716) COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [679] ClinicalTrials.gov (NCT04354246) COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [680] ClinicalTrials.gov (NCT01103635) Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma. U.S. National Institutes of Health.
• [681] ClinicalTrials.gov (NCT03454451) CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers. U.S. National Institutes of Health.
• [682] ClinicalTrials.gov (NCT03781362) Study of CPI-100 in Patients With Advanced Tumors. U.S. National Institutes of Health.
• [683] ClinicalTrials.gov (NCT03953742) Study of CPI-200 in Patients With Advanced Tumors. U.S. National Institutes of Health.
• [684] ClinicalTrials.gov (NCT00900809) Neukoplast (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [685] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027375)
• [686] ClinicalTrials.gov (NCT03881488) Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies. U.S. National Institutes of Health.
• [687] A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
• [688] ClinicalTrials.gov (NCT02138955) A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer. U.S. National Institutes of Health.
• [689] Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
• [690] ClinicalTrials.gov (NCT02426723) Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients. U.S. National Institutes of Health.
• [691] ClinicalTrials.gov (NCT01977638) Phase 1 Trial of CXD101 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [692] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034732)
• [693] ClinicalTrials.gov (NCT00560716) A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [694] Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol. 1995;36(6):513-23.
• [695] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025369)
• [696] ClinicalTrials.gov (NCT00947739) Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [697] Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol. 1993;32(6):437-44.
• [698] ClinicalTrials.gov (NCT00839631) Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors. U.S. National Institutes of Health.
• [699] Phase I study of DABIS maleate given once every 3 weeks. Eur J Cancer. 1991;27(12):1635-7.
• [700] The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991 May 1;51(9):2286-90.
• [701] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [702] ClinicalTrials.gov (NCT02171221) Phase I Study of Oral DFP-11207 in Solid Tumors. U.S. National Institutes of Health.
• [703] ClinicalTrials.gov (NCT03943004) Trial of DFP-14927 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [704] ClinicalTrials.gov (NCT03891953) Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [705] ClinicalTrials.gov (NCT02092792) A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors. U.S. National Institutes of Health.
• [706] ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
• [707] ClinicalTrials.gov (NCT03934359) A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [708] ClinicalTrials.gov (NCT02688101) Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [709] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014200)
• [710] ClinicalTrials.gov (NCT01966445) Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors. U.S. National Institutes of Health.
• [711] ClinicalTrials.gov (NCT04419532) A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [712] ClinicalTrials.gov (NCT01288430) A Study of DS-2248, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [713] ClinicalTrials.gov (NCT01877382) A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [714] ClinicalTrials.gov (NCT01588678) A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [715] ClinicalTrials.gov (NCT02279433) A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b. U.S. National Institutes of Health.
• [716] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034336)
• [717] ClinicalTrials.gov (NCT02076451) Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [718] ClinicalTrials.gov (NCT02252211) Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers. U.S. National Institutes of Health.
• [719] ClinicalTrials.gov (NCT03416816) A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile. U.S. National Institutes of Health.
• [720] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027262)
• [721] ClinicalTrials.gov (NCT00459823) A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours. U.S. National Institutes of Health.
• [722] ClinicalTrials.gov (NCT04144140) Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101. U.S. National Institutes of Health.
• [723] ClinicalTrials.gov (NCT00441870) Study of EC0225 for the Treatment of Refractory or Metastatic Tumors. U.S. National Institutes of Health.
• [724] ClinicalTrials.gov (NCT00852189) Study of EC0489 for the Treatment of Refractory or Metastatic Tumors. U.S. National Institutes of Health.
• [725] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039335)
• [726] ClinicalTrials.gov (NCT04238364) A Study to Evaluate the Safety, Tolerability and Amount of Drug Levels in Blood of EI1071 in Healthy Volunteers. U.S. National Institutes of Health.
• [727] ClinicalTrials.gov (NCT01679847) Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.. U.S. National Institutes of Health.
• [728] ClinicalTrials.gov (NCT01435096) BN80927 in Patients With Advanced Malignant Solid Tumors. U.S. National Institutes of Health.
• [729] ClinicalTrials.gov (NCT01110083) First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [730] Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
• [731] Clinical pipeline report, company report or official report of Multimmune GmbH.
• [732] ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
• [733] ClinicalTrials.gov (NCT03873883) First-in-Human Study of EOS100850 in Patients With Cancer. U.S. National Institutes of Health.
• [734] A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res. 2014 Oct 1;20(19):5009-22.
• [735] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003708)
• [736] 2011 Pipeline of Santaris Pharma.
• [737] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004610)
• [738] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [739] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034271)
• [740] ClinicalTrials.gov (NCT03690154) A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML. U.S. National Institutes of Health.
• [741] ClinicalTrials.gov (NCT04074759) FPT155 in Patients With Advanced Solid Tumors (FPT155-001). U.S. National Institutes of Health.
• [742] ClinicalTrials.gov (NCT02243150) Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1. U.S. National Institutes of Health.
• [743] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002476)
• [744] ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
• [745] ClinicalTrials.gov (NCT02829372) Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101). U.S. National Institutes of Health.
• [746] Clinical pipeline report, company report or official report of Genentech (2011).
• [747] ClinicalTrials.gov (NCT01875705) A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [748] ClinicalTrials.gov (NCT03576131) GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors. U.S. National Institutes of Health.
• [749] ClinicalTrials.gov (NCT04083599) GEN1042 Safety Trial in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health.
• [750] ClinicalTrials.gov (NCT04424641) A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health.
• [751] ClinicalTrials.gov (NCT03917381) GEN1046 Safety Trial in Patients With Malignant Solid Tumors. U.S. National Institutes of Health.
• [752] ClinicalTrials.gov (NCT00942799) Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [753] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030147)
• [754] ClinicalTrials.gov (NCT00054977) Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors. U.S. National Institutes of Health.
• [755] The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88.
• [756] ClinicalTrials.gov (NCT04250597) Study of GNX102 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [757] ClinicalTrials.gov (NCT00034554) Study of gp75 Vaccine in Patients With Stage III and IV Melanoma. U.S. National Institutes of Health.
• [758] ClinicalTrials.gov (NCT04450732) Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors. U.S. National Institutes of Health.
• [759] ClinicalTrials.gov (NCT03954704) Study of GS-1423 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [760] ClinicalTrials.gov (NCT05007782) A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
• [761] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7939).
• [762] ClinicalTrials.gov (NCT01118611) Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [763] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
• [764] ClinicalTrials.gov (NCT02082977) A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma. U.S. National Institutes of Health.
• [765] ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health.
• [766] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028863)
• [767] ClinicalTrials.gov (NCT03666988) First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL). U.S. National Institutes of Health.
• [768] ClinicalTrials.gov (NCT03843359) Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [769] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [770] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5684).
• [771] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7033).
• [772] ClinicalTrials.gov (NCT04446351) Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [773] ClinicalTrials.gov (NCT01951027) Phase I Study GX-G3 in Healthy Subjects. U.S. National Institutes of Health.
• [774] ClinicalTrials.gov (NCT03775525) Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602). U.S. National Institutes of Health.
• [775] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037203)
• [776] ClinicalTrials.gov (NCT00105170) Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [777] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042636)
• [778] Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel). 2015 Jul 6;3(3):519-43.
• [779] Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
• [780] ClinicalTrials.gov (NCT04390737) Evaluate the Safety and Clinical Activity of HH2853. U.S. National Institutes of Health.
• [781] ClinicalTrials.gov (NCT00939172) TTP607 in Refractory Solid Malignancies. U.S. National Institutes of Health.
• [782] ClinicalTrials.gov (NCT04116710) A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors. U.S. National Institutes of Health.
• [783] ClinicalTrials.gov (NCT00879905) A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [784] Clinical pipeline report, company report or official report of Vical.
• [785] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [786] ClinicalTrials.gov (NCT03208959) A Trial of HTI-1090 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [787] Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun. 2009; 9: 5.
• [788] ClinicalTrials.gov (NCT02049489) A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma. U.S. National Institutes of Health.
• [789] ClinicalTrials.gov (NCT04553692) Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers. U.S. National Institutes of Health.
• [790] Clinical pipeline report, company report or official report of Immatics.
• [791] ClinicalTrials.gov (NCT04306224) A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas. U.S. National Institutes of Health.
• [792] ClinicalTrials.gov (NCT01288989) A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [793] ClinicalTrials.gov (NCT01346358) A Study of IMC-CS4 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [794] ClinicalTrials.gov (NCT01646203) A Study of IMC-TR1 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [795] ClinicalTrials.gov (NCT01234012) Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1. U.S. National Institutes of Health.
• [796] ClinicalTrials.gov (NCT04622774) First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [797] ClinicalTrials.gov (NCT00721669) A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [798] ClinicalTrials.gov (NCT01609556) First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors. U.S. National Institutes of Health.
• [799] ClinicalTrials.gov (NCT01963715) A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors. U.S. National Institutes of Health.
• [800] ClinicalTrials.gov (NCT00040560) Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer. U.S. National Institutes of Health.
• [801] Clinical pipeline report, company report or official report of INmune Bio.
• [802] ClinicalTrials.gov (NCT03809624) Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB). U.S. National Institutes of Health.
• [803] ClinicalTrials.gov (NCT03715933) Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas. U.S. National Institutes of Health.
• [804] ClinicalTrials.gov (NCT03652077) A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies. U.S. National Institutes of Health.
• [805] ClinicalTrials.gov (NCT03522142) A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies. U.S. National Institutes of Health.
• [806] ClinicalTrials.gov (NCT04242199) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [807] ClinicalTrials.gov (NCT00051675) Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas. U.S. National Institutes of Health.
• [808] ClinicalTrials.gov (NCT00255333) INNO-105 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [809] ClinicalTrials.gov (NCT00003713) Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [810] ClinicalTrials.gov (NCT04443088) A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors. U.S. National Institutes of Health.
• [811] ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [812] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034247)
• [813] ClinicalTrials.gov (NCT03518554) A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [814] ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health.
• [815] ClinicalTrials.gov (NCT00651365) A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.. U.S. National Institutes of Health.
• [816] ClinicalTrials.gov (NCT03926013) A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors. U.S. National Institutes of Health.
• [817] ClinicalTrials.gov (NCT03573310) A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS. U.S. National Institutes of Health.
• [818] ClinicalTrials.gov (NCT04397276) A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors. U.S. National Institutes of Health.
• [819] ClinicalTrials.gov (NCT04006301) First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation. U.S. National Institutes of Health.
• [820] ClinicalTrials.gov (NCT04137900) Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [821] ClinicalTrials.gov (NCT04418167) JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations. U.S. National Institutes of Health.
• [822] ClinicalTrials.gov (NCT00574977) Safety Study of Modified Vaccinia Virus to Cancer. U.S. National Institutes of Health.
• [823] ClinicalTrials.gov (NCT04237649) KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [824] ClinicalTrials.gov (NCT04242147) A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.. U.S. National Institutes of Health.
• [825] Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003 Apr 15;21(8):1452-8.
• [826] A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatmen... Cancer Biol Ther. 2009 Apr;8(8):676-82.
• [827] KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther. 2004 Dec;3(12):1639-49.
• [828] ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.
• [829] ClinicalTrials.gov (NCT01110226) Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies. U.S. National Institutes of Health.
• [830] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6057).
• [831] ClinicalTrials.gov (NCT02014909) A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors. U.S. National Institutes of Health.
• [832] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006614)
• [833] ClinicalTrials.gov (NCT01106508) A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [834] ClinicalTrials.gov (NCT00100672) Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [835] ClinicalTrials.gov (NCT01610050) A Phase I Study of LFA102 in Japanese Patients. U.S. National Institutes of Health.
• [836] Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9.
• [837] ClinicalTrials.gov (NCT03301896) Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [838] ClinicalTrials.gov (NCT03030417) Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [839] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020661)
• [840] ClinicalTrials.gov (NCT02341508) A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab inSubjects With Neuropathic Pain. U.S. National Institutes of Health.
• [841] ClinicalTrials.gov (NCT01058616) Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour. U.S. National Institutes of Health.
• [842] ClinicalTrials.gov (NCT04130542) Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy. U.S. National Institutes of Health.
• [843] ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health.
• [844] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8248).
• [845] ClinicalTrials.gov (NCT01139788) A Study of LY2624587 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [846] ClinicalTrials.gov (NCT01115751) A Study in Patients With Advanced or Metastatic Cancer. U.S. National Institutes of Health.
• [847] ClinicalTrials.gov (NCT02014116) A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body. U.S. National Institutes of Health.
• [848] Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemother Pharmacol. 2001 Jun;47(6):525-31.
• [849] ClinicalTrials.gov (NCT03770494) A Study of LY3405105 in Participants With Advanced Cancer. U.S. National Institutes of Health.
• [850] ClinicalTrials.gov (NCT04521686) Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations. U.S. National Institutes of Health.
• [851] ClinicalTrials.gov (NCT03752177) A Study of LY3415244 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [852] ClinicalTrials.gov (NCT04148937) A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. U.S. National Institutes of Health.
• [853] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034531)
• [854] ClinicalTrials.gov (NCT04170153) M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors. U.S. National Institutes of Health.
• [855] ClinicalTrials.gov (NCT01971515) First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [856] ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.
• [857] ClinicalTrials.gov (NCT04501770) A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors. U.S. National Institutes of Health.
• [858] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033868)
• [859] ClinicalTrials.gov (NCT03842085) Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor. U.S. National Institutes of Health.
• [860] ClinicalTrials.gov (NCT03922204) A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies. U.S. National Institutes of Health.
• [861] ClinicalTrials.gov (NCT03526835) A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [862] Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consec... Cancer Chemother Pharmacol. 2004 May;53(5):370-6.
• [863] ClinicalTrials.gov (NCT00944905) Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). U.S. National Institutes of Health.
• [864] ClinicalTrials.gov (NCT00730652) Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma. U.S. National Institutes of Health.
• [865] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014; 32(1): 87-93.
• [866] ClinicalTrials.gov (NCT01577745) A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [867] ClinicalTrials.gov (NCT00796055) Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors. U.S. NationalInstitutes of Health.
• [868] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7749).
• [869] A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.
• [870] ClinicalTrials.gov (NCT03946800) A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [871] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030291)
• [872] ClinicalTrials.gov (NCT03889275) A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors. U.S. National Institutes of Health.
• [873] ClinicalTrials.gov (NCT03530397) A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [874] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041453)
• [875] ClinicalTrials.gov (NCT01809912) Safety Study of MG1102 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [876] ClinicalTrials.gov (NCT03761017) MGD019 DART Protein in Unresectable/Metastatic Cancer. U.S. National Institutes of Health.
• [877] Targeting Toll-like receptors: emerging therapeutics Nat Rev Drug Discov. 2010 Apr;9(4):293-307.
• [878] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032581)
• [879] ClinicalTrials.gov (NCT03918278) A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001). U.S. National Institutes of Health.
• [880] ClinicalTrials.gov (NCT00104364) A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED). U.S. National Institutes of Health.
• [881] ClinicalTrials.gov (NCT00880568) Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED). U.S. National Institutes of Health.
• [882] ClinicalTrials.gov (NCT02132754) Study of MK-4166 in Participants With Advanced Solid Tumors (MK-4166-001). U.S. National Institutes of Health.
• [883] ClinicalTrials.gov (NCT03739138) Intratumoral/Intralesional Administration of MK-4621/JetPEI With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002). U.S. National Institutes of Health.
• [884] ClinicalTrials.gov (NCT03564691) Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001). U.S. National Institutes of Health.
• [885] ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
• [886] ClinicalTrials.gov (NCT00559182) A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001). U.S. National Institutes of Health.
• [887] ClinicalTrials.gov (NCT00423254) Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.. U.S. National Institutes of Health.
• [888] ClinicalTrials.gov (NCT02045095) A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [889] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5696).
• [890] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035447)
• [891] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027250)
• [892] ClinicalTrials.gov (NCT02040558) Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors. U.S. National Institutes of Health.
• [893] ClinicalTrials.gov (NCT01212276) A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma. U.S. National Institutes of Health.
• [894] ClinicalTrials.gov (NCT02546921) This First in Human Study of the New Therapeutic Antibody MOv18 IgE in Patients With Advanced Cancer.
• [895] ClinicalTrials.gov (NCT00387153) Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer. U.S. National Institutes of Health.
• [896] Clinical pipeline report, company report or official report of Myriad Genetics Inc.
• [897] ClinicalTrials.gov (NCT03739931) Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants With Advanced Malignancies. U.S. National Institutes of Health.
• [898] ClinicalTrials.gov (NCT03510104) Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [899] ClinicalTrials.gov (NCT03490669) Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors. U.S. National Institutes of Health.
• [900] ClinicalTrials.gov (NCT01453387) MSC2015103B in Solid Tumors. U.S. National Institutes of Health.
• [901] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027582)
• [902] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
• [903] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031326)
• [904] ClinicalTrials.gov (NCT04029922) Study of MT-5111 in HER2-positive Solid Tumors (MT-5111). U.S. National Institutes of Health.
• [905] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034069)
• [906] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041064)
• [907] ClinicalTrials.gov (NCT02179515) Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM). U.S. National Institutes of Health.
• [908] ClinicalTrials.gov (NCT01748019) ST1968 Intravenous (Weekly) in Solid Tumors. U.S. National Institutes of Health.
• [909] ClinicalTrials.gov (NCT03808870) A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer. U.S. National Institutes of Health.
• [910] ClinicalTrials.gov (NCT01999491) A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [911] ClinicalTrials.gov (NCT03476681) QUILT-3.017: Study of NEO-201 in Solid Tumors. U.S. National Institutes of Health.
• [912] ClinicalTrials.gov (NCT03970382) A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [913] ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health.
• [914] ClinicalTrials.gov (NCT03852511) First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE). U.S. National Institutes of Health.
• [915] ClinicalTrials.gov (NCT04053283) First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector. U.S. National Institutes of Health.
• [916] ClinicalTrials.gov (NCT04068896) Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy. U.S. National Institutes of Health.
• [917] ClinicalTrials.gov (NCT01417546) NHS-IL12 for Solid Tumors. U.S. National Institutes of Health.
• [918] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020174)
• [919] ClinicalTrials.gov (NCT01415297) Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors. U.S. National Institutes of Health.
• [920] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029161)
• [921] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039434)
• [922] ClinicalTrials.gov (NCT00046696) A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [923] ClinicalTrials.gov (NCT04182516) Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
• [924] ClinicalTrials.gov (NCT04041310) Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors. U.S. National Institutes of Health.
• [925] ClinicalTrials.gov (NCT03292783) This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001. U.S. National Institutes of Health.
• [926] ClinicalTrials.gov (NCT00923520) A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies. U.S. NationalInstitutes of Health.
• [927] Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumours. Eur J Cancer. 2007 January; 43(1): 78-86.
• [928] ClinicalTrials.gov (NCT02723240) NUC-3373 in Advanced Solid Tumours (NuTide:301). U.S. National Institutes of Health.
• [929] Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours. J Clin Oncol (Meeting Abstracts) May 2008 vol. 26 no. 15_suppl 14615.
• [930] ClinicalTrials.gov (NCT00199836) A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.. U.S. National Institutes of Health.
• [931] ClinicalTrials.gov (NCT03549000) A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.. U.S. National Institutes of Health.
• [932] ClinicalTrials.gov (NCT02414516) A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [933] ClinicalTrials.gov (NCT03931681) A Study of OKI-179 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [934] ClinicalTrials.gov (NCT01800812) Effects of OM-174 in Adult Patients With Solid Tumors. U.S. National Institutes of Health.
• [935] ClinicalTrials.gov (NCT01555242) A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas. U.S. National Institutes of Health.
• [936] ClinicalTrials.gov (NCT02482441) A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10. U.S. National Institutes of Health.
• [937] ClinicalTrials.gov (NCT01345201) A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. U.S. National Institutes of Health.
• [938] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8451).
• [939] ClinicalTrials.gov (NCT01703572) A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies. U.S. National Institutes of Health.
• [940] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016015)
• [941] ClinicalTrials.gov (NCT04140526) Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001). U.S. National Institutes of Health.
• [942] ClinicalTrials.gov (NCT04348916) Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors. U.S. National Institutes of Health.
• [943] ClinicalTrials.gov (NCT01556789) Phase 1 Study of ONT-10 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [944] ClinicalTrials.gov (NCT02360345) Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly. U.S. National Institutes of Health.
• [945] ClinicalTrials.gov (NCT02058017) OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy. U.S. National Institutes of Health.
• [946] ClinicalTrials.gov (NCT02250157) A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [947] OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74.
• [948] ClinicalTrials.gov (NCT01762410) Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors. U.S. National Institutes of Health.
• [949] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [950] Clinical pipeline report, company report or official report of CDG Therapeutics.
• [951] ClinicalTrials.gov (NCT02475109) Study of Topical Ocular PAN-90806 in PDR.
• [952] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036039)
• [953] ClinicalTrials.gov (NCT03786484) Study of PBF-999 in Solid Tumour Advanced Cancer. U.S. National Institutes of Health.
• [954] ClinicalTrials.gov (NCT01505153) Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer. U.S. National Institutes of Health.
• [955] ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health.
• [956] ClinicalTrials.gov (NCT01380249) PDM08 Clinical Trial in Advanced Solid Tumors. U.S. National Institutes of Health.
• [957] ClinicalTrials.gov (NCT00002946) Penclomedine in Treating Patients With Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [958] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7424).
• [959] ClinicalTrials.gov (NCT01105533) A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors. U.S. National Institutes of Health.
• [960] ClinicalTrials.gov (NCT01891669) A Study Of PF-06263507 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [961] ClinicalTrials.gov (NCT02078752) A Study Of PF-06647263 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [962] ClinicalTrials.gov (NCT02129205) A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [963] ClinicalTrials.gov (NCT02122146) A Study Of PF-06664178 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [964] ClinicalTrials.gov (NCT03854227) A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [965] ClinicalTrials.gov (NCT04152018) Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health.
• [966] ClinicalTrials.gov (NCT03685591) PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [967] ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health.
• [968] ClinicalTrials.gov (NCT04458259) A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [969] ClinicalTrials.gov (NCT00557505) A Study Of PF-03732010 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [970] Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51.
• [971] ClinicalTrials.gov (NCT00706355) A Study of PF-04217903 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [972] ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
• [973] ClinicalTrials.gov (NCT02044861) Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [974] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [975] ClinicalTrials.gov (NCT01779336) Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors. U.S. National Institutes of Health.
• [976] ClinicalTrials.gov (NCT01299636) Study of PM060184 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [977] ClinicalTrials.gov (NCT01141257) Study of Angiocal in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug. U.S. National Institutes of Health.
• [978] ClinicalTrials.gov (NCT03886831) A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
• [979] More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer. Pharmaceutical Research and Manufacturers of America report. 2012.
• [980] ClinicalTrials.gov (NCT02266745) A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [981] ClinicalTrials.gov (NCT04430348) PTX-35 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [982] NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
• [983] Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012 Mar;1823(3):742-55.
• [984] ClinicalTrials.gov (NCT00081211) Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck. U.S. National Institutes of Health.
• [985] ClinicalTrials.gov (NCT01407380) Study of PWT33597 Mesylate in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
• [986] ClinicalTrials.gov (NCT00522652) Phase I Trial of PX-478. U.S. National Institutes of Health.
• [987] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029294)
• [988] ClinicalTrials.gov (NCT04430842) Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S. U.S. National Institutes of Health.
• [989] Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res. 2008 May 15;14(10):3089-97.
• [990] ClinicalTrials.gov (NCT04053673) RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study. U.S. National Institutes of Health.
• [991] Clinical pipeline report, company report or official report of Zensun.
• [992] ClinicalTrials.gov (NCT00871559) A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [993] ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health.
• [994] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036915)
• [995] ClinicalTrials.gov (NCT04140500) Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [996] Clinical pipeline report, company report or official report of Roche
• [997] ClinicalTrials.gov (NCT04303858) A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [998] ClinicalTrials.gov (NCT03973333) Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab. U.S. National Institutes of Health.
• [999] ClinicalTrials.gov (NCT04158583) A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors.. U.S. National Institutes of Health.
• [1000] Clinical pipeline report, company report or official report of Roche.
• [1001] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035594)
• [1002] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029782)
• [1003] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027393)
• [1004] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039398)
• [1005] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040445)
• [1006] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038284)
• [1007] RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinic... Blood. 2008 Feb 1;111(3):1357-65.
• [1008] ClinicalTrials.gov (NCT00658892) Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma. U.S. National Institutes of Health.
• [1009] ClinicalTrials.gov (NCT03444714) Phase I Study of RiMO-301 With Radiation in Advanced Tumors. U.S. National Institutes of Health.
• [1010] ClinicalTrials.gov (NCT04252339) RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1011] ClinicalTrials.gov (NCT04526106) First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors. U.S. National Institutes of Health.
• [1012] Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35.
• [1013] ClinicalTrials.gov (NCT01143753) A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours. U.S. National Institutes of Health.
• [1014] ClinicalTrials.gov (NCT01383733) A Study of RO5458640 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1015] ClinicalTrials.gov (NCT02381561) Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy. U.S. National Institutes of Health.
• [1016] ClinicalTrials.gov (NCT04336241) Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors. U.S. National Institutes of Health.
• [1017] ClinicalTrials.gov (NCT03815682) RPTR-147 in Patients With Selected Solid Tumors and Lymphomas. U.S. National Institutes of Health.
• [1018] ClinicalTrials.gov (NCT03646071) A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1019] ClinicalTrials.gov (NCT03454243) Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (TITAN). U.S. National Institutes of Health.
• [1020] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036509)
• [1021] ClinicalTrials.gov (NCT04418661) Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [1022] ClinicalTrials.gov (NCT04009681) A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101). U.S. National Institutes of Health.
• [1023] ClinicalTrials.gov (NCT01235871) A Single and Multiple-Dose Study of SB1578. U.S. National Institutes of Health.
• [1024] Epigenetics in vascular disease - therapeutic potential of new agents. Curr Vasc Pharmacol. 2014 Jan;12(1):77-86.
• [1025] ClinicalTrials.gov (NCT04460456) A Study of SBT6050 Alone and in Combination With Pembrolizumab in Patients With Advanced HER2 Expressing Solid Tumors. U.S. National Institutes of Health.
• [1026] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035473)
• [1027] ClinicalTrials.gov (NCT04254107) A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer. U.S. National Institutes of Health.
• [1028] ClinicalTrials.gov (NCT04389632) A Study of SGN-B6A in Advanced Solid Tumors. U.S. National Institutes of Health.
• [1029] ClinicalTrials.gov (NCT04042480) A Study of SGN-CD228A in Advanced Solid Tumors. U.S. National Institutes of Health.
• [1030] ClinicalTrials.gov (NCT01517464) A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors (SGT94-01). U.S. National Institutes of Health.
• [1031] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5709).
• [1032] ClinicalTrials.gov (NCT04606472) A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1033] ClinicalTrials.gov (NCT00277836) Study Evaluating MST-997 in Advanced Malignant Solid Tumors. U.S. National Institutes of Health.
• [1034] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7640).
• [1035] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023175)
• [1036] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5670).
• [1037] ClinicalTrials.gov (NCT00519662) Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors. U.S. National Institutes of Health.
• [1038] ClinicalTrials.gov (NCT04609579) Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma. U.S. National Institutes of Health.
• [1039] ClinicalTrials.gov (NCT04234113) Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1040] ClinicalTrials.gov (NCT04511845) A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).. U.S. National Institutes of Health.
• [1041] ClinicalTrials.gov (NCT04084951) Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1042] ClinicalTrials.gov (NCT00896207) Studying Different Formulations of SR13668 in Healthy Volunteers. U.S. National Institutes of Health.
• [1043] ClinicalTrials.gov (NCT04374877) Study of SRF388 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1044] ClinicalTrials.gov (NCT04336098) Study of SRF617 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1045] ClinicalTrials.gov (NCT04291079) SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON). U.S. National Institutes of Health.
• [1046] ClinicalTrials.gov (NCT00276913) A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1047] ClinicalTrials.gov (NCT04505839) First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors. U.S. National Institutes of Health.
• [1048] ClinicalTrials.gov (NCT04247126) A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors. U.S. National Institutes of Health.
• [1049] ClinicalTrials.gov (NCT03489369) Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
• [1050] ClinicalTrials.gov (NCT03489343) Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
• [1051] ClinicalTrials.gov (NCT04363242) A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body.. U.S. National Institutes of Health.
• [1052] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014468)
• [1053] ClinicalTrials.gov (NCT04780217) A Clinical Study of T3011 When Administered Via Intravenous Infustion in Patients With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1054] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012192)
• [1055] ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health.
• [1056] Clinical pipeline report, company report or official report of Takeda.
• [1057] ClinicalTrials.gov (NCT00535522) A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [1058] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8200).
• [1059] Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci. 2013Apr;104(4):486-94.
• [1060] ClinicalTrials.gov (NCT04420884) A Study of TAK-676 and TAK-676 in Combination With Pembrolizumab in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1061] ClinicalTrials.gov (NCT00948467) Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
• [1062] ClinicalTrials.gov (NCT01179399) Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
• [1063] ClinicalTrials.gov (NCT00006254) VNP20009 in Treating Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1064] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007714)
• [1065] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040598)
• [1066] Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.Clin Cancer Res. 2006 Sep 1;12(17):5207-15.
• [1067] ClinicalTrials.gov (NCT01215864) Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1068] ClinicalTrials.gov (NCT00002137) A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4. U.S. National Institutes of Health.
• [1069] ClinicalTrials.gov (NCT00820508) Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies. U.S. National Institutes of Health.
• [1070] Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012 Oct;11(10):790-811.
• [1071] ClinicalTrials.gov (NCT01139151) 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies. U.S. National Institutes of Health.
• [1072] ClinicalTrials.gov (NCT00964756) A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers. U.S. National Institutes of Health.
• [1073] ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
• [1074] Clinical pipeline report, company report or official report of I-MAB Biopharma.
• [1075] ClinicalTrials.gov (NCT04025216) A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers. U.S. National Institutes of Health.
• [1076] ClinicalTrials.gov (NCT03429218) First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1077] ClinicalTrials.gov (NCT03604783) Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1078] ClinicalTrials.gov (NCT04328740) Phase 1 Study of Oral TP-1454. U.S. National Institutes of Health.
• [1079] ClinicalTrials.gov (NCT03715504) Study of TP-3654 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1080] ClinicalTrials.gov (NCT03829436) TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers. U.S. National Institutes of Health.
• [1081] ClinicalTrials.gov (NCT04344795) Phase 1a/1b Study of TPST-1495 in Subjects With Solid Tumors. U.S. National Institutes of Health.
• [1082] ClinicalTrials.gov (NCT03993873) Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET. U.S. National Institutes of Health.
• [1083] ClinicalTrials.gov (NCT03859752) TR1801-ADC in Patients With Tumors That Express c-Met. U.S. National Institutes of Health.
• [1084] ClinicalTrials.gov (NCT01409343) TrasGEX Dose Escalation Study. U.S. National Institutes of Health.
• [1085] ClinicalTrials.gov (NCT00492830) Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1086] ClinicalTrials.gov (NCT01259518) Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas. U.S. National Institutes of Health.
• [1087] ClinicalTrials.gov (NCT02628574) Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab. U.S. National Institutes of Health.
• [1088] AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-Oct 22-26, 2007, San Francisco, CA.
• [1089] ClinicalTrials.gov (NCT04495296) A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1090] ClinicalTrials.gov (NCT03654547) Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer. U.S. National Institutes of Health.
• [1091] ClinicalTrials.gov (NCT03884556) TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers. U.S. National Institutes of Health.
• [1092] ClinicalTrials.gov (NCT04485013) TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers. U.S. National Institutes of Health.
• [1093] ClinicalTrials.gov (NCT01290471) Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
• [1094] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029692)
• [1095] ClinicalTrials.gov (NCT01307267) A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab. U.S. National Institutes of Health.
• [1096] Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med. 2013 Mar 8;11:62.
• [1097] ClinicalTrials.gov (NCT00647114) A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED). U.S. National Institutes of Health.
• [1098] ClinicalTrials.gov (NCT00753415) A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002). U.S. National Institutes of Health.
• [1099] ClinicalTrials.gov (NCT04135352) A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001). U.S. National Institutes of Health.
• [1100] ClinicalTrials.gov (NCT01514123) Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1101] Clinical pipeline report, company report or official report of VITRAC Therapeutics.
• [1102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038245)
• [1103] ClinicalTrials.gov (NCT01895491) Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer. U.S. National Institutes of Health.
• [1104] ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health.
• [1105] ClinicalTrials.gov (NCT01849744) Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies. U.S. National Institutes of Health.
• [1106] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8382).
• [1107] ClinicalTrials.gov (NCT01486329) VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer. U.S. National Institutes of Health.
• [1108] Pharmacokinetics and safety of bromotetrandrine (BrTet,W198) after single-dose intravenous administration in healthy Chinese volunteers. Journal of Clinical Pharmacy and Therapeutics (2010) 35, 113-119.
• [1109] ClinicalTrials.gov (NCT01621542) Clinical Study of WT2725 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
• [1110] A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 August; 44(12): 1684-1692.
• [1111] ClinicalTrials.gov (NCT00028522) R(+)XK469 in Treating Patients With Advanced Neuroblastoma. U.S. National Institutes of Health.
• [1112] ClinicalTrials.gov (NCT00796484) Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors. U.S. National Institutes of Health.
• [1113] ClinicalTrials.gov (NCT03845166) A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors. U.S. National Institutes of Health.
• [1114] ClinicalTrials.gov (NCT00460278) Study of XL418 in Adults With Solid Tumors. U.S. National Institutes of Health.
• [1115] ClinicalTrials.gov (NCT03849469) A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4). U.S. National Institutes of Health.
• [1116] ClinicalTrials.gov (NCT03752398) A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3). U.S. National Institutes of Health.
• [1117] ClinicalTrials.gov (NCT04250155) An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1118] ClinicalTrials.gov (NCT00455052) A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [1119] ClinicalTrials.gov (NCT03552718) QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.. U.S. National Institutes of Health.
• [1120] YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79(2):213-20.
• [1121] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026315)
• [1122] ClinicalTrials.gov (NCT04257617) A Trial of ZL-1201 in Subjects With Advanced Cancer. U.S. National Institutes of Health.
• [1123] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7965).
• [1124] ClinicalTrials.gov (NCT03821233) A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers. U.S. National Institutes of Health.
• [1125] Stereocontrolled organocatalytic synthesis of prostaglandin PGF2alpha in seven steps. Nature. 2012 Sep 13;489(7415):278-81.
• [1126] A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66.
• [1127] Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6.
• [1128] A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
• [1129] PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.
• [1130] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [1131] VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
• [1132] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [1133] Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
• [1134] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [1135] Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
• [1136] Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
• [1137] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002510)
• [1138] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002454)
• [1139] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002426)
• [1140] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000315)
• [1141] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004282)
• [1142] Clinical pipeline report, company report or official report of Exelixis.
• [1143] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000729)
• [1144] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000771)
• [1145] Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol. 1995;35(4):271-7.
• [1146] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005849)
• [1147] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002535)
• [1148] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002474)
• [1149] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000796)
• [1150] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002018)
• [1151] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003844)
• [1152] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017022)
• [1153] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000874)
• [1154] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009459)
• [1155] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003889)
• [1156] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002707)
• [1157] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000740)
• [1158] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001664)
• [1159] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019051)
• [1160] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007242)
• [1161] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010224)
• [1162] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006853)
• [1163] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002443)
• [1164] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 463).
• [1165] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002464)
• [1166] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005099)
• [1167] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000841)
• [1168] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003227)
• [1169] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009063)
• [1170] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003064)
• [1171] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004410)
• [1172] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018390)
• [1173] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007051)
• [1174] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011729)
• [1175] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008265)
• [1176] ClinicalTrials.gov (NCT00028873) R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy. U.S. National Institutes of Health.
• [1177] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2775).
• [1178] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2740).
• [1179] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017888)
• [1180] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008798)
• [1181] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002671)
• [1182] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002442)
• [1183] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005106)
• [1184] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000904)
• [1185] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002632)
• [1186] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002418)
• [1187] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003868)
• [1188] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009673)
• [1189] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002425)
• [1190] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004215)
• [1191] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004297)
• [1192] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003110)
• [1193] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033914)
• [1194] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002716)
• [1195] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000879)
• [1196] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004159)
• [1197] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002565)
• [1198] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000120)
• [1199] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000818)
• [1200] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260)
• [1201] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002432)
• [1202] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8367).
• [1203] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001279)
• [1204] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008971)
• [1205] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001994)
• [1206] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002566)
• [1207] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001587)
• [1208] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010383)
• [1209] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004905)
• [1210] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004890)
• [1211] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001916)
• [1212] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004862)
• [1213] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010052)
• [1214] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7714).
• [1215] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011860)
• [1216] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6498).
• [1217] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002753)
• [1218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010699)
• [1219] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020424)
• [1220] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015936)
• [1221] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003304)
• [1222] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004580)
• [1223] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004581)
• [1224] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016506)
• [1225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024847)
• [1226] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8474).
• [1227] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015142)
• [1228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003875)
• [1229] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004166)
• [1230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031507)
• [1231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007988)
• [1232] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005581)
• [1233] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011175)
• [1234] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008574)
• [1235] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014192)
• [1236] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022182)
• [1237] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002537)
• [1238] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030700)
• [1239] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013684)
• [1240] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007982)
• [1241] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007669)
• [1242] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010155)
• [1243] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000815)
• [1244] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004826)
• [1245] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021611)
• [1246] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394)
• [1247] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006432)
• [1248] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013121)
• [1249] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022435)
• [1250] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022436)
• [1251] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004103)
• [1252] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017972)
• [1253] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026275)
• [1254] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011360)
• [1255] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011615)
• [1256] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024789)
• [1257] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002020)
• [1258] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012080)
• [1259] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020753)
• [1260] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621)
• [1261] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021862)
• [1262] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024763)
• [1263] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018371)
• [1264] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004630)
• [1265] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018698)
• [1266] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002473)
• [1267] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022826)
• [1268] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028258)
• [1269] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028214)
• [1270] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032638)
• [1271] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034474)
• [1272] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003891)
• [1273] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016219)
• [1274] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002021)
• [1275] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001813)
• [1276] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011907)
• [1277] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012262)
• [1278] ClinicalTrials.gov (NCT00547261) Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer. U.S. National Institutes of Health.
• [1279] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000891)
• [1280] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004409)
• [1281] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003155)
• [1282] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6011).
• [1283] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019128)
• [1284] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000732)
• [1285] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009282)
• [1286] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016916)
• [1287] ClinicalTrials.gov (NCT00234481) Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia. U.S. National Institutes of Health.
• [1288] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007052)
• [1289] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004376)
• [1290] Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
• [1291] The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. Biopharm Drug Dispos. 1997 Jul;18(5):433-42.
• [1292] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [1293] Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6;5(4):552-8.
• [1294] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [1295] Clinical pipeline report, company report or official report of Celgene Corporation.
• [1296] Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
• [1297] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006389)
• [1298] Clinical pipeline report, company report or official report of Atara Biotherapeutics.
• [1299] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029157)
• [1300] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019759)
• [1301] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7711).
• [1302] Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12.
• [1303] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022289)
• [1304] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023898)
• [1305] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897)
• [1306] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep;16(9):787-810.
• [1307] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019225)
• [1308] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018517)
• [1309] Preclinical and clinical studies of clindamycin-2-phosphate (author's transl). Jpn J Antibiot. 1977 Jan;30(1):42-50.
• [1310] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006586)
• [1311] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021167)
• [1312] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019949)
• [1313] Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
• [1314] HDAC inhibitors repress the polycomb protein BMI1. Cell Cycle. 2010 Jul 15; 9(14): 2722-2730.
• [1315] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024278)
• [1316] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026610)
• [1317] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026584)
• [1318] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017941)
• [1319] Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin Ther Targets. 2017 Feb;21(2):145-157.
• [1320] Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92.
• [1321] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021526)
• [1322] Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 3;24(5):774-781.
• [1323] Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95.
• [1324] Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell. 1995 Nov;7(11):1941-50.
• [1325] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022337)
• [1326] Clinical pipeline report, company report or official report of Jyant Technologies.
• [1327] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024256)
• [1328] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024269)
• [1329] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019408)
• [1330] Selective extraction of an intrinsic fat-cell plasma-membrane glycoprotein by Triton X-100. Correlation with [3H]cytochalasin B binding activity. FEBS Lett. 1977 Nov 1;83(1):71-5.
• [1331] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016645)
• [1332] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026397)
• [1333] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030251)
• [1334] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012041)
• [1335] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007583)
• [1336] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022659)
• [1337] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [1338] Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
• [1339] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024728)
• [1340] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020976)
• [1341] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018144)
• [1342] Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacol Res. 2020 Jun;156:104772.
• [1343] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026975)
• [1344] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [1345] Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
• [1346] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7505).
• [1347] Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res. 2004 Aug 1;10(15):5271-81.
• [1348] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025136)
• [1349] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [1350] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004681)
• [1351] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002321)
• [1352] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7973).
• [1353] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031939)
• [1354] Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis. Mol Biol Cell. 2007 October; 18(10): 4024-4036.
• [1355] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020768)
• [1356] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017146)
• [1357] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019239)
• [1358] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007472)
• [1359] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025089)
• [1360] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003022)
• [1361] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005451)
• [1362] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018473)
• [1363] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012949)
• [1364] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015053)
• [1365] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)
• [1366] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8027).
• [1367] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009078)
• [1368] Spectroscopic study of fluorescent peptides for prenyl transferase assays. J Pharm Biomed Anal. 2005 Mar 9;37(3):417-22.
• [1369] Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995 Nov 15;55(22):5310-4.
• [1370] A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer. 2004 Feb 23;90(4):800-4.
• [1371] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006929)
• [1372] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005130)
• [1373] Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014 Aug 5;349:g4643.
• [1374] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004174)
• [1375] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001915)
• [1376] A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
• [1377] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016830)
• [1378] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004903)
• [1379] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004901)
• [1380] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011416)
• [1381] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004913)
• [1382] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007476)
• [1383] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006498)
• [1384] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016567)
• [1385] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004971)
• [1386] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005535)
• [1387] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010054)
• [1388] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007439)
• [1389] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004568)
• [1390] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011348)
• [1391] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013446)
• [1392] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003301)
• [1393] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008011)
• [1394] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015113)
• [1395] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011791)
• [1396] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015455)
• [1397] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011353)
• [1398] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003256)
• [1399] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005359)
• [1400] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013297)
• [1401] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004963)
• [1402] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010289)
• [1403] Inhibition of heat shock protein 90 (Hsp90) modulates macrophage stimulating-1 receptor (MSR1) expression and signaling, and reduces pancreatic tumor growth. Cancer Res May 1, 2009 69; 2835.
• [1404] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000843)
• [1405] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002530)
• [1406] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000840)
• [1407] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4273).
• [1408] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013537)
• [1409] 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
• [1410] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011061)
• [1411] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003249)
• [1412] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004519)
• [1413] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004322)
• [1414] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005191)
• [1415] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014429)
• [1416] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008710)
• [1417] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019332)
• [1418] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003910)
• [1419] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026868)
• [1420] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5077).
• [1421] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027592)
• [1422] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006823)
• [1423] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020633)
• [1424] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019437)
• [1425] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018767)
• [1426] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037691)
• [1427] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026574)
• [1428] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013182)
• [1429] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006641)
• [1430] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002714)
• [1431] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004259)
• [1432] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007537)
• [1433] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000903)
• [1434] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001885)
• [1435] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026172)
• [1436] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021498)
• [1437] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000745)
• [1438] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024821)
• [1439] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016615)
• [1440] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004592)
• [1441] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007803)
• [1442] P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem. 1997 Nov 15;250(1):115-21.
• [1443] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011081)
• [1444] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020980)
• [1445] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021472)
• [1446] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011303)
• [1447] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003801)
• [1448] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007547)
• [1449] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000265)
• [1450] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004116)
• [1451] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012504)
• [1452] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019319)
• [1453] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025719)
• [1454] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016996)
• [1455] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002431)
• [1456] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024125)
• [1457] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007105)
• [1458] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016901)
• [1459] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012807)
• [1460] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012642)
• [1461] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005287)
• [1462] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004231)
• [1463] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022134)
• [1464] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001282)
• [1465] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004355)
• [1466] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000906)
• [1467] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006373)
• [1468] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2809).
• [1469] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004359)
• [1470] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031168)
• [1471] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012051)
• [1472] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021235)
• [1473] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004163)
• [1474] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007406)
• [1475] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007007)
• [1476] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025763)
• [1477] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029368)
• [1478] XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 1999 Jun;35(6):1014-9.
• [1479] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006898)
• [1480] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023132)
• [1481] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026449)
• [1482] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009540)
• [1483] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003738)
• [1484] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009542)
• [1485] Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6.
• [1486] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [1487] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771).
• [1488] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
• [1489] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811).
• [1490] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1816).
• [1491] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1525).
• [1492] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880).
• [1493] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
• [1494] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
• [1495] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
• [1496] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1495).
• [1497] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [1498] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [1499] Ambazone as a membrane active antitumor drug. Biophys Chem. 1990 Apr;35(2-3):287-300.
• [1500] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
• [1501] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
• [1502] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [1503] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809).
• [1504] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1805).
• [1505] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
• [1506] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640).
• [1507] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7495).
• [1508] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
• [1509] Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell. 2014 Jul 31;158(3):534-48.
• [1510] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5681).
• [1511] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [1512] A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy. Adv Drug Deliv Rev. 2019 Jul;147:37-43.
• [1513] J Clin Oncol 33, 2015 (suppl; abstr 2545).
• [1514] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987).
• [1515] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
• [1516] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
• [1517] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810).
• [1518] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8475).
• [1519] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
• [1520] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2829).
• [1521] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
• [1522] Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5809-12.
• [1523] Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92.
• [1524] Discovery of a Small-Molecule Probe for V-ATPase Function. J Am Chem Soc. 2015 Apr 29;137(16):5563-8.
• [1525] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 653).
• [1526] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
• [1527] Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
• [1528] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
• [1529] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8044).
• [1530] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 80).
• [1531] A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63.
• [1532] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839).
• [1533] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6046).
• [1534] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
• [1535] Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
• [1536] Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
• [1537] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
• [1538] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063).
• [1539] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [1540] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).
• [1541] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1490).
• [1542] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8048).
• [1543] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643).
• [1544] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606).
• [1545] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
• [1546] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549).
• [1547] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).
• [1548] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
• [1549] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030).
• [1550] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879).
• [1551] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
• [1552] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1638).
• [1553] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845).
• [1554] Lycobetaine acts as a selective topoisomerase IIbeta poison and inhibits the growth of human tumour cells. Br J Cancer. 2001 November; 85(10): 1585-1591.
• [1555] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6005).
• [1556] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220).
• [1557] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254).
• [1558] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1833).
• [1559] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2847).
• [1560] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
• [1561] Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013 Apr;12(4):427-37.
• [1562] Recent progress in protein farnesyltransferase inhibition. IDrugs. 2000 Nov;3(11):1336-45.
• [1563] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
• [1564] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
• [1565] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
• [1566] Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86.
• [1567] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8008).
• [1568] Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202.
• [1569] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
• [1570] Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
• [1571] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836).
• [1572] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2766).
• [1573] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8679).
• [1574] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4967).
• [1575] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618).
• [1576] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1989).
• [1577] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2286).
• [1578] US patent application no. 7,425,545, Modulation of C-reactive protein expression.
• [1579] US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression.
• [1580] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [1581] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 336).
• [1582] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
• [1583] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621).
• [1584] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 148).
• [1585] Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
• [1586] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2833).
• [1587] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5928).
• [1588] Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
• [1589] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
• [1590] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
• [1591] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2041).
• [1592] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 314).
• [1593] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619).
• [1594] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
• [1595] Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64.
• [1596] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1625).
• [1597] Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis. Food Funct. 2018 Apr 25;9(4):2005-2014.
• [1598] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [1599] A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45.
• [1600] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2169).
• [1601] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642).
• [1602] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
• [1603] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8538).
• [1604] Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
• [1605] Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
• [1606] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5700).
• [1607] Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6.
• [1608] Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: di... J Med Chem. 2010 Jan 28;53(2):798-810.
• [1609] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
• [1610] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824).
• [1611] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
• [1612] Determination of PNU-248686A, a novel matrix metalloproteinase inhibitor, in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. J Chromatogr A. 2003 Feb 14;987(1-2):249-56.
• [1613] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 732).
• [1614] Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26.
• [1615] CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. Korean J Physiol Pharmacol. 2016 Mar;20(2):161-8.
• [1616] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
• [1617] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973).
• [1618] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [1619] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1619).
• [1620] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 239).
• [1621] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [1622] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503).
• [1623] N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9.
• [1624] p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response.Nat Commun. 2018 Mar 9;9(1):1021.
• [1625] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
• [1626] Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84.
• [1627] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5070).
• [1628] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7005).
• [1629] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536).
• [1630] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [1631] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8042).
• [1632] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
• [1633] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8664).
• [1634] WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83.
• [1635] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2707).
• [1636] ClinicalTrials.gov (NCT01941927) Trametinib With GSK2141795 in BRAF Wild-type Melanoma. U.S. National Institutes of Health.
• [1637] Clinical pipeline report, company report or official report of Kinex Pharmaceuticals.
• [1638] ClinicalTrials.gov (NCT01390818) Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
• [1639] MGI PHARMA Initiates Drug Combination Trial of Irofulven and Taxotere in Patients With Advanced Cancers; Phase 1 Dose-Escalating Trial to Evaluate Novel Combination Therapy. 2001 Business Wire
• [1640] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.